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BOOK 1:  RECEPTOR-MEDIATED ACTIVATION OF CANONICAL  
WNT SIGNALING 
 
CHAPTER 1:  INTRODUCTION TO CANONICAL WNT SIGNALING 
 
Introduction 
Canonical Wnt, or Wnt/β-catenin, signaling controls various cell fates in 
metazoan development and is misregulated in several cancers and developmental 
disorders. Binding of a Wnt ligand to its transmembrane co-receptors Frizzled (Fz) and 
low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6) inhibits phosphorylation 
and degradation of the transcriptional co-activator β-catenin, which then translocates to 
the nucleus to regulate target gene expression (Figure 1.1).  In the work described in 
Chapters 2 and 3, I performed studies to determine the mechanism by which the Wnt co-
receptors Fz and LRP5/6 activate canonical Wnt signaling.  As an introduction to these 
studies, I summarize the discovery and history of canonical Wnt signaling as well as our 
current understanding of the roles and mechanisms of Wnt signaling. 
 
Discovery of Canonical Wnt Signaling 
Development of a multicellular organism with complex tissues and organs 
requires extensive communication between cells (reviewed in Gerhart, 1999).  Secretion 
from one cell of a protein ligand that binds a protein receptor on the plasma membrane of 
another cell and promotes a molecular response in that receptor cell is one strategy by  
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Figure 1.1:  Schematic of Canonical Wnt Signaling.  In the absence of a Wnt ligand, β-
catenin concentrations are kept low in the cytoplasm.  Cytosolic β-catenin becomes 
bound by a destruction complex consisting of two scaffold proteins, Axin and the 
adenomatous polyposis coli (APC) protein, as well as a kinase, glycogen synthase kinase 
3 (GSK3).  GSK3 within the destruction complex phosphorylates β-catenin leading to its 
recognition by an E3 ubiquitin ligase and its subsequent polyubiquitination and 
proteasome-mediated degradation.  However, in the presence of a Wnt ligand, the ligand 
binds its co-receptors Fz and LRP5/6, which leads to inhibition of destruction complex 
formation or activity.  As a result, β-catenin escapes degradation and accumulates in the 
cytoplasm.  β-catenin then translocates to the nucleus where it binds transcription factors 
of the T cell factor/lymphoid enhancer factor (TCF/LEF) family and activates a cell-type-
specific transcriptional program.  Figure adapted from (Tolwinski and Wieschaus, 2004).    
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which metazoa achieve cell-cell communication.  In some cases, the ligand (such as a 
steroid hormone) can traverse the plasma membrane and bind an intracellular receptor.  
In addition, when ligand and receptor are both plasma membrane-bound proteins (as in 
Notch signaling), neighboring cells can communicate in a manner that leads to 
transduction of signals within both the ligand- and receptor-containing cells.  Despite the 
vast diversity of morphology and function throughout metazoa, relatively few signaling 
pathways exist; and their components and mechanisms have been remarkably well-
conserved throughout evolution.  For example, it has been proposed that only 17 different 
types of intercellular signaling pathways exist (Gerhart, 1999).  Some of these pathways 
play roles in early developmental events as well as adult physiology, while other 
pathways are thought only to have roles in adult physiology.  Importantly, mutations in 
humans that affect these signaling pathways cause numerous developmental disorders 
and adult diseases.  Because relatively few signaling pathways control so many biological 
events throughout metazoa, intense study of the roles and mechanisms of these signaling 
pathways offers profound insight into biological regulation and disease. 
The Wnt signaling pathway comprises one class of cell-cell communication that is 
conserved throughout metazoa, required in development and adult physiology, and 
misregulated in a number of diseases (reviewed in Clevers, 2006; Klaus and Birchmeier, 
2008; Logan and Nusse, 2004).  This signaling pathway was named for its protein 
ligands, called Wnts; and the historical discoveries that led to this name reflect the 
importance of this pathway in development and disease.  In 1976, a Drosophila mutant 
was identified in which wing development was drastically inhibited; and this mutant was 
named wingless (Sharma and Chopra, 1976).  The wingless gene was later found to also 
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affect segment polarity in the Drosophila early embryonic cuticle (Nusslein-Volhard and 
Wieschaus, 1980).  These studies suggested developmental roles for the Wingless 
protein.  In 1982, it was discovered that the Mouse Mammary Tumor Virus in mice 
promoted oncogenesis by increasing expression of a gene called Integration 1 (Int1) 
(Nusse and Varmus, 1982).  In 1987, an intriguing connection between the wingless and 
Int1 genes was discovered:  wingless was the Drosophila ortholog of Int1 in the mouse 
(Cabrera et al., 1987; Rijsewijk et al., 1987).  Thus, a gene that was required for multiple 
aspects of fly development was also an oncogene.  As a result, the word “Wnt” was 
coined to combine wingless and Int1 (Nusse et al., 1991), reflecting its roles in 
development and cancer in flies and mammals.  This finding spurred a great deal of 
interest in the role of Wnt proteins in biology and cancer.  In addition, questions 
concerning the connections between development and cancer have culminated in 
investigation of the role of Wnts in stem cell biology (Reya and Clevers, 2005).  Thus, 
the discovery and naming of Wnts exemplify the conservation of cell-cell signaling 
pathways throughout metazoa and their diverse roles in biology and disease. 
The discovery, cloning, and naming of Wnts led to further elucidation of their 
developmental roles.  In 1967, a mutant called swaying was shown to affect balance in 
mice (Lane, 1967).  Mutations in this gene inhibited proper cerebellar development. 
Cloning of the swaying gene revealed that the phenotype was caused by a loss-of-
function mutation in the Wnt-1 gene (Thomas and Capecchi, 1990; Thomas et al., 1991).  
Thus, after identification of a role for Wnts in cancer in mice, a developmental role for 
Wnt-1 was also found in mice.  Wnts also provided a molecular explanation for the work 
of Spemann and Mangold who demonstrated that transplantation of dorsal tissue to 
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ventral regions of the amphibian embryo induced formation of an ectopic trunk and head 
(Spemann and Mangold, 1924).  Part of the molecular basis for these transplantation 
results was revealed when it was shown that injection of Wnt mRNA was sufficient to 
induce formation of an ectopic head and trunk in Xenopus laevis embryos (McMahon and 
Moon, 1989).  As was the case for wingless in flies, Wnts were found to regulate 
development in vertebrates. 
In addition to affecting development and oncogenesis in model organisms, the 
Wnt pathway was found to play major roles in human disease.  C-terminal truncation of 
the adenomatous polyposis coli (APC) protein, a cytoplasmic negative regulator of Wnt 
signaling, promotes constituitive activation of Wnt signaling and is found in over 85% of 
colorectal cancers (Ashton-Rickardt et al., 1989; de Lau et al., 2007; Groden et al., 1991).  
Thus, misregulation of Wnt signaling lies at the heart of one of the most common forms 
of human cancers.  Mutations in several other Wnt components have been found in 
colorectal cancers.  Although studies identifying a role for Wnts in colorectal cancers 
have been most compelling and comprehensive, evidence suggests that misregulation of 
Wnt signaling also contributes to many other cancers including hepatocellular carcinoma, 
breast cancer, skin cancer, lung cancer, Wilms’ tumors, and prostate cancer (Klaus and 
Birchmeier, 2008).  With regard to the roles of the Wnt co-receptors Fz and LRP5/6 in 
oncogenesis, Fz7 is overexpressed in hepatocellular carcinoma (Merle et al., 2004), and 
mutations that cause deletions within LRP5 can promote parathyroid cancers (Bjorklund 
et al., 2007).  Indeed, it is likely that aberrant Wnt activation is involved in multiple 
aspects of tumorigenesis in numerous cancers.  In addition to its roles in cancer, 
misregulation of Wnt signaling promotes several other types of human disease.  Loss-of-
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function mutations in Wnt-3 have been shown to cause tetra-amelia in which patients fail 
to develop arms and legs (Niemann et al., 2004).  Loss-of-function mutations in the Wnt 
co-receptor Fz4 can cause Familial Exudative Vitreoretinopathy, in which retinal 
angiogenesis is defective (Robitaille et al., 2002).  In addition, loss-of-function mutations 
in the Wnt co-receptor LRP5 cause loss-of-bone-density diseases such as osteoarthritis, 
while gain-of-function mutations in LRP5 (or loss-of-function mutations in LRP5/6 
antagonists such as Sclerostin) promote diseases characterized by increased bone density 
(reviewed in Balemans and Van Hul, 2007).  Thus, Wnt signaling is tightly regulated to 
promote proper levels of osteogenesis.  These disorders reflect roles for Wnt signaling in 
multiple tissues during human development as well as in adult physiology.  Given such a 
diversity of diseases caused by misregulation of Wnt signaling, it is likely that 
polymorphisms in Wnt signaling components contribute in significant but less drastic 
ways to numerous other prominent diseases such as cardiovascular disease (Mani et al., 
2007), diabetes (Cauchi and Froguel, 2008), and neurodegenerative disease (De Ferrari et 
al., 2007).  Further study of the roles of Wnt signaling in these diseases promises to lead 
to improvement in diagnosis, management, and treatment of a great number of human 
diseases.  
The mechanisms by which loss of Wnt signaling prevents important 
developmental processes and by which gain of Wnt signaling promotes oncogenesis may 
be unified through an understanding of the role of Wnt signaling in stem cell biology.  
Stem cells have dual ability to self-renew and to differentiate into specialized cell-types.  
As it has been shown that Wnt signaling is required for maintenance of stem cell niches 
in development, certain Wnt-mediated developmental disorders may arise from loss of 
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stem cell populations (Reya and Clevers, 2005).   In adult physiology, the role of Wnt 
signaling in stem cell maintenance has been partially characterized in colonic crypts.  
Epithelial cells in intestinal crypts form a continuous sheet that is completely regenerated 
about every 7 days (reviewed in Reya and Clevers, 2005).  Stem cells reside near the 
bottom of these crypts where they self-regenerate or engender transit-amplifying 
progenitor cells that differentiate into specific epithelial cell-types.  Homeostasis is 
achieved as cells at the tops of the crypts are shed or undergo apoptosis.  Importantly, 
mice with mutations that inhibit Wnt signaling display loss of the stem cell compartment 
of the crypt (Korinek et al., 1998).  It is also suggested that a gradient of Wnt signaling 
that is strongest at the bottom of crypts is required for stem cell and/or progenitor cell 
activity and maintenance (Hendriksen et al., 2008).  These data suggest Wnts may be 
required for stem cell and/or progenitor cell maintenance in the crypt.  Importantly, 
colorectal-cancer-associated mutations that overactivate Wnt signaling lead to crypts with 
increased populations of progenitor cells and enhanced cell proliferation (Kim et al., 
2004).  Overall, these data suggest that Wnt signaling may regulate colonic crypt 
maintenance by its effects on stem cell and/or progenitor cell populations in the colon, 
and colorectal cancer may arise from over-activation of Wnt signaling that leads to 
expansion of colonic stem cell populations.  Activation of stem cell populations may also 
lie at the heart of observations that Wnt signaling is involved in regenerative biology, 
including regeneration of zebrafish tail fins (Stoick-Cooper et al., 2007), Xenopus limb 
buds (Yokoyama et al., 2007a), and deer antlers (Mount et al., 2006).  As a result, a 
greater understanding of the role of Wnts in stem cell biology may uncover fundamental 
disease mechanisms and lead to development of therapies for Wnt-related diseases. 
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Historical Elucidation of Canonical Wnt Pathway Components 
Early work with Wnts revealed that they play major roles in development of 
experimentally amenable model organisms.  Genetic mutations in Wnts affect segment 
polarity of the Drosophila embryonic cuticle, and Wnt mRNA injection promotes 
duplication of the primary body axis in Xenopus.  In addition, mutations in Wnts alter 
various aspects of mouse development.  These discoveries provided a theoretical 
foundation by which use of these whole organism experimental systems could uncover 
new genes in Wnt signaling. 
In Drosophila, screens for genes that affected patterning of the early embryonic 
cuticle identified a number of genes that would later be shown to be intimately involved 
in transduction of a Wnt signal.  In the early 1990’s, genes named for their altered cuticle 
denticle patterns such as armadillo (the Drosophila ortholog of β-catenin, a protein 
previously shown to localize to and function in adherens junctions) (Riggleman et al., 
1990; Riggleman et al., 1989), dishevelled (Dsh) (Klingensmith et al., 1994; 
Noordermeer et al., 1994), shaggy (the Drosohila ortholog of glycogen synthase kinase 3 
(GSK3)) (Siegfried et al., 1992), and frizzled (Fz) (Bhanot et al., 1996) were shown to 
genetically interact with wingless mutations.  Epistasis and biochemical studies in 
Drosophila provided a basic understanding of how a Wnt signal is transduced:  Wnt 
ligand binds the plasma membrane-bound Fz receptor and signals through Dsh to inhibit 
GSK3-mediated phosphorylation and degradation of β-catenin (Peifer et al., 1994a; 
Peifer et al., 1994b; Siegfried et al., 1994).  Multiple aspects of this model were 
confirmed in vertebrates with mRNA injection-mediated axis duplication in Xenopus.  In 
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unrelated work to determine the role of the APC gene mutated in familial adenomatous 
polyposis, it was found that APC bound β-catenin and was required for its degradation 
(Rubinfeld et al., 1993; Su et al., 1993).  Studies of the mouse Fused gene in Xenopus 
development led to the discovery of another conserved Wnt component Axin that, like 
GSK3 and APC, is required for β-catenin degradation (Zeng et al., 1997).  Biochemical 
studies in cultured cells revealed that GSK3, APC, and Axin physically associate in a 
complex (called the β-catenin destruction complex) that constituitively promotes β-
catenin degradation (Behrens et al., 1998).  Thus, the combination of work in Drosophila, 
Xenopus, mouse, and, later, in cultured mammalian cells suggested that Wnt binds Fz and 
signals through Dsh to inhibit destruction complex activity and allow β-catenin levels to 
rise in the cytoplasm (Figure 1.1).   
Through work initiated in cultured cells and confirmed in Xenopus and 
Drosophila, the ultimate function of Wnt signaling was revealed to be activation of a 
transcriptional program.  In 1991, the transcription factors T cell factor (TCF) and 
lymphoid enhancer factor (LEF) were cloned from cultured cells (Travis et al., 1991; van 
de Wetering et al., 1991).  In studies to determine their function, it was discovered in 
1996 that these proteins bind β-catenin in the nucleus (Behrens et al., 1996; Molenaar et 
al., 1996).  Importantly, interaction of β-catenin with TCF/LEF was shown to be required 
for Wnt signaling responses in Drosophila, Xenopus, and cultured mammalian cells 
(Behrens et al., 1996; Molenaar et al., 1996; van de Wetering et al., 1997).  Thus, it was 
determined that the role of Wnt-mediated stabilization of β-catenin is to allow its nuclear 
translocation and TCF/LEF-dependent transcriptional activity.  As a result of this work, a 
major tool for the study of Wnt signaling was invented:  researchers developed a TCF 
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Optimal Promoter (TOPFlash) reporter plasmid in which TCF binding sites were placed 
upstream of a luciferase gene, allowing a quantifiable readout of Wnt-mediated 
transcription in cultured cells and whole organisms (Molenaar et al., 1996).  In addition, 
this work led to discovery of Wnt target genes such as the homeobox gene ultrabithorax 
that provided clues for the role of Wnt signaling in development and the oncogene c-Myc 
that provided clues to the role of Wnt signaling in cancer (He et al., 1998; Riese et al., 
1997). 
Many more genes involved in Wnt signaling, including the functionally redundant 
Wnt co-receptors LRP5/6 that were independently identified in 2000 through Drosophila 
and mouse genetic screens (Pinson et al., 2000; Wehrli et al., 2000), have been 
discovered through genetic and biochemical approaches.  While major mechanistic 
questions remain, a great deal of progress has been made in understanding Wnt signal 
transduction since the discovery that the oncogene Int1 was the mammalian ortholog of 
the Drosophila wingless gene.    
 
Current Molecular Models for Canonical Wnt Signaling 
Although many aspects of the mechanism of Wnt signaling are controversial and 
currently under study, here I describe a general mechanism by which Wnt signaling is 
likely transduced.  In cells secreting a Wnt ligand, Wnts undergo several post-
translational modifications.  In the endoplasmic reticulum (ER) and Golgi apparatus, 
Wnts are N-glycoyslated and acylated with palmitic acid and palmitoleic acid (Smolich et 
al., 1993; Takada et al., 2006; Willert et al., 2003).  These modifications are thought to 
affect the folding, trafficking, and stability of Wnt proteins.  Upon secretion, Wnts may 
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travel numerous cell diameters as monomers, protein complexes, on liposomes, or by 
transcytosis to reach their intended receptor cell (Gallet et al., 2008; Panakova et al., 
2005).  In the extracellular matrix, certain proteoglycans may be important in regulation 
of Wnt trafficking (Reichsman et al., 1996).  In addition, several secreted molecules have 
been reported to bind Wnts and inhibit their interaction with receptors.  For example, Wnt 
inhibitory factor (WIF) and secreted Frizzled-related protein (sFRP) are secreted 
molecules that bind Wnts and inhibit their interaction with Fz (Hsieh et al., 1999; Rattner 
et al., 1997).  Other secreted molecules such as Dickkopf (Dkk), Wise, and Sclerostin 
(SOST) bind the Wnt co-receptor LRP5/6 and likely act to prevent its Wnt-mediated 
activation (Glinka et al., 1998; Itasaki et al., 2003; Li et al., 2005).  However, these 
LRP5/6 binding molecules may activate Wnt signaling in certain experimental contexts 
(reviewed in Cselenyi and Lee, 2008).  In addition to secreted inhibitors, secreted Wnt 
agonists such as Norrin and R-spondin have been reported to synergize with Wnts or 
activate Wnt signaling independently of Wnts (Kamata et al., 2004; Xu et al., 2004).  
Nonetheless, when a Wnt ligand arrives at its target cell, it binds and forms a complex 
with both of its co-receptors, Fz and LRP5/6.  It has been suggested that Wnts serve to 
bring Fz and LRP5/6 in close association, as synthetic association of these proteins is 
sufficient to activate Wnt signaling (Baig-Lewis et al., 2007; Zeng et al., 2008).   
Upon binding of a Wnt ligand to its receptors, a signal is transduced that 
culminates in inhibition of β-catenin degradation.  As a major question in Wnt signaling 
is how a signal is transduced from the plasma membrane, an understanding of the 
topology of Wnt co-receptors may provide clues to their roles in pathway activation.  Fz 
is a seven-pass transmembrane protein with a topology similar to G protein coupled 
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receptors (GPCRs) (Malbon, 2004).  As a result, it has been suggested that Fz may 
activate Wnt signaling by activation and dissociation of heterotrimeric G proteins (Wang 
and Malbon, 2004).  Such a mechanism would have profound implications for the 
mechanism of Wnt signaling and for development of therapeutics that target Wnt 
signaling.  Although work has suggested that G proteins may affect Wnt signaling, it is 
not clear whether Fz acts as a GPCR in this process.  The role of G proteins in Wnt 
signaling is discussed more extensively in Chapter 3.  In the ER, Fz is retained by the 
inhibitory Wnt pathway component Shisa, suggesting trafficking of Fz may be tightly 
regulated (Yamamoto et al., 2005).  LRP5 and LRP6 are two type I single-span 
transmembrane proteins that likely have identical biochemical activities (Figure 1.2) 
(reviewed in He et al., 2004).  The extracellular domain of these proteins contains four 
Tyr-Trp-Thr-Asp (YWTD) β-propeller domains each followed C-terminally by an 
epidermal growth factor- (EGF) like domain (Herz and Bock, 2002).  The two N-terminal 
pairs of YWTD β-propeller and EGF-like domains are likely involved in binding Wnts 
(Itasaki et al., 2003), whereas the two C-terminal pairs of YWTD β-propeller and EGF-
like domains are likely involved in binding the LRP5/6 antagonists Dkks (Mao et al., 
2001a).  Towards the membrane, three low-density lipoprotein receptor (LDLR) type A 
domains on the extracellular domain are found at the C-terminus of the four YWTD β-
propeller and EGF-like domains (Herz and Bock, 2002).  In response to Wnt signaling, 
the intracellular domain of LRP5/6 becomes phosphorylated by GSK3 on the Ser residue 
of each of five Pro-Pro-Pro-Ser-Pro (PPPSP) motifs (Zeng et al., 2005).  In addition,  
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Figure 1.2:  Schematic of LRP5/6 Protein Domains.  LRP5, LRP6, and Arrow are 
depicted with their extracellular YWTD β-propellers, EGF-like domains, and LDLR type 
A domains as well their intracellular PPPSP motifs.  Schematic adapted from (He, et al., 
2004).    
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numerous Ser and Thr residues flanking the PPPSP motif are phosphorylated by casein 
kinase 1 gamma (CK1γ) in response to a Wnt signal (Davidson et al., 2005).  
Phosphorylation of the LRP5/6 intracellular domain by GSK3 and CK1γ is required for 
Wnt signaling.  Of note, expression of the extracelluar domain of LRP5/6 can be used to 
inhibit Wnt signaling presumably by sequestering Wnts or preventing Fz activation 
(Tamai et al., 2000).  Also, expression of the intracellular domain of LRP5/6 
constituitively activates LRP5/6 mediate signaling (Mao et al., 2001b).  Unlike the 
overexpression of the LRP5/6 intracellular domain, overexpression of full-length LRP5/6 
is not sufficient to activate signaling in the absence of Wnts (Tamai et al., 2000).  Thus, it 
has been suggested that Wnt ligands may mechanistically activate signaling by relieving 
the LRP5/6 extraceulluar domain’s constituitive inhibition of the LRP5/6 intracellular 
domain.  As with Fz, trafficking and maturation of LRP5/6 is likely a tightly regulated 
process.  In the ER, proper maturation of LRP5/6 is regulated by the chaperone MesD 
(Hsieh et al., 2003).  In addition, glycosylation and palmitoylation of LRP5/6 are required 
for its proper maturation and trafficking to the plasma membrane (Abrami et al., 2008). 
Upon binding of a Wnt ligand to Fz and LRP5/6, the cytoplasmic protein Dsh 
becomes phosphorylated and activated (Yanagawa et al., 1995).  Activation of Dsh has 
been shown to require certain amino acids on Fz, suggesting that Fz is involved in 
activation of Dsh (Zeng et al., 2008).  Dsh binds a number of proteins including kinases, 
phosphatases, and G proteins that potentially regulate Wnt signaling (Malbon and Wang, 
2006).  While some roles for Dsh are still somewhat enigmatic, Dsh is required for Wnt-
mediated oligomerization and phosphorylation of LRP5/6 by GSK3 and CK1γ of Ser and 
Thr resides on and around PPPSP motifs of LRP5/6 (Bilic et al., 2007; Davidson et al., 
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2005; Zeng et al., 2008; Zeng et al., 2005).  Phosphorylated PPPSP motifs on LRP5/6 
directly bind Axin (Tamai et al., 2004).  Thus, Wnt- and Dsh-activated LRP5/6 recruits 
and binds the destruction complex likely containing Axin, APC, β-catenin, GSK3, and 
casein kinase 1 alpha (CK1α) (Bilic et al., 2007; Yamamoto et al., 2006).  Axin-bound 
GSK3 enhances phosphorylation of PPPSP motifs on LRP5/6, potentiating its activation 
and destruction complex recruitment (Zeng et al., 2008).  Significant recruitment of the 
β-catenin destruction complex to LRP5/6 has been shown to occur within 5 minutes of 
addition of Wnt ligand (Mao et al., 2001b), and this interaction is likely a relatively stable 
one (Bilic et al., 2007; Yamamoto et al., 2006).  
 The β-catenin destruction complex that maintains low concentrations of β-catenin 
in the cytosol and is recruited to LRP5/6 in response to a Wnt signal is composed of two 
scaffold proteins (Axin and APC), two kinases (GSK3 and CK1α), the protein 
phosphatase 2A (PP2A), the E3 ubiquitin ligase beta-transducin repeat-containing protein 
(β-TRCP), the Wilms tumor suppressor gene (WTX), and β-catenin (Behrens et al., 1998; 
Gao et al., 2002; Liu et al., 1999a; Major et al., 2007; Seeling et al., 1999).  There may be 
additional key components in this complex, and the stoichiometry of the complex has not 
been determined.  Concentrations of Axin, and in some cases APC, are likely limiting for 
destruction complex formation (Benchabane et al., 2008; Lee et al., 2003).  Thus, 
regulation of the levels of these proteins is critical for proper regulation of β-catenin 
degradation.  Within the destruction complex, the kinase CK1α phosphorylates β-catenin 
at Ser45, which primes β-catenin for subsequent GSK3 phosphorylation at 
Ser33/Ser37/Thr41 (Liu et al., 2002).  These GSK3 phosphorylation sites on β-catenin 
are subsequently recognized by the E3 ubiquitin ligase, β-TrCP (Liu et al., 1999a).  This 
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interaction allows for Skp1-Cullin-F-box- (SCF) mediated poly-ubiquitination and 
proteasome-mediated degradation of β-catenin (Latres et al., 1999).  Like the other 
proteins in this complex, WTX is required for optimal degradation of β-catenin, though 
its precise role has not been elucidated (Major et al., 2007).  PP2A within the destruction 
complex also likely acts to promote efficient degradation of β-catenin (Seeling et al., 
1999).  Thus, this destruction complex leads to efficient, constituitive degradation of β-
catenin, keeping levels of β-catenin low in the cytoplasm.  Inhibition of the destruction 
complex by Wnt signaling or by mutation (such as truncating mutations of APC) leads to 
higher levels of β-catenin in the cytoplasm and increased β-catenin-mediated 
transcription.   
 Several distinct mechanisms are commonly cited to explain how Wnt-activated 
co-receptors inhibit β-catenin destruction complex formation or activity.  In each of the 
following mechanisms, β-catenin stabilization occurs by inhibition of GSK3’s 
phosphorylation of β-catenin, which is required for its polyubiquitination and 
degradation.  In one such mechanism, Dsh bound to the Dsh homologous (DIX) domain 
of Axin in response to a Wnt signal recruits GSK3 binding protein (GBP) which directly 
inhibits GSK3’s phosphorylation of β-catenin within the destruction complex (Farr et al., 
2000; Yost et al., 1998).  Although this mechanism has been confirmed in Xenopus 
embryos, a GBP ortholog has not been identified in Drosophila and genetic knockout of 
the three identified GBP proteins in mouse does not disrupt its development (van 
Amerongen et al., 2005).  Thus, while GBP may play some role in Wnt signaling, it is 
likely not the sole mechanism by which a signal is transduced.  Similarly, it has been 
shown that Wnt signaling may induce inhibitory Ser9/Ser21 phosphorylation of 
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GSK3β/GSK3α, inhibiting GSK3’s ability to phosphorylate β-catenin (Yokoyama et al., 
2007b).  However, mice with mutation of these amino acids on GSK3 do not display 
developmental abnormalities (McManus et al., 2005).  In another often-cited mechanism, 
Wnt signaling promotes dissociation of the β-catenin destruction complex (Liu et al., 
2005; Nusse, 2005).  Importantly, this study did not show that destruction complex 
dissociation correlates with Wnt-mediated transcription (Liu et al., 2005).  Also, several 
studies have not been able to reproduce results showing Wnt-mediated destruction 
complex dissociation (Bilic et al., 2007; Hendriksen et al., 2008; Yamamoto et al., 2006).  
Thus, it seems unlikely that a Wnt signal is transduced primarily via GBP, inhibitory 
phosphorylation of GSK3, or destruction complex dissociation.     
 It has also been suggested that Wnts inhibit destruction complex activity by 
inhibiting GSK3’s phosphorylation of β-catenin within the destruction complex at 
activated LRP5/6.  In support of this possibility, recruitment of the β-catenin destruction 
complex to LRP5/6 temporally coincides with inhibition of β-catenin phosphorylation 
(Bryja et al., 2007; Mao et al., 2001b).  Both events are detected beginning around five 
minutes after Wnt stimulation.  In contrast to the destruction complex dissociation model, 
it has been shown that the entire destruction complex stably localizes at LRP5/6 in 
response to a Wnt signal (Bilic et al., 2007; Hendriksen et al., 2008; Yamamoto et al., 
2006).  Finally, immunofluorescence studies have revealed that dephosphorylated β-
catenin accumulates on Axin at GSK3-phosphorylated LRP6 in response to a Wnt signal 
(Hendriksen et al., 2008).  In addition to these studies, our work in egg extract and in 
vitro kinase assays reveals that GSK3-phosphorylated LRP6 can directly inhibit GSK3’s 
phosphorylation of β-catenin within the destruction complex (Cselenyi et al., 2008).  
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Thus, several lines of evidence support a mechanism by which GSK3’s phosphorylation 
of β-catenin is inhibited within the β-catenin destruction complex upon its recruitment to 
Wnt-activated LRP5/6. 
 Evidence in mammalian cultured cells, Xenopus embryos and egg extract, and 
Drosophila embryos also suggests that a Wnt signal may be transduced via degradation 
of Axin (Cselenyi et al., 2008; Kofron et al., 2007; Mao et al., 2001b; Tolwinski et al., 
2003; Yamamoto et al., 1999).  In all four systems, it has been shown that Wnt-activated 
LRP6 promotes degradation of Axin.  Because Axin concentrations are limiting for 
destruction complex formation, degradation of Axin would be predicted to efficiently 
promote stabilization of β-catenin (Lee et al., 2003).  Despite the correlation between 
Wnt signaling and Axin degradation, it has not been shown that Wnt-mediated decreases 
in Axin levels actually plays a role in β-catenin stabilization.  Importantly, experiments in 
cultured cells have suggested that Wnts stabilize β-catenin hours before Axin degradation 
can be detected (Hino et al., 2005; Liu et al., 2005; Willert et al., 1999).  Thus, it is 
possible that other mechanisms such as direct inhibition of GSK3’s phosphorylation of β-
catenin are responsible for initial transduction of a Wnt signal while degradation of Axin 
plays a role in potentiation of a signal.  Thus, the precise mechanism by which a Wnt 
signal is transduced from the Wnt receptor complex is not known, but degradation of 
Axin and direct inhibition of GSK3’s phosphorylation of β-catenin within the destruction 
complex at LRP5/6 are two potential means by which signaling may be achieved.   
 Although the mechanism by which β-catenin phosphorylation and degradation 
becomes inhibited is controversial, it has been well-documented that β-catenin levels in 
the cytoplasm begin to rise within approximately one hour after incubation with Wnt 
 19 
ligand (Bryja et al., 2007; Liu et al., 2005).  This rise in β-catenin levels might be 
explained simply by destruction complex inhibition in the context of constituitively 
translated endogenous β-catenin.  It has been suggested that upon Wnt signaling, LRP5/6 
bound to the destruction complex is rapidly endocytosed and that this internalization 
event is required for Wnt signaling (Yamamoto et al., 2006).  However, the mechanistic 
basis for the role of endocytosis in Wnt signaling is not understood.  By a mechanism that 
has not been well-defined, β-catenin is transported to the nucleus.  Indeed, detection of 
nuclear β-catenin is a common cell biological assay for activation of Wnt signaling.  
Transport of β-catenin to the nucleus might require Rac1 GTPase activity and might 
involve nuclear shuttling by known destruction complex components Dsh, APC, and 
Axin (Cong and Varmus, 2004; Gan et al., 2008; Henderson, 2000; Wu et al., 2008).  In 
the nucleus, β-catenin binds and relieves Groucho-mediated constituitive inhibition of 
TCF/LEF (Levanon et al., 1998; Roose et al., 1998).  The β-catenin/TCF/LEF complex 
also binds a number of transcriptional co-activators with specificity towards Wnt-
mediated transcription including as Pygopus, Legless, and Parafibromin (Kramps et al., 
2002; Mosimann et al., 2006).  This Wnt-dependent nuclear complex then promotes an 
extensive cell-type specific transcriptional program that depends on the epigenetic status 
of the cell in which signaling occurs.  Increases in concentrations of proteins encoded by 
these genes are often detected after about 4 hours of incubation with Wnt ligand (Jho et 
al., 2002).  Some common genes transcribed in Wnt-activated cells include the mitogenic 
oncogene c-Myc, which drives cell proliferation and growth (He et al., 1998).  Cyclin D1 
is also activated, albeit indirectly, in cells undergoing Wnt signaling (Inoki et al., 2006).  
Other Wnt transcriptional targets include the inhibitors of Wnt signal transduction Dkk 
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(an extracellular inhibitor of LRP5/6), Naked (an antagonist of Dsh activity), and Axin2, 
which provide negative feedback loops that downregulate signaling to return β-catenin 
levels to their basal state (Gonzalez-Sancho et al., 2005; Jho et al., 2002; Zeng et al., 
2000).  Thus, an organism can coordinate the activity and identity of certain groups of 
cells via Wnt-mediated activation of cell-type-specific transcriptional programs. 
 
Non-Canonical Wnt Signaling 
Wnt signaling that promotes β-catenin-mediated transcription is called canonical 
Wnt, or Wnt/β-catenin, signaling.  Wnts have also been noted to signal through pathways 
that do not involve β-catenin.  These β-catenin-independent Wnt signaling pathways are 
collectively called non-canonical Wnt signaling pathways (Semenov et al., 2007; Veeman 
et al., 2003).  These non-canonical pathways have diverse biological roles and molecular 
mechanisms.  Notably, none of these pathways has been characterized as completely as 
canonical Wnt signaling.  Importantly, non-canonical Wnt signaling increases the 
diversity of Wnt-mediated events, allowing Wnts to assume an even greater number of 
roles in development and disease. 
The best characterized non-canonical Wnt signaling event is known as planar cell 
polarity (PCP) signaling.  In PCP signaling, a Wnt ligand mediates cytoskeletal 
rearrangement within a cell, often mediating shifts in cell polarity during development 
(reviewed in Zallen, 2007).  During vertebrate gastrulation, Wnt/PCP signaling is 
involved in a process called convergence and extension whereby medial migration and 
intercalation of mesodermal cells causes elongation of the embryo’s primary body axis 
(Zallen, 2007).  This pathway has been studied in Xenopus and zebrafish where it has 
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been shown to involve certain Wnt ligands, Fz, LRP5/6, and the cytoplasmic Dsh protein 
(Tahinci et al., 2007; Theisen et al., 1994; Zallen, 2007).  Consistent with Fz’s potential 
role as a GPCR, it has been shown in Drosophila that this signaling pathway likely 
involves Fz-dependent heterotrimeric G protein dissociation (Katanaev et al., 2005).  
Activation of the PCP pathway affects cell polarity by signaling through multiple proteins 
that affect the actin cytoskeleton (Kaltschmidt et al., 2002).  Notably, the PCP pathway in 
Drosophila may not utilize Wnt ligands; instead, signaling may occur through interaction 
between neighboring cells of plasma-membrane-bound proteins including Fz (Chen et al., 
2008).  In addition to PCP signaling, cell movements during vertebrate gastrulation 
involve another non-canonical Wnt signaling pathway whereby Wnt5a and Fz2 activate 
calcium flux (Slusarski et al., 1997b).  As with PCP signaling, data from experiments in 
zebrafish suggest a role for G proteins in Wnt/Ca++ signaling (Slusarski et al., 1997a). 
 In addition to Fz and LRP5/6, two receptor tyrosine kinases (RTKs) have been 
identified as Wnt receptors that activate β-catenin-independent signaling events.  The 
RTK Ryk binds Wnts and activates a signaling pathway that affects axon guidance in 
mice (Lu et al., 2004).  Another RTK Ror2 also binds Wnts and acts through jun N-
terminal kinase (JNK) to affect convergence and extension movements in vertebrate 
gastrulation (Oishi et al., 2003).  Thus, the diversity of Wnt-mediated biological events 
may be increased by addition of these recently discovered Wnt receptors.        
 In addition to non-canonical Wnt signaling that affects the cytoskeleton, it has 
been shown that Wnts can mediate β-catenin-independent transcriptional events.  In 
studies of myogenesis in the mouse, it has been shown that non-canonical Wnt signaling 
can activate cAMP response element-binding factor- (CREB) mediated transcription in a 
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pathway that involves adenylyl cyclase and protein kinase A (PKA) activation (Chen et 
al., 2005).  In osteoblastogenesis, Wnt3a signals through Gα proteins to activate protein 
kinase C delta (PKCδ) (Tu et al., 2007).  This signaling event occurs independently of β-
catenin and plays a role in transcription of certain genes required for osteogenesis.  Thus, 
non-canonical Wnt-signaling can mediate important transcriptional events that occur 
independently of β-catenin regulation. 
 Adding another layer of complexity to Wnt signaling, canonical Wnt signaling 
can have profound effects on other cell signaling pathways.  This type of regulation in 
which one signaling event affects another is commonly referred to as crosstalk.  Crosstalk 
between Wnt signaling and the mammalian target of rapamycin (mTOR) pathway as well 
as the bone morphogenetic protein (BMP) pathway may allow for crossregulation of 
these ubiquitous signaling pathways.  Specifically, it has been shown that canonical Wnt 
signaling inhibits GSK3’s phosphorylation of the tuberous sclerosis complex 2 (TSC2) 
protein, possibly within the β-catenin destruction complex (Inoki et al., 2006).  This 
event causes activation of the mTOR pathway.  The relationship between canonical Wnt 
and mTOR signaling may be rather intimate, as the gene Cyclin D1 thought to be a 
common and direct target of Wnt/β-catenin signaling, has been shown instead to be a 
target of Wnt-mediated mTOR activation (Inoki et al., 2006).  Similarly in BMP 
signaling, canonical Wnt signaling prevents GSK3 phosphorylation of the Smad1 protein 
within the β-catenin destruction complex, enhancing Smad1-mediated signaling 
(Fuentealba et al., 2007).  These authors discovered that certain developmental events 
regulated by Wnt signaling were actually mediated by Smad1 activity and not, as had 
been previously presumed, β-catenin activity (Fuentealba et al., 2007).  Importantly, 
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many proteins involved in Wnt signaling have multiple biological functions, and Wnts 
may exert their effects in part by modulating their β-catenin-independent activities.  It 
should also be noted that TCF-dependent transcription can be activated by processes 
independent of Wnts or even β-catenin (Yi and Merrill, 2007).  Thus, one clue to the 
diverse roles of Wnt signaling in biology may come from the realization that Wnt/β-
catenin signaling is only one of a great number of Wnt-mediated events in biology.  
Moreover, organisms likely utilize crosstalk between these pathways to increase the 
diversity and specificity of responses to Wnt signals.  
  
Analysis of Receptor-Mediated Activation of Canonical Wnt Signaling in Xenopus 
Egg Extract  
Given the importance of the Wnt co-receptors in development and disease, I 
sought to further characterize the molecular mechanisms by which Fz and LRP5/6 
activate Wnt signaling.  Mutations in both Fz and LRP5/6 lead to a certain developmental 
disorders and cancers.  In addition, signaling receptors are often good candidates for the 
development of novel molecular therapies.  As a result, I hypothesize that mechanistic 
elucidation of receptor-mediated activation of Wnt/β-catenin signaling will promote a 
better understanding of the role of Wnt signaling in disease and lead to development of 
novel therapies to treat these diseases. 
 Specifically, I sought to define the mechanism by which LRP6 inhibits β-catenin 
degradation and to determine the role of G proteins downstream of Fz activation in β-
catenin regulation.  I primarily utilized biochemically tractable, cell-free Xenopus egg 
extract to address these questions.  Xenopus egg extract has been used extensively to 
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reveal fundamental aspects of cell cycle and cytoskeletal regulation (Gard and Kirschner, 
1987; Miake-Lye and Kirschner, 1985).  In egg extract, the molecular determinants and 
kinetics of β-catenin regulation are identical to those described for β-catenin in intact 
cells (Lee et al., 2001; Lee et al., 2003; Salic et al., 2000).  By utilizing Xenopus egg 
extract to determine the roles of LRP6 and G proteins in Wnt signaling, I was able to 
perform a number of experimental procedures that would have been very difficult or 
impossible to achieve in intact cells.  For example, I was able to add precise 
concentrations of proteins and quantify their effects; and, I was able to immunodeplete 
endogenous proteins and replace them with certain mutants that allowed me to test 
specific hypotheses.  In addition to using Xenopus egg extract, I reconstituted activity of 
LRP6 and G proteins in assays containing only purified, recombinant components in 
order to test my hypotheses with even greater biochemical detail and control.  Finally, to 
confirm the conclusions gleaned from my biochemical studies in egg extract and in 
assays containing purified components, I tested predictions from these models in intact 
cells and whole organisms.  I draw the following major conclusions from my work in 
these systems:  LRP6 activates canonical Wnt signaling independently of Axin 
degradation by inhibiting GSK3’s phosphorylation of β-catenin; and Gαo, Gαi, Gαq, and 
Gβγ promote β-catenin stabilization by inhibiting GSK3’s phosphorylation of β-catenin.    
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BOOK 1:  RECEPTOR-MEDIATED ACTIVATION OF CANONICAL  
WNT SIGNALING 
 
CHAPTER 2:  LRP6 TRANSDUCES A CANONICAL WNT SIGNAL 
INDEPENDENTLY OF AXIN DEGRADATION BY INHIBITING GSK3’S 
PHOSPHORYLATION OF β-CATENIN 
 
Most work described in this chapter has been published (Cselenyi et al., 2008). 
 
Introduction 
The best-characterized form of Wnt signaling is the Wnt/β-catenin, or canonical 
Wnt, pathway.  During Wnt/β-catenin signaling, a Wnt ligand binds transmembrane co-
receptors Frizzled (Fz) and low-density lipoprotein receptor-related protein 5 or 6 
(LRP5/6) and initiates a process that leads to stabilization and nuclear translocation of β-
catenin.  In the nucleus, β-catenin binds transcription factors of the T cell 
factor/lymphoid enhancer factor (TCF/LEF) family and activates a Wnt/β-catenin 
transcriptional program. 
Although the mechanism by which a Wnt ligand mediates β-catenin stabilization 
is poorly understood, regulation of β-catenin levels in the absence of Wnt signaling has 
been well-characterized.  In the absence of a Wnt ligand, β-catenin is marked for 
degradation through its interaction with a destruction complex consisting of two scaffold 
proteins, Axin and adenomatous polyposis coli protein (APC), and two kinases, glycogen 
synthase kinase 3 (GSK3) and casein kinase 1a (CK1α) (Logan and Nusse, 2004).  CK1α 
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phosphorylation of β-catenin primes it for subsequent phosphorylation by GSK3, which 
targets β-catenin for ubiquitin-mediated proteolysis (Logan and Nusse, 2004).  It is 
hypothesized that Wnt signal transduction stabilizes β-catenin by inhibiting destruction 
complex formation or activity.   
The Wnt co-receptor LRP5/6 is required for Wnt/β-catenin signaling (Pinson et 
al., 2000; Tamai et al., 2000; Wehrli et al., 2000).  Although LRP6 is more potent than 
LRP5 in certain assays, experiments have not revealed qualitative differences in their 
mechanisms of action (Mi and Johnson, 2005).  Wnt signaling through LRP5/6 has been 
proposed to inhibit destruction complex formation by promoting degradation of the 
destruction complex scaffold Axin.  LRP5 overexpression was initially shown to promote 
Axin degradation in cultured mammalian cells (Mao et al., 2001b).  Genetic studies in 
Drosophila indicate that activation of the Wnt pathway by Arrow, the LRP5/6 ortholog, 
decreases steady-state Axin levels (Tolwinski et al., 2003).  Wnt signaling through LRP6 
also promotes degradation of endogenous Axin in Xenopus oocytes and embryos (Kofron 
et al., 2007).  Because the concentration of Axin is significantly lower than that of other 
destruction complex components, decreases in Axin concentrations represent a 
potentially robust mechanism for β-catenin stabilization (Lee et al., 2003).  As a result, 
LRP5/6-mediated Axin degradation has been proposed to be a critical event in 
transduction of a Wnt signal (Tolwinski and Wieschaus, 2004). 
Although there is strong evidence that signaling by LRP5/6 reduces Axin levels, 
Wnt-mediated stabilization of β-catenin in cultured mammalian cells occurs 
approximately two hours before substantial changes in Axin levels are detected (Hino et 
al., 2005; Liu et al., 2005; Willert et al., 1999).  These data suggest that Axin degradation 
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may not be required for initial signal transmission; alternatively, turnover of a small, 
localized pool of Axin may be necessary for signaling but may be undetected in these 
experiments.  In fact, such a mechanism has been described for β-catenin: the vast 
majority of β-catenin is associated with cadherins at cellular membranes, and only the 
small, cytoplasmic pool of β-catenin protein is stabilized in response to Wnt signaling 
(Heasman et al., 1994; Peifer et al., 1994b).  Here, we reconstitute LRP6 signaling in 
biochemically tractable Xenopus egg extract, which has been used to accurately 
reconstitute cytoplasmic aspects of Wnt signal transduction (Lee et al., 2001; Major et al., 
2007; Salic et al., 2000).  Using this system, we test current models positing that LRP6 
stabilizes β-catenin via degradation of Axin or sequestration of Axin (Figure 2.1).  
Notably, we find that LRP6 can promote β-catenin stabilization in the absence of Axin 
degradation by directly inhibiting GSK3’s phosphorylation of β-catenin. 
 
Methods 
 
Plasmids and Recombinant Proteins 
Axin truncation mutants were made by PCR from full length, Myc-tagged mouse 
Axin and subcloned in pCS2.  AxinΔ298-437 and AxinΔ437-506 have been previously 
described (Salic et al., 2000).  AxinSA harbors Ser-Ala mutations at the following 
predicted GSK3 phosphorylation sites: SANDSEQQSLS.  We refer to mouse Axin 
(GenBank Accession: XM_914907) amino acid (aa) 126 as “start methionine” 
(CSLMQSP).  Mouse and human LRP6ICD (aa1397-1614) (GenBank Accessions:   
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Figure 2.1:  Previously Published Models for the Mechanism by which LRP6 
Stabilizes β-catenin.  In the absence of a Wnt ligand, the destruction complex (Axin, 
APC, and GSK3) promotes phosphorylates of β-catenin, leading to its ubiquitin-mediated 
degradation.  In the presence of a Wnt ligand, LRP6 promotes degradation of Axin, 
which may promote β-catenin stabilization by inhibiting destruction complex formation 
(Tolwinski and Wieschaus, 2004).  Alternatively, Wnt-activated LRP6 recruits Axin and 
may sequester it away from other destruction complex components (Nusse, 2005a).  
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NM_008514 and NM_002336, respectively) were subcloned into pET11-D or pCS2 
using a PCR-based approach.  For Lrp6ICD mRNA (Figure 2.2 only), the intracellular 
domain of mouse LRP6 with an N-terminal myristoylation target sequence was 
engineered into pCS2.  For BiFC, YN (YFP1-154), YC (YFP155-238), LRP6ICD with 
an N-myristoylation sequence, and human β-catenin were cloned into pCS2.  Fusions for 
BiFC were separated by a Ser-Gly-Gly-Gly-Gly-Ser linker.  All oligonucleotide primer 
sequences are available upon request. 
For LRP6ICD purification, BL21 cells harboring LRP6ICD-pET11-D were 
grown to OD600 of 0.3 at 37°C and induced with IPTG (0.3 µg/ml) for 9 hr.  Induced 
bacteria were harvested and protein was purified on Nickel NTA-beads (Qiagen).  Eluted 
protein was concentrated to 1 mg/ml, flash frozen, and stored at –80°C.  For GST-
ubiquitin purification, protein was expressed and purified as above but induced with 
IPTG (1 µg/ml) for 4 hr and purified on glutathione resin. 
 
mRNA Synthesis and RT-PCR  
Capped RNA for embryo injection was synthesized from linearized plasmid DNA 
templates using mMessage mMachine (Ambion).  Animal caps were cut from stage 9 
embryos and cultured in 75% MMR until stage 11.  RT-PCR for siamois, Xnr3, and ODC 
were performed using primers and conditions previously described (Tahinci et al., 2007).  
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Xenopus Egg Extract Degradation Assay and Depletion 
Xenopus egg extract was prepared and degradation assays were performed as 
described (Salic et al., 2000).  Extract was incubated with LRP6ICD at a concentration of 
1.6 µM unless otherwise noted.  In Axin depletion experiments, IVT proteins were made 
in wheat germ lysate (Promega).  Dsh and Axin immunodepletions were performed and 
confirmed as described (Salic et al., 2000) with modifications.  Xenopus egg extract was 
incubated with an equal volume of Protein A-Affiprep beads (BioRad) bound to either 
Dsh or Axin polyclonal antibodies.  Incubation was performed at 4°C for 2 hr with 
inversion every 10 min.  In Figure 2.7, Axin antibody was covalently conjugated to 
Protein A magnetic beads (NEB) for depletion.  
 
λ  Phosphatase Treament 
Samples (0.8 ml) from a Xenopus egg extract degradation assay were added to λ 
phosphatase buffer (12.5 ml) and 400 U λ phosphatase (NEB), incubated for 30 min at 
30°C, and then diluted in sample buffer.  Samples were then processed for SDS-PAGE 
and autoradiography.    
 
Ubiquitination Assay 
Radiolabeled, IVT Axin (1 µl) was incubated at RT with 17.5 µl egg extract 
supplemented with GST-ubiquitin (50 µg/ml) in the presence or absence of LRP6ICD.  
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At indicated times, the reaction was diluted with 100 µl Buffer A (50 mM Tris pH 8, 200 
mM NaCl, 0.1% Tween-20, and 0.1 mM PMSF) and applied to 5 µl glutathione-
Sepharose beads.  After 2 hr shaking at 4°C, the beads were washed with 3 ml Buffer A, 
1 ml Buffer B (50 mM Tris pH 8, 50 mM NaCl, and 0.1 mM PMSF), and eluted with 
sample buffer and analyzed by SDS-PAGE and autoradiography. 
 
Trypsin Digest  
Xenopus egg extract (3 µl) was incubated with IVT, radioloabeled Axin (0.5 µl) 
and GSK3 (15 µg/ml) for 30 min.  Bovine pancreatic trypsin (0.38 mg/ml) (Sigma) was 
added and samples were incubated at RT for 80 sec.  Soybean trypsin inhibitor (0.8 
mg/ml) (Sigma) and sample buffer were then added for analysis by SDS-PAGE and 
autoradiography. 
 
Axin/LRP6ICD Binding Assay 
For Axin pull down, Nickel-NTA beads (10 µl) (Qiagen), LRP6ICD (10 µg), egg 
extract (20 µl), and radiolabeled, wheat germ IVT Axin (2 µl) were combined.  Sample 
volume was adjusted to 40 µl with Buffer A, and samples were incubated at RT for 30 
min.  Buffer A (200 µl) was then added followed by 2 hr shaking at 4°C.  Beads were 
washed with 9 ml Buffer A, and protein was eluted from beads with sample buffer and 
analyzed by SDS-PAGE and autoradiography. 
 
Immunoprecipitation 
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For IP, egg extract (50 µl) was incubated with or without LRP6ICD and IVT β-
catenin (3 µl) for 2 hr.  Buffer A (700 µl) was added to extract with Protein A beads 
covalently conjugated to myc or Axin antibody followed by 2 hr shaking at 4°C.  Beads 
were washed with Buffer A (4 ml), eluted with sample buffer, and analyzed by SDS-
PAGE and immunoblot. 
 
Tau Phosphorylation  
Recombinant Tau (rPeptide, Tau-441) was added to egg extract (40 µg/ml) 
supplemented with GSK3 (NEB) (5 µg/ml).  After 2 hr incubation at RT, extracts were 
immunoblotted.  
 
Kinase Assay 
LRP6ICD or LRP6ICD(PPPAPX5) (4.1 µM), MBP-Axin (0.1 µM) (Salic et al., 
2000), GSK3 (0.79 µM) (NEB), and CK1 (1.37 µM) (NEB) were pre-incubated with 500 
µM ATP and kinase buffer (20 mM HEPES (pH 7.5), 300 mM NaCl, 2 mM DTT, 1 mM  
EDTA, 10 mM MgCl2, and 0.2% Tween 20) for 10 min at RT.  His6-β-catenin (0.22 µM) 
(Salic et al., 2000) and Tau (0.34 µM) (rPeptide Tau-441) were then added and samples 
were removed for immunoblotting after 45 min at RT.  
 
Immunoblotting 
Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and immunoblotted.  Bands were visualized using horseradish peroxidase-conjugated 
secondary antibodies and SuperSignal West Pico or Femto Chemiluminescent Substrate 
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(Pierce).  For reblotting, membranes were stripped by incubation in NaOH (0.4 M) for 15 
min followed by 15 min in H2O and reblocking.  αTubulin was blotted with DM1α 
(Sigma) [1:5,000 dilution].  β-catenin P33/37/41 antibody was purchased from Cell 
Signaling [1:1,000 kinase assay] [1:250 egg extract].  β-catenin P45 antibody was 
purchased from Cell Signaling [1:500].  N-termal Xenopus-β-catenin antibody was a 
generous gift from Barry Gumbiner [1:3,000].  Antibodies for Axin immunodepletion 
and immunoprecipitation were described previously (Salic et al., 2000).  Axin antibody 
for immunoblot was purchased from R & D (Anti-human/mouse/rat Axin 1) [1:100].  
Antibodies to Dsh were described previously (Salic et al., 2000) [1:100].  GSK3 was 
blotted with IH8 (Affinity Bioreagents) [1:500].  6XHistidine tag was blotted with the 
MCA1396 antibody (Serotec).  Phospho-LRP6 (Ser1490) was purchased from Cell 
Signaling [1:500].  Myc was blotted with 9E10 (Sigma) [1:500].  Total Tau was blotted 
with T-1308-1 (rPeptide) [1:15,000].  Antibody to Tau P396 was purchased from Cell 
Signaling [1:500]. 
 
Cell Culture, Transfection, and Bimolecular Fluorescence Complementation (BiFC) 
HEK293 cells were transfected with Lipofectamine 2000 (Invitrogen) and 
maintained in Dulbecco's modified essential medium (DMEM) supplemented with 10% 
fetal bovine serum and antibiotics.  Cells were grown at 37°C in 5% CO2 for 24 hr and 
then incubated at 30°C for 20 hr.  Cells were fixed at RT for 20 min on fibronectin-
coated coverslips with 4% formaldehyde in CB buffer (10 mM MES pH 6.1, 138 mM 
KCl, 3 mM MgCl, 2 mM EGTA) supplemented with 11.66% w/v Sucrose.  Slides were 
mounted with VectorShield containing DAPI stain and imaged using Nikon Eclipse 80i 
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fluorescence microscope with a Nikon 60xA objective and a Cool Snap ES camera.  YFP 
signal was measured by excitation at 515 nm and emission at 555 nm.   All images were 
taken under identical settings.  
 
Results 
 
Recombinant LRP6 Intracellular Domain Protein Activates Wnt/β-catenin 
Signaling in Xenopus Embryos.   
LRP5/6 is a single-span transmembrane Wnt co-receptor.  Expression of the 
LRP5/6 intracellular domain in cultured mammalian cells accurately recapitulates 
LRP5/6 signal transduction, promoting β-catenin stabilization and regulating Wnt/β-
catenin target gene expression (Mi et al., 2006; Mi and Johnson, 2005).  Notably, the 
intracellular domain of LRP6 was recently reported to be generated by a Wnt3a-
regulated, γ-secretase-mediated event, suggesting that the LRP6 intracellular domain may 
play a physiological role in Wnt signaling (Mi and Johnson, 2007).  To obtain soluble 
LRP6 for analysis in biochemically tractable Xenopus egg extract, we bacterially 
expressed and purified recombinant polypeptide encoding the LRP6 intracellular domain 
lacking its transmembrane domain (LRP6ICD; Figure 2.2A and B).   
We first tested whether LRP6ICD activates Wnt/β-catenin signaling in vivo.  
Ventral injection of LRP6ICD protein into Xenopus embryos at a concentration similar to 
that of other pathway components (Lee et al., 2003) induces complete axis duplication 
and promotes transcription of Wnt/β-catenin targets, siamois and Xnr3, in ectodermal  
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Figure 2.2:  Recombinant LRP6ICD Activates Wnt Signaling In Vivo and in 
Xenopus Egg Extract.  (A)  LRP6ICD spans the intracellular domain of mouse LRP6 
(aa1397-1614) and does not include its transmembrane domain.  ECD, extracellular 
domain; ICD, intracellular domain; TM, transmembrane domain; HT, 6Xhistidine tag.  
(B)  Coomassie-stained gel of recombinant LRP6ICD (1 µg) purified from bacteria.  This 
purification was performed by Kristin Kalie Jernigan (K.K.J.) and Christopher Stephen 
Cselenyi (C.S.C.).  (C)  Injection of LRP6ICD protein (33 nM) into each ventral 
blastomere of 4-cell Xenopus embryos promotes development of a complete ectopic axis 
(bottom left panel, embryo side view; bottom right panel, embryo ventral view) in 73% of 
embryos (n=15).  A lower dose of LRP6ICD protein (20 nM) promotes axis duplication 
in 46% of embryos (n=15).  This experiment was performed by Emilios Tahinci (E.T.).  
(D)  Injection of LRP6ICD (33 nM) at the 4-cell stage promotes ectopic transcription of 
Wnt/β-catenin targets Xnr3 and siamois in animal caps as assayed by RT-PCR.  WE, 
whole embryos; Caps, animal caps; WE-RT, no reverse transcriptase added; ODC, 
ornithine decarboxylase (loading control).  This experiment was performed by E.T.  (E)  
Addition of LRP6ICD (1.6 µM) to Xenopus egg extract prevents degradation of 
radiolabeled, IVT β-catenin and promotes degradation of radiolabeled, IVT Axin and 
Axin2.  This experiment was performed by K.K.J. and C.S.C.  (F)  Unlike LRP6ICD, 
LRP6ICD(PPPAPX5) (1.6 µM) does not inhibit β-catenin degradation or promote Axin 
degradation.  (G)  LRP6ICD promotes a reduced mobility of IVT, radiolabeled Axin on 
SDS-PAGE in addition to Axin degradation.   Treatment with λ phosphatase reverses the 
LRP6ICD-induced Axin mobility shift. 
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explants (Figure 2.2C and D).  Our results provide phenotypic and transcriptional 
evidence that recombinant LRP6ICD protein purified from bacteria promotes Wnt/β-
catenin signaling in vivo. 
 
LRP6ICD Promotes β-catenin Stabilization and Axin Degradation in Xenopus Egg 
Extract.   
To establish a cell-free system that would facilitate biochemical analysis of LRP6 
signaling, we tested whether recombinant LRP6ICD, which activates Wnt signaling in 
vivo, prevents degradation of β-catenin in Xenopus egg extract.  We find that LRP6ICD 
protein prevents degradation of radiolabeled, in vitro-translated (IVT) β-catenin in 
Xenopus egg extract (Fig.  2E).  Consistent with a proposed mechanism for LRP6 
signaling, we demonstrate that LRP6ICD also stimulates degradation of IVT Axin and 
Axin2 (Figure 2.2E).  We also tested whether LRP6ICD induces phosphorylation of 
Axin.  We find λ phosphatase reverses the LRP6ICD-mediated upward mobility shift of 
the Axin protein detected by SDS-PAGE, suggesting that LRP6ICD promotes Axin 
phosphorylation (Figure 2.2G).  However, in the presence of LRP6ICD, the total Axin 
signal is decreased even after λ phosphatase treatment, consistent with LRP6ICD 
mediating Axin degradation. 
The ability of LRP6 to stabilize β-catenin is dependent on GSK3’s 
phosphorylation of the serine residue on at least one of five Pro-Pro-Pro-Ser-Pro (PPPSP) 
motifs on LRP6 (Tamai et al., 2004; Zeng et al., 2005).  If LRP6ICD accurately 
reconstitutes endogenous LRP6 signaling in extract, LRP6ICD’s activity should be 
dependent on intact PPPSP motifs.  An LRP6 construct in which all five PPPSP motifs 
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have been mutated to PPPAP (PPPAPX5) does not bind Axin or stabilize β-catenin in 
cultured cells (Tamai et al., 2004).  This construct also fails to activate Wnt target genes 
in Xenopus ectodermal explants (Tamai et al., 2004).  To test whether LRP6ICD 
signaling in egg extract requires intact PPPSP motifs, we expressed and purified 
LRP6ICD(PPPAPX5) protein from bacteria.  In contrast to LRP6ICD, we find that 
LRP6ICD(PPPAPX5) does not inhibit β-catenin degradation or stimulate Axin 
degradation in egg extract (Figure 2.2F).  We also find that LRP6ICD, but not 
LRP6ICD(PPPAPX5), is phosphorylated at PPPSP Ser1490 in egg extract as assayed by 
immunoblot with a previously characterized phospho-LRP6 (Ser1490) antibody (Tamai 
et al., 2004; Zeng et al., 2005) (Figure 2.8C).  Requirement of these PPPSP motifs 
suggests LRP6ICD in extract functions in a manner that is similar to that of LRP6 in 
cultured cells and Xenopus embryos. 
 
LRP6ICD Signals Independently of Dishevelled in Xenopus Egg Extract and 
Embryos.   
Dishevelled (Dsh) is a cytoplasmic protein required for signaling downstream of 
Fz and upstream of the β-catenin destruction complex (Logan and Nusse, 2004).  In 
cultured mammalian cells, overexpression of LRP6 that lacks its extracellular domain 
promotes Wnt signaling despite downregulation of Dsh by RNAi or overexpression of a 
dominant-negative form of Dsh (Li et al., 2002), suggesting the intracellular domain of 
LRP6 can signal independently of Dsh.  More recently, it was shown that Dsh is required 
for LRP6 oligomerization and phosphorylation (Bilic et al., 2007), which are necessary 
for LRP6-mediated activation of Wnt/β-catenin signaling.  Interestingly, LRP6 expressed 
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without its extracellular domain bypasses this requirement for Dsh and is constituitively 
oligomerized and phosphorylated (Bilic et al., 2007).  These data suggest that LRP6ICD 
may mimic Dsh-activated LRP6 and circumvent the requirement for Dsh in Wnt/β-
catenin signaling.   
To test whether LRP6ICD signaling in Xenopus egg extract bypasses its 
requirement for Dsh, we immunodepleted endogenous Dsh from egg extract (Salic et al., 
2000).  Depletion of Dsh (Figure 2.3A) did not affect the ability of LRP6ICD to stabilize 
β-catenin or promote Axin degradation (Figure 2.3B).  To determine if Dsh is required 
for LRP6ICD signaling in vivo, we tested whether Xdd1 (a dominant negative form of 
Dsh (Sokol, 1996)) prevents LRP6’s activation of the Wnt/β-catenin pathway in Xenopus 
embryos.  In mRNA co-injection experiments, Xdd1 inhibits Wnt8-induced secondary 
axis formation but has no effect on the ability of LRP6ICD to induce secondary axes 
(Figure 2.3C).  Thus, our data in Xenopus egg extract and embryos demonstrate that 
LRP6ICD signals independently of Dsh and are consistent with a model in which 
LRP6ICD mimics Dsh-activated LRP6 in Wnt/β-catenin signaling (Bilic et al., 2007).   
Phosphorylation and activation of LRP6 (upon Wnt signaling) are believed to be 
due to relief of a conformational constraint mediated by LRP6’s extracellular domain, 
and this may explain why the intracellular domain of LRP6 mimics a constitutively 
phosphorylated and active form of the receptor (Bilic et al., 2007).  Axin-bound GSK3 
has been suggested to play a role in phosphorylation and activation of LRP6 (Zeng et al., 
2008).  Because phosphorylation of LRP6 is a prerequisite for its binding to Axin (Tamai 
et al., 2004), however, the initial phosphorylation of LRP6 may occur by a pool of GSK3 
that is not bound to Axin.  In egg extract where Axin has been immunodepleted, we find  
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Figure 2.3:  LRP6ICD Signals Independenly of Dsh in Xenopus Egg Extract and 
Embryos.  (A)  Immunoblot of Dsh-depleted and mock-depleted (Protein A beads) egg 
extract.  (B)  Dsh depletion does not affect the ability of LRP6ICD to promote β-catenin 
stabilization or Axin degradation in egg extract.  (C)  To compare Xdd1 mRNA-mediated 
suppression of Xwnt8 mRNA-induced and LRP6ICD mRNA-induced axis duplication, 
mRNAs were titrated to promote axis duplication in 50-60% of injected embryos.   
Dominant negative Dsh (Xdd1) (1 ng RNA) prevents axis duplication by Wnt8 (1pg 
RNA) but not by LRP6ICD (500 pg).  For duplication assays, Xenopus embryos were 
injected in each ventral blastomere at the 4-cell stage.  This experiment was performed by 
E.T.   
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that LRP6ICD still becomes phosphorylated at PPPSP Ser 1490 as assayed by 
immunoblot, suggesting that initial LRP6 phosphorylation may occur independently of 
Axin. 
 
LRP6ICD-Mediated Axin Degradation Occurs Via the Ubiquitin/Proteasome 
Pathway and Is Distinct from GSK3-Regulated Axin Degradation.   
To identify the mechanism by which LRP6 promotes Axin degradation, we tested 
whether LRP6ICD induces Axin degradation via a ubiquitin-mediated, proteasome-
dependent process.  We find LRP6ICD promotes Axin ubiquitination in Xenopus egg 
extract (Figure 2.4A).  Furthermore, we show that inhibition of the proteasome with 
MG132 prevents Axin degradation, leading to accumulation of a slower migrating form 
of Axin (Figure 2.4B).  Thus, our data indicate that, consistent with results from intact 
Xenopus oocytes (Kofron et al., 2007), Axin degradation is proteasome-dependent in egg 
extract. 
To uncover structural elements of Axin required for its LRP6-mediated 
degradation, we analyzed a panel of truncated Axin polypeptides.  We identified a 
minimal Axin fragment (Axin375-809) that degrades in response to LRP6ICD (Figures 
2.4C and 2.5).  This minimal fragment includes the GSK3, β-catenin, and PP2A binding 
sites on Axin (Fagotto et al., 1999).  However, deletion of the GSK3 or β-catenin binding 
domain from full-length Axin does not prevent its LRP6ICD-mediated turnover (Figure 
2.4C); thus, binding of Axin to GSK3 or β-catenin may not be required for LRP6-
mediated degradation of Axin.  Interestingly, amino acids 375-427 appear to be required 
in the large N-terminal truncation mutants (compare Axin375-809 and Axin427-809) but  
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Figure 2.4:  LRP6ICD Mediates Axin Degradation Independently of GSK3 
Inhibition.  (A)  LRP6ICD stimulates addition of GST-ubiquitin to radiolabeled, IVT 
Axin in egg extract.  GST-ubiquitin conjugates were pulled down with glutathione beads 
at indicated times and analyzed by SDS-PAGE and autoradiography.  Asterisk indicates 
full-length Axin.  This experiment was performed by K.K.J.  (B)  Addition of the 
proteasome inhibitor MG132 (1 mM) to egg extract inhibits LRP6ICD-mediated Axin 
degradation.  This experiment was performed by Curtis Thorne.  (C)  Degradation of 
Axin mutants in egg extract in the presence of LRP6ICD.  RGS, RGS domain; GBS, 
GSK3 Binding Site; βBS, β-catenin Binding Site; DIX, DIX domain.  The indicated 
LRP5/6 binding region on Axin is based on previous Axin-LRP5 and Axin-Arr yeast 
two-hybrid studies (Mao et al., 2001b; Tolwinski et al., 2003); dotted lines represent 
large deletions of Axin that were not further mapped, and the borders of Axin-LRP5/6 
interaction likely reside within the dotted lines.  (D) LRP6ICD promotes degradation of 
Axin and Axin375-869, whereas the GSK3 inhibitor BIO (50 mg/ml, Calbiochem) 
promotes degradation of Axin but not Axin375-869.  (E)  LRP6ICD promotes 
degradation of Axin and Axin375-869, whereas the GSK3 inhibitor LiCl (50 mM) 
promotes degradation of Axin but not Axin375-869.  (F)  Inhibition of GSK3-mediated 
Axin phosphorylation (by LiCl (50 mM) or mutagenesis (AxinSA)), but not incubation 
with LRP6ICD, alters the trypsin proteolysis pattern of IVT Axin after incubation in egg 
extract for 30 min (note bands at level of asterisk).  All experiments used equal 
concentrations of IVT Axin.  An SDS-PAGE autoradiograph of IVT Axin and AxinSA 
prior to trypsin treatment is shown at right. 
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Figure 2.5:  LRP6ICD Stimulates Degradation of Axin Truncation Mutants in Egg 
Extract.  (A)  IVT, radiolabeled Axin degradation assays in the presence or absence of 
LRP6ICD in Xenopus egg extract.   Samples were analyzed at either 0 hr and 3 hr (two 
lanes) or 0 hr, 1 hr, and 3 hr (three lanes).   In all experiments, wild-type Axin is used to 
confirm LRP6ICD activity (data not shown).   Amino acids corresponding to mAxin’s 
initiation methionine, RGS domain, GSK3 Binding Site, β-catenin Binding Site, and DIX 
domain are shown.   Axin with internal deletions of the GSK3 and β-catenin binding sites 
are AxinΔ298-437 and AxinΔ437-506, respectively.   Predicted GSK3 phosphorylation 
sites on Axin mutated in AxinSA are indicated with bold text.  (B)  To highlight effects 
of LRP6ICD on Axin stability, egg extracts with low basal Axin turnover were used for 
experiments in Figure  2.5A.   In other batches of egg extract, Axin truncation mutants 
lacking putative GSK3 phosphorylation sites shown to regulate Axin stability have 
increased rates of basal degradation compared to wild-type Axin.   In these extracts, 
LRP6ICD retains the ability to promote degradation of these Axin truncation mutants 
(data not shown). 
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not in the internally truncated AxinΔGBS; we believe this may result from abnormal 
folding of certain truncation mutants, redundancy within Axin regarding sequences 
required for LRP6ICD-mediated Axin degradation, and/or dimerization of certain Axin 
mutants with endogenous Axin (Luo et al., 2005).  Notably, we find that the region of 
Axin identified to bind LRP5/6 by yeast two-hybrid assays (Mao et al., 2001b; Tolwinski 
et al., 2003), also appears to be required for its LRP6-mediated degradation (Figure 
2.4C).  These data are consistent with a model in which LRP6/Axin binding is required 
for LRP6-mediated Axin degradation. 
Several models for Wnt pathway activation involve inhibition of GSK3, positing 
global inhibition of GSK3 within the cell or specific inhibition of GSK3 within the β-
catenin destruction complex.  Either mechanism would allow β-catenin levels to rise 
because its phosphorylation, which is necessary for its degradation, is blocked.  
Experiments suggest an inherent feed-forward mechanism whereby GSK3 inhibition also 
stimulates Axin degradation by preventing phosphorylation of Axin, which is normally 
required for its stability (Yamamoto et al., 1999).  Thus, we tested whether LRP6ICD 
promotes Axin degradation by inhibiting GSK3-mediated phosphorylation of Axin.   
If LRP6ICD promotes turnover of Axin by inhibiting its GSK3-mediated 
phosphorylation, Axin mutants that degrade in response to LRP6ICD should also be able 
to degrade in response to GSK3 inhibition.  Alternatively, if LRP6ICD-mediated Axin 
turnover does not occur via GSK3 inhibition, certain Axin mutants may degrade in 
response to LRP6ICD but not in response to GSK3 inhibition.  We find evidence in 
support of the latter model.  Both LRP6ICD and the GSK3 inhibitor BIO (Figure 2.4D) 
promote turnover of full-length Axin; in contrast, Axin375-869 degrades in response to 
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LRP6ICD but not the GSK3 inhibitor BIO (Figure 2.4D).  Another GSK3 inhibitor, 
lithium (50 mM), also promotes turnover of full-length Axin but not Axin375-869 
(Figure 2.4E).  Furthermore, Axin mutants lacking previously identified GSK3 
phosphorylation and binding sites as well as an Axin mutant (AxinSA) in which 
predicted GSK3 phosphorylated serines are mutated to alanines (Yamamoto et al., 1999) 
degrade in response to LRP6ICD (Figures 2.4C and 2.5).  Together, these data indicate 
that LRP6 is unlikely to promote Axin degradation via a mechanism that inhibits GSK3-
mediated stabilization of Axin.   
Distinct mechanisms underlying LRP6-mediated and GSK3 inhibition-mediated 
Axin degradation may induce different Axin conformations.  Because changes in a 
protein’s conformation may expose or conceal certain tryptic cleavage sites, a protein’s 
tryptic proteolysis pattern is traditionally used to detect conformational changes (Liu et 
al., 2005; Moroney and McCarty, 1982; Stukenberg and Kirschner, 2001).  Incubation of 
radiolabeled, IVT Axin in egg extract followed by partial trypsin proteolysis results in a 
characteristic Axin digestion pattern upon analysis by SDS-PAGE and autoradiography 
(Figure 2.4F).  Trypsin digestion of Axin lacking GSK3 phosphorylation (either via 
mutation (AxinSA) or incubation with a GSK3 inhibitor (LiCl)) results in a proteolysis 
pattern distinct from wild-type Axin.  Incubation of Axin with LRP6ICD, however, 
yields a digestion pattern that is indistinguishable from that of Axin alone.  Because 
addition of LRP6ICD and inhibition of GSK3 phosphorylation have distinct effects on 
Axin conformation as assayed by trypsin digest, we propose that LRP6 signaling and 
GSK3 inhibition affect Axin, at least in part, through different mechanisms.  These 
biochemical data are consistent with genetic evidence in Drosophila embryos that Arrow, 
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the Drosophila LRP5/6 ortholog, can promote Axin degradation in the absence of GSK3 
activity (Tolwinski et al., 2003).   
 
GSK3’s Phosphorylation Sites on Axin Contribute Additively to Axin Stability. 
To better understand how GSK3’s phosphorylation of Axin regulates its stability, 
we made point mutations of serines in Axin’s predicted GSK3 phosphorylation region 
(SANDSEQQSLS) (Figure 2.6A).  In previous work, mutation of this region to 
AANDAEQQALS decreased the half-life of Axin transfected into cultured mammalian 
cells.  Notably, the half-life of wild-type Axin could be decreased similarly by addition of 
a GSK3 inhibitor to these cells.  As the serines in this region are GSK3 consensus sites, it 
was suggested that GSK3 phosphorylation of these sites regulates Axin stability.  
However, further investigation of these putative phosphorylation sites was not 
undertaken.  We find that these serines contribute to Axin stability in an additive fashion.  
Wild-type Axin containing all four serines was most stable in egg extract, and 
degradation increased significantly as the number of serines mutated to alanine was 
increased (Figure 2.6A).  Thus, we find that all of the SANDSEQQSLS serines affect 
Axin stability, and that these serines contribute to Axin stability in an additive fashion.  
Such a finding is consistent with a mechanism whereby these phosphorylated serines 
contribute to binding of another protein that regulates Axin stability or contribute to Axin 
assuming a conformation with a decreased half-life. 
Because we found that wild-type Axin incubated with a GSK3 inhibitor or 
AxinSA (AANDAEQQSLA) has a distinct trypsin proteolysis pattern from wild-type 
Axin, we tested whether mutations of fewer serines also affected Axin conformation.   
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Figure 2.6:  GSK3’s Phosphorylation Sites on Axin Contribute Additively to Axin 
Stability.  (A)  Basal degradation of Axin mutants with Ser-Ala substitutions in the 
GSK3 phosphorylation region (S1ANDS2EQQS3LS4) increases with the number of Ala 
mutations.  For simplification, only serine residues (and not intervening residues) are 
noted in figure.  Basal degradation of Axin with 4 Ser > 3 Ser > 2 Ser > 1 Ser.  Fold 
degradation is (0 hr band)/(3 hr band) as quantified by ImageQuant analysis of digital 
PhosphorImager file.  (B)  Trypsin proteolysis pattern of Axin in egg extract is altered by 
mutations of GSK3 phosphorylation region.  Axin(SSSS, 4 Ser) produces a trypsin 
proteolysis fragment that is less abundant in Axin(SSAS, 3 Ser) and absent in 
Axin(ASSA, 2 Ser) and Axin(AASA, 1 Ser).  Note bands shown at right of asterisks.  (C)  
As shown in Figure 2.4F, inhibition of GSK3-mediated Axin phosphorylation (by LiCl 
(50 mM)) or mutagenesis (AxinSA(AASA, 1 Ser)) alters the trypsin proteolysis pattern 
of IVT Axin after incubation in egg extract for 30 min.  Notably, AxinSR(RRRS) has a 
proteolysis pattern similar to AxinSA(AASA).  Note bands at levels of asterisks.  (D)  
Ser-Ala substitutions in the GSK3 phosphorylation region of Axin affect LiCl-mediated 
alterations in their trypsin proteolysis patterns.  Axin(SSSS, 4 Ser), Axin(SSAS, 3 Ser), 
and Axin(ASSA, 2 Ser) have LiCl-sensitive trypsin proteolysis pattern, while 
Axin(AASA, 1 Ser) does not.  Note LiCl sensitive bands marked by * and #.    
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Given the effects of such mutations on Axin stability, we hypothesized that these serines 
would affect Axin’s confirmation as assayed by trypsin digest in an additive fashion.  
Indeed, incubation of radiolabeled wild-type Axin in egg extract followed by trypsin 
proteolysis leads to a proteolysis pattern in which there is a prominent band that is 
decreased in intensity with mutation of one serine and absent with mutation of two or 
three serines (Figure 2.6B).  We attempted to make an Axin mutant that would be 
constituitively stable and insensitive to GSK3 inhibition by replacing these serines with 
negatively charged, possibily phospho-mimetic aspartic acid residues; however, this 
mutant was most similar to the AxinSA mutant, suggesting that these substituted amino 
acids were not sufficiently similar to phosphorylated serines (Figure 2.6C).  To further 
explore the role of these serines as GSK3 phosphorylation sites, we tested whether our 
serine to alanine substitution mutants were sensitive to GSK3 inhibition by assaying their 
trypsin proteolysis patterns.  We find that the proteolysis patterns of mutants with four, 
three, and two serines retain sensitivity to LiCl-mediated GSK3 inhibition (Figure 2.6D).  
This result supports our hypothesis that these four serines contribute to Axin stability and 
conformation in an additive fashion.  Although this mechanism for control of Axin 
stability appears to be independent of LRP6-mediated regulation of Axin stability and 
beyond the scope of this work, an understanding of the mechanism by which this region 
affects Axin stability will contribute significantly to our knowledge of the mechanism of 
Wnt/β-catenin signaling. 
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LRP6ICD-Mediated β-catenin Stabilization Does Not Require Axin Degradation.   
Although we hypothesize that LRP6-mediated degradation of Axin, a required 
component of the β-catenin destruction complex, leads to β-catenin stabilization, we 
wanted to determine whether this is the only mechanism by which LRP6ICD stabilizes β-
catenin.  To explicitly test this model, we assessed whether LRP6ICD can stabilize β-
catenin in egg extract in which endogenous Axin is replaced by a non-degradable Axin 
mutant, Axin1-713 (Figure 2.7D).  Axin1-713, like full-length Axin, ventralizes Xenopus 
embryos (indicative of inhibition of Wnt/β-catenin signaling) (data not shown), 
stimulates β-catenin degradation in egg extract (Figure 2.7D), and binds LRP6ICD in egg 
extract (Figure 2.7A).  Thus, Axin1-713 retains all measurable activities of full-length 
Axin except that it is not degraded in response to LRP6ICD (Figure 2.4C).  Consistent 
with the requirement of Axin for destruction complex formation, immunodepletion of 
endogenous Axin from extract (Figure 2.7B) prevented β-catenin degradation (Salic et 
al., 2000) (Figure 2.7D).  Addition of IVT Axin1-713 to Axin-depleted extract restored 
β-catenin degradation to an extent similar to that of addition of full-length Axin.  We then 
tested whether LRP6ICD inhibits β-catenin degradation in Axin1-713-rescued extract.  
As shown in Figure 2.7D, LRP6ICD inhibits β-catenin degradation in extract where 
endogenous Axin is replaced by either full-length Axin or non-degradable Axin1-713.  
Thus, LRP6ICD can inhibit β-catenin degradation independently of Axin degradation in 
Xenopus egg extract. 
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Figure 2.7.  LRP6ICD Promotes β-catenin Stabilization in the Absence of Axin 
Degradation.  (A)  Axin and non-degradable Axin1-713, but not Axin1-427, bind 
LRP6ICD in egg extract.  Radiolabeled Axin, Axin1-713, and Axin1-427 were incubated 
with 6XHis-tagged LRP6ICD and pulled down with nickel beads.   Binding was 
performed in egg extract to increase the stringency of binding reaction conditions and 
because post-translational modification of LRP6 (e.g.  phosphorylation) is important for 
Axin/LRP6 binding.   The signal representing 10% of the total amount of IVT used in the 
binding experiments is indicated.   LRP6ICD increases the amount of Axin and Axin1-
713, but not Axin1-427, that is pulled down with nickel beads.   IVT Axin and Axin1-713 
pulled down with nickel beads in the presence of LRP6ICD also display a similar 
increase in mobility on SDS-PAGE.   These data suggest Axin and Axin1-713 bind LRP6 
in a similar manner.   Binding of nickel beads to 6XHis-tagged LRP6ICD occupies the 
Ni++ sites on the nickel resin, potentially blocking its nonspecific binding to IVT Axin.   
This likely explains why there is less IVT Axin background binding in the lane with 
LRP6ICD compared to IVT Axin alone.  (B)  Western blot confirms immunodepletion of 
Axin from Xenopus Egg Extract.  Axin immunoblot of mock (Protein A bead) and Axin-
depleted egg extract from Figures 2.7D.  Western blotting of tubulin is performed as 
loading control. (C)  Western blot confirms immunodepletion of Axin from Xenopus egg 
extract.  Axin immunoblot of mock (Protein A bead) and Axin-depleted egg extract from 
Figures 2.8D and 2.8E.  Western blotting of tubulin is performed as loading control.  (D)  
LRP6ICD inhibits β-catenin degradation in extract where endogenous Axin is replaced 
by non-degradable Axin1-713.  Addition of IVT Axin or Axin1-713 restores the ability 
of Axin-depleted extract to degrade radiolabeled β-catenin.  LRP6ICD inhibits both IVT 
Axin and Axin1-713-induced β-catenin-degradation.  This experiment was performed by 
K.K.J. and C.S.C. 
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LRP6ICD Prevents GSK3-Mediated Phosphorylation of β-catenin. 
We next sought to identify the mechanism by which LRP6 stabilizes β-catenin 
independently of Axin degradation.  It has been proposed that LRP6 might inhibit β-
catenin degradation by promoting dissociation of the β-catenin destruction complex 
(Nusse, 2005) (Figure 2.1).  To test this model, we immunoprecipitated Axin from egg 
extract incubated in the presence or absence of LRP6ICD and immunoblotted for GSK3 
or β-catenin.  As shown in Figure 2.8A and B, LRP6ICD (at a concentration that fully 
inhibits β-catenin degradation in Xenopus egg extract) does not affect Axin’s ability to 
bind GSK3 or β-catenin.  Thus, our data suggest that LRP6 does not stabilize β-catenin 
by sequestering Axin from GSK3 or β-catenin. 
Alternatively, LRP6 could stabilize β-catenin by directly preventing its 
phosphorylation within the destruction complex.  CK1α phosphorylates β-catenin at 
Ser45 (P45) to prime it for GSK3’s phosphorylation at Ser33/Ser37/Thr41 (P33/37/41), 
which is required for β-catenin polyubiquitination and degradation (Liu et al., 2002).  
Previous studies showed Wnt signaling inhibits GSK3-mediated β-catenin 
phosphorylation but does not inhibit CK1a-mediated β-catenin phosphorylation (Liu et 
al., 2002).  We therefore tested whether LRP6ICD inhibits appearance of GSK3-
phosphorylated β-catenin in egg extract.  Significantly, LRP6ICD, like the GSK3 
inhibitor lithium, inhibits GSK3-mediated phosphorylation of β-catenin (Figure 2.8C).  If 
LRP6 stabilizes β-catenin through inhibition of β-catenin phosphorylation, LRP6ICD’s 
requirement for intact PPPSP motifs to stabilize β-catenin should extend to LRP6ICD’s 
inhibition of β-catenin phosphorylation.  Indeed, LRP6ICD(PPPAPX5), which does not 
inhibit degradation of β-catenin (Figure 2.2F), does not inhibit GSK3’s phosphorylation  
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Figure 2.8:  LRP6ICD’s Inhibition of GSK3-Mediated β-catenin Phosphorylation 
Stabilizes β-catenin in the Absence of Axin Degradation.  (A)  LRP6ICD does not 
affect the ability of Axin to bind GSK3 or β-catenin in egg extract.  Endogenous Axin 
was immunoprecipitated from extract and immunoblotted for GSK3, β-catenin, and Axin.  
(B)  LRP6ICD Does Not Inhibit Myc-Tagged Axin Binding to GSK3 or β-catenin in Egg 
Extract.  IVT, Myc-Axin was incubated in egg extract in the presence or absence of 
LRP6ICD.   Myc-Axin was then immunoprecipitated with Myc-conjugated beads and 
immunoblotted for Myc, β-catenin, or GSK3.   IVT β-catenin was supplemented to 
extract to enhance its signal.  (C)  Incubation of LiCl (50 mM) or LRP6ICD (but not 
LRP6ICD(PPPAPX5)) in egg extract (30 min) inhibits phosphorylation of endogenous β-
catenin at GSK3 target sites P33/37/41.  Immunoblot of LRP6ICD from the same gel 
reveals LRP6ICD, but not LRP6ICD(PPPAPX5), is phosphorylated at the PPPSP 
Ser1490.  All samples were blotted from a single gel.  (D)  Levels of endogenous β-
catenin in egg extract are not affected by Axin depletion.  Immunoblot for endogenous β-
catenin demonstrates that manipulations shown in Figure 8E do not affect total β-catenin 
levels.   This likely reflects the fact that the β-catenin involved in Wnt signal transduction 
represents only a small, cytoplasmic fraction of total β-catenin.   The vast majority of β-
catenin in cells and egg extracts belongs to a stable, membrane-bound pool of β-catenin 
that is not normally regulated by the destruction complex or Wnt signaling (Heasman et 
al., 1994; Peifer et al., 1994b).  (E)  LRP6ICD inhibits GSK3-mediated β-catenin 
phosphorylation in extract in which endogenous Axin is replaced by non-degradable 
Axin1-713.  Axin depletion did not affect total β-catenin levels as assayed by 
immunoblot (Figure 2.8D).  Depletion of endogenous Axin prevents β-catenin P33/37/41 
phosphorylation.  Addition of IVT Axin1-713 restores β-catenin phosphorylation in 
Axin-depleted extract.  LRP6ICD inhibits IVT Axin1-713-induced β-catenin 
phosphorylation.  Extracts were analyzed after 2 hr incubation.  All samples were blotted 
from a single gel; intervening lanes were removed for clarity. 
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of β-catenin (Figure 2.8C).  Notably, we find that LRP6’s PPPSP serine Ser1490 is 
phosphorylated in extracts (Figure 2.8C).  Thus, LRP6ICD inhibits phosphorylation of β-
catenin likely through a mechanism that requires serine phosphorylated PPPSP motifs. 
Phosphorylation of β-catenin by GSK3 requires its recruitment into the β-catenin 
destruction complex, which is mediated in part by Axin.  Thus, it was possible that 
LRP6ICD-induced inhibition of GSK3’s phosphorylation of β-catenin is a direct 
consequence of LRP6-mediated Axin degradation.  To address this possibility, we tested 
whether LRP6ICD inhibits β-catenin P33/37/41 phosphorylation in egg extract in which 
Axin is replaced by non-degradable Axin1-713 (Figure 2.8D and E).  Axin depletion 
(Figure 2.7C) from extract inhibited GSK3’s phosphorylation of β-catenin, consistent 
with Axin’s role as a required scaffold for this phosphorylation event.  Addition of non-
degradable IVT Axin1-713 to Axin-depleted extract restored β-catenin P33/37/41 
phosphorylation.  LRP6ICD blocked this Axin1-713-induced β-catenin phosphorylation 
(Figure 2.8E), demonstrating that LRP6ICD can inhibit phosphorylation of β-catenin by 
GSK3 independently of Axin degradation. 
LRP6ICD in egg extract could specifically prevent β-catenin phosphorylation or 
act as a general GSK3 inhibitor (possibly by GSK3 sequestration (Mi et al., 2006)).  If 
the former is correct, LRP6 should inhibit β-catenin phosphorylation without affecting 
phosphorylation of another GSK3 substrate (e.g.  Tau) (Figure 2.9A).  In egg extract 
supplemented with exogenous GSK3, recombinant Tau is phosphorylated at its well-
characterized GSK3 target site Ser396 (P396) (Hong et al., 1997).  In contrast to lithium, 
which robustly inhibits GSK3’s phosphorylation of both β-catenin and Tau, LRP6ICD 
inhibits phosphorylation of β-catenin but not of Tau.  Thus, our data indicate that levels  
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Figure  2.9:  LRP6ICD Directly and Specifically Inhibits GSK3’s Phosphorylation of 
β-catenin.  (A)  LiCl (50 mM) inhibits phosphorylation of β-catenin P33/37/41 and 
exogenous Tau P396 by GSK3, whereas LRP6ICD inhibits phosphorylation of β-catenin 
but not Tau by GSK3.  Extract was supplemented with GSK3 to enhance detection of 
phosphorylated Tau as previously described (Yost et al., 1998).  β-catenin and Tau from 
the same reaction sample were immunoblotted from a single gel; intervening lanes were 
removed for clarity.  (B) and (D)  In an in vitro kinase assay containing purified, 
recombinant Axin (0.1 µM), GSK3 (0.79 µM), CK1 (1.37 µM), Tau (0.34 µM) and β-
catenin (0.22 µM), LRP6ICD (4.1 µM) inhibits phosphorylation of β-catenin P33/37/41 
by GSK3 without inhibiting the phosphorylation of Tau P396 by GSK3.  (C)  LRP6ICD 
does not inhibit CK1 phosphorylation of β-catenin in vitro.  In an in vitro kinase assay 
with recombinant, purified proteins, LRP6ICD does not inhibit phosphorylation of β-
catenin P45 by CK1.   For this figure, nitrocellulose membrane from Figure 2.9B was 
stripped and re-blotted with antibody to β-catenin P45.  (E)  In a kinase reaction in which 
recombinant Axin is absent, phosphorylation of β-catenin by GSK3 is inhibited by 
LRP6ICD but not by LRP6ICD(PPPAPX5).  For (B), (C), (D), and (E), β-catenin and 
Tau were incubated in the same reaction and immunoblotted from a single gel. 
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of LRP6ICD that stabilize β-catenin in egg extract inhibit GSK3-mediated β-catenin 
phosphorylation without affecting global GSK3 activity.  Our finding that LRP6ICD does 
not act by inhibiting total GSK3 activity is also supported by our data demonstrating that 
LRP6ICD and lithium have distinct effects on Axin’s trypsin proteolysis pattern and that 
LRP6 promotes Axin degradation independently of GSK3 inhibition (Figures 2.4C, D, E, 
F, and 2.5).  Although previous experiments suggested that LRP6 inhibits global GSK3 
activity, the concentration of LRP6 intracellular domain in those experiments was not 
reported and may have been significantly greater than the concentration of LRP6ICD 
used in our experiments (Mi et al., 2006).   Indeed, we detected inhibition of GSK3’s 
phosphorylation of both β-catenin and Tau at higher concentrations of LRP6ICD than 
those required to inhibit β-catenin phosphorylation in our assays. 
 
LRP6ICD Directly Inhibits GSK3-Mediated β-catenin Phosphorylation.   
The simplest model for LRP6 signaling is that it directly inhibits β-catenin 
phosphorylation by GSK3.  Alternatively, LRP6-mediated inhibition of β-catenin 
phosphorylation may require additional components.  To determine if LRP6ICD is 
sufficient to inhibit GSK3-mediated β-catenin phosphorylation, we tested whether we 
could reconstitute LRP6 signaling with purified components.   
In a kinase assay with purified, recombinant proteins, LRP6ICD inhibits GSK3-
mediated phosphorylation of β-catenin at P33/37/41 without inhibiting CK1’s 
phosphorylation of β-catenin at P45 (Figure 2.9B, C, and D).  Importantly, the 
concentration of LRP6ICD tested does not inhibit GSK3’s phosphorylation of Tau in the 
same reaction, demonstrating that inhibition of β-catenin phosphorylation by LRP6ICD is 
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not a result of general inhibition of GSK3 activity (Figure 2.9B and C).  Thus, LRP6ICD 
preferentially inhibits GSK3’s phosphorylation of β-catenin in a kinase assay with 
purified components.   
The ability of GSK3 to phosphorylate β-catenin independently of Axin (albeit 
inefficiently) in our purified system allowed us to test whether LRP6ICD inhibits GSK3’s 
phosphorylation of β-catenin directly or indirectly (via a conformational change of Axin 
upon its binding to LRP6ICD).  Significantly, we find that Axin is not required for 
LRP6ICD’s inhibition of β-catenin P33/37/41 phosphorylation (Figure 2.9B).  In 
addition, CK1g’s phosphorylation plays a role in LRP6 signaling in vivo (Davidson et al., 
2005), but CK1 is not required for LRP6ICD activity in our kinase assay (Figure 2.9B 
and D).  These results demonstrate that LRP6ICD can directly inhibit GSK3-mediated 
phosphorylation of β-catenin and that this inhibition does not require other components. 
Next, we tested whether LRP6 requires intact PPPSP motifs to inhibit GSK3’s 
phosphorylation of β-catenin in our purified system.  Unlike LRP6ICD, 
LRP6ICD(PPPAPX5) does not inhibit GSK3’s phosphorylation of β-catenin (Figure 
2.9D), demonstrating that LRP6’s PPPSP motifs are required for LRP6 to inhibit β-
catenin phosphorylation in vitro.  In a kinase assay with recombinant proteins, GSK3 
phosphorylates LRP6 in a manner that requires intact PPPSP motifs (data not shown and 
(Mi et al., 2006)).  Thus, we infer that phosphorylation of PPPSP serines by GSK3 is 
required for LRP6’s ability to inhibit β-catenin phosphorylation in our purified, 
reconstituted system.  Our purified system exhibits specific properties that are consistent 
with in vivo and egg extract data: 1) requirement for PPPSP serines (Tamai et al., 2004; 
Zeng et al., 2005), 2) specificity for inhibition of β-catenin and not Tau phosphorylation 
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(Figure 2.9A), and 3) inhibition of β-catenin phosphorylation by GSK3 but not CK1 (Liu 
et al., 2002).  Thus, we believe these studies recapitulate distinct properties of LRP6-
mediated signaling in vivo. 
 
LRP6ICD Associates with β-catenin In Vivo.  
Given that LRP6ICD is sufficient to inhibit GSK3-mediated β-catenin 
phosphorylation in a kinase assay with purified proteins, we hypothesized that LRP6ICD 
may directly interact with β-catenin to prevent its GSK3-mediated phosphorylation.  To 
determine whether β-catenin and LRP6ICD can interact in cultured mammalian cells, we 
performed Bimolecular Fluorescence Complementation (BiFC) between β-catenin and 
LRP6ICD (Hu et al., 2002).  In this assay, interacting proteins that are fused to N- and C-
terminal halves, respectively, of yellow fluorescent protein (YFP) bring the two halves of 
YFP in close enough association to produce a functional, fluorescent YFP molecule.  
BiFC-mediated fluorescence requires a relatively stable protein-protein interaction in the 
range of several seconds and detects direct or very close interactions within protein 
complexes (Hu et al., 2002).  Similar to fluorescence energy transfer (FRET), BiFC 
indicates a potential for physical interaction in a cell.  As a positive control, cells 
transfected with N- and C-terminal halves of YFP fused to separate Glutathione S-
Transferase (GST) proteins (which have been shown to oligomerize) produce 
cytoplasmic YFP fluorescence in approximately 50% of cells (Figure 2.10).  In contrast, 
none of the cells transfected with N-and C-terminal halves of YFP fused to LRP6ICD and 
GST, respectively, or fused to GST and β-catenin, respectively, produce any detectable 
fluorescent signal (Figure 2.10).  In addition, the individual fusion proteins, when  
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Figure 2.10:  BiFC Analysis of LRP6ICD and β-catenin Interaction In Vivo.  
Fluorescence is detected in HEK293 cells transfected with plasmids encoding LRP6ICD-
YN plus β-catenin-YC and GST-YN plus GST-YC (positive control).   No fluorescence 
is detected in cells transfected with plasmids encoding LRP6ICD-YN plus GST-YC, β-
catenin-YC plus GST-YN, or any of the individual fusion constructs.  YN and YC 
represent the N-terminal (1-154) and C-terminal (155-238) halves of YFP, respectively.  
DAPI staining (blue) is used to visualize cell nuclei.  This experiment was performed by 
K.K.J. 
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expressed in cells alone, do not produce fluorescence (data not shown).  Importantly, 
cells transfected with N- and C-terminal halves of YFP fused to LRP6ICD and β-catenin, 
respectively, produce functional, fluorescent YFP in approximately 15% of cells (Figure 
2.10).  These results indicate that LRP6ICD and β-catenin form a stable interaction in 
vivo (likely within the Axin complex). 
 
Discussion 
We provide evidence that LRP6 can promote β-catenin stabilization 
independently of Axin degradation by inhibiting GSK3’s phosphorylation of β-catenin.  
This mechanism is consistent with cultured cell experiments demonstrating Wnt-
mediated stabilization of β-catenin in the absence of Axin degradation (Liu et al., 2005).  
Intriguingly, we find that LRP6 directly and specifically inhibits GSK3’s phosphorylation 
of β-catenin in vitro, independently of Axin.  It has been previously shown that addition 
of Wnt ligand to cultured mammalian cells rapidly induces recruitment of Axin to 
LRP5/6 (Mao et al., 2001b).  We propose that this interaction between LRP5/6 and Axin 
serves to bring LRP5/6 in close proximity to β-catenin and GSK3, allowing for inhibition 
of β-catenin phosphorylation.  Consistent with this hypothesis, we find that LRP6ICD 
and β-catenin can interact in cultured cells (Figure 2.10).  We also find that LRP6 
requires intact PPPSP motifs to directly inhibit GSK3’s phosphorylation of β-catenin.  
Thus, we propose a working model (Figure 2.11).  A Wnt signal induces GSK3’s and 
CK1γ’s phosphorylation of LRP5/6, which promotes the binding of Axin to LRP5/6 
(Davidson et al., 2005; Zeng et al., 2005).  Axin thereby brings β-catenin and GSK3 in 
close proximity to LRP5/6 where its phosphorylated PPPSP motifs are involved in  
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Figure 2.11.  Our Model for the Mechanism by which LRP6 Stabilizes β-catenin.  In 
the absence of a Wnt ligand, the destruction complex (Axin, APC, and GSK3) promotes 
phosphorylates of β-catenin, leading to its ubiquitin-mediated degradation.  In the 
presence of a Wnt ligand, LRP6 promotes degradation of Axin, which may promote β-
catenin stabilization by inhibiting destruction complex formation.  Additionally, Wnt-
activated LRP6 recruits and binds the destruction complex, allowing LRP6 to directly 
inhibit of GSK3’s phosphorylation of β-catenin within the destruction complex.  
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mediating inhibition of GSK3’s phosphorylation of β-catenin.  Analysis of the molecular 
details of this interaction may help elucidate the mechanism by which LRP6 prevents β-
catenin phosphorylation. 
While the work described here was in press, Hendriksen et al. reported that 
dephosphorylated β-catenin accumulates at activated, phosphorylated LRP6 in response 
to canonical Wnt signaling in cultured mammalian cells (Hendriksen et al., 2008).  This 
finding further supports our model in which Wnt-activated LRP6 directly inhibits GSK3's 
phosphorylation of β-catenin within the destruction complex at the plasma membrane 
(Figure 2.11).  The results from Hendriksen et al. also argue against previously published 
models (Figure 2.1).  In argument against LRP6 acting by binding Axin and sequestering 
it away from destruction complex components such as β-catenin, Hendrikson et al. find 
that Axin recruited to LRP6 in response to canonical signaling remains bound to β-
catenin (Hendriksen et al., 2008).  In argument against LRP6 acting solely by Axin 
degradation, Hendrikson et al. find that β-catenin phosphorylation and degradation are 
inhibited while β-catenin remains bound to Axin (Hendriksen et al., 2008).  These 
findings by Hendrikson et al. also demonstrate that egg extracts and purified protein 
assays accurately recapitulate Wnt signaling mechanisms utilized in intact cells.  Thus, 
we suggest that further use of the experimental systems described in our work will aid in 
elucidation of the precise mechanistic pathway by which LRP6 activates canonical Wnt 
signaling. 
While some studies have shown that overexpression of the LRP5/6 intracellular 
domain alone is sufficient to promote canonical Wnt signaling (Mi et al., 2006; Mi and 
Johnson, 2005), other studies suggest that the LRP5 intracellular domain requires its 
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transmembrane domain or an N-terminal hydrophobic moiety (to promote membrane 
association) in order to activate the Wnt pathway (Mao et al., 2001b).  In our 
experiments, LRP6ICD lacking such a motif is sufficient to induce ectopic Wnt/β-catenin 
signaling in Xenopus embryos and egg extract.  Differences in the abilities of these 
LRP5/6 intracellular fragments to activate Wnt signaling may simply reflect differences 
in levels of expression and/or stability of the constructs rather than differences in 
localization. 
Because Axin is the limiting factor in β-catenin destruction complex formation, 
we predict Axin degradation (though not required for all aspects of β-catenin 
stabilization) plays an important role in LRP5/6-mediated Wnt signal transduction (Lee et 
al., 2003).  Thus, we suggest both LRP5/6-mediated inhibition of β-catenin 
phosphorylation and stimulation of Axin degradation contribute significantly to Wnt/β-
catenin signaling (Figure 2.11).  The existence of two mechanisms by which LRP5/6 
mediates β-catenin stabilization may allow for more robust transduction of a Wnt signal.  
Furthermore, these two mechanisms are fundamentally different and could lead to distinct 
downstream responses.  Regulation of the relative contributions of both mechanisms for 
stabilizing β-catenin would allow an organism to fine-tune sensitivity to Wnt signals for 
precise temporal and spatial control of tissue patterning.  Moreover, it is likely that 
additional mechanisms not described here further contribute to the robustness and 
regulation of Wnt-mediated β-catenin stabilization (Liu et al., 2005; Yost et al., 1998).   
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Future Directions 
 
What Are the Roles and Mechanisms of LRP6-Mediated Inhibition of GSK3’s 
Phosphorylation of β-catenin? 
Given our work in egg extract and in vitro kinase assays as well as the work of 
others showing that β-catenin’s GSK3-mediated phosphorylation is inhibited on Axin at 
Wnt-activated LRP6 in cells (Hendriksen et al., 2008), the mechanistic basis of this 
phenomenon should be elucidated.   
First, amino acids of LRP6ICD required for its inhibition of GSK3’s 
phosphorylation of β-catenin should be identified.  It has been shown that LRP6ICD acts 
in a modular fashion, such that five discrete PPPSP-containing regions contribute 
cooperatively to LRP6’s activity.  In support of this hypothesis, a single PPPSP-
containing module retaining only 16 amino acids from LRP6 has been shown to promote 
canonical signaling in cultured cells and Xenopus embryos.  Reconstitution of the activity 
of this 16 amino acid, single PPPSP-containing LRP6ICD fragment in egg extract and the 
in vitro kinase assay would significantly accelerate discovery of amino acids critical to 
LRP6ICD’s inhibition of β-catenin phosphorylation.  Thus, extensive mutation of 
conserved amino acids in this region can be undertaken to determine the molecular basis 
of this interaction.  Study of these mutant fragments in the kinase assay with the purified 
mutant LRP6ICD fragment, GSK3, and β-catenin would provide a very specific, 
quantifiable readout of LRP6’s inhibition of β-catenin phosphorylation.  Study of the 
effects of these mutant fragments on β-catenin phosphorylation in egg extract may 
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support data from the in vitro kinase assay in a more biological context.  Importantly, 
these LRP6ICD mutant fragments could be tested for their ability to bind Axin and 
promote Axin degradation in egg extract.  Point mutants of single PPPSP-containing 
fragments of LRP6ICD that do not inhibit GSK3’s phosphorylation of β-catenin in a 
kinase assay but do bind Axin and promote Axin degradation would be especially helpful 
in mechanistic studies because they would allow dissection of LRP6ICD’s two major 
signaling activities:  Axin degradation and inhibition of GSK3’s phosphorylation of β-
catenin.  These LRP6ICD mutants that could promote Axin degradation without 
inhibiting GSK3’s phosphorylation could be tested for their ability to stabilize β-catenin 
in egg extracts and promote Wnt-mediated transcription in Xenopus embryos and 
cultured cells.  These experiments will be used to determine whether LRP6ICD’s 
inhibition of GSK3-mediated β-catenin phosphorylation is required for Wnt signaling, 
which is an important, outstanding question in the study of Wnt signal transduction.  
Ideally, this question could be answered in a more biological, genetic context.  Mutation 
of a key amino acid in a single PPPSP containing region could be applied to all of the 
remaining PPPSP modules to obtain a complete LRP6 that retains only the ability to 
promote Axin degradation without directly inhibiting β-catenin phosphorylation.  
Replacement of wild-type Arrow (or LRP5 and LRP6) with such a mutant Arrow (or 
LRP5 and LRP6) using homologous recombination in Drosophila (or mouse) could be 
used to determine whether LRP6’s direct inhibition of β-catenin phosphorylation is 
necessary for canonical Wnt signal transduction in the context of development of a whole 
animal.  Moreover, cell lines derived from such a mouse could be used to address more 
kinetic and mechanistic aspects of this question.  Thus, mutation of LRP6ICD could 
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uncover its molecular basis for inhibition of β-catenin phosphorylation and its role in 
biology.    
Second, the molecular basis for LRP6-mediated inhibition of GSK3’s 
phosphorylation of β-catenin could be uncovered using mutants of β-catenin or GSK3.  
For example, LRP6 may directly bind β-catenin and affect its ability to be 
phosphorylated by GSK3.  If this is the case, direct interaction between β-catenin and 
LRP6ICD could be assayed by immunoprecipitation experiments carried out with these 
recombinant proteins.  If an interaction is detected, regions on β-catenin required for this 
interaction could be mapped and mutated to understand the molecular basis of this 
interaction.  Identification of such a binding region may provide clues for how this 
binding event leads to inhibition of β-catenin’s phosphorylation by GSK3.  Alternatively, 
LRP6ICD may interact with GSK3 in a manner that affects its substrate specificity, 
interrupting its phosphorylation of β-catenin but not other substrates.  Mutation of certain 
regions of GSK3 may be helpful in elucidating such a mechanism.  As with LRP6ICD 
mutants, these mutations of β-catenin and GSK3 may affect LRP6ICD-mediated 
inhibition of GSK3 phosphorylation of β-catenin without inhibiting Axin degradation.  
Such mutants could be used to uncouple and study the role of these two mechanisms for 
LRP5/6 activity. 
Third, structural studies of these proteins may directly reveal their mechanisms of 
action.  As it has been suggested that a complex of LRP6ICD, Axin, β-catenin, and 
GSK3 is rather stable in cells, this complex may be reconstituted with recombinant 
proteins and used for crystallography studies to reveal the mechanism by which LRP6 
directly inhibits GSK3’s phosphorylation of β-catenin. 
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Lastly, identification of amino acids on LRP6, β-catenin, and GSK3 required for 
their functional interaction may have important medical applications.  Such sites may be 
mutated in diseases affecting canonical Wnt signaling.  In addition, a crystal structure of 
this functional complex could be used to initiate rational drug discovery to identify a 
small molecule inhibitor of LRP5/6-mediated inhibition of GSK3’s phosphorylation of β-
catenin.   
 
What Are the Roles and Mechanisms of LRP6-Mediated Axin Degradation? 
Our work has confirmed that LRP6 promotes degradation of Axin independently 
of GSK3’s phosphorylation of Axin in a manner that likely requires LRP6/Axin binding.  
However, further work should be carried out to understand how LRP6 promotes Axin 
degradation.  As we find that LRP6ICD promotes poly-ubiquitination of Axin, we can 
use the minimal Axin fragment that degrades in response to LRP6ICD in order to identify 
ubiquitinated lysines on Axin required for its degradation.  As there are only about a 
dozen conserved lysines on this Axin fragment, each lysine can be mutated to determine 
which is necessary for Axin’s LRP6ICD-mediated degradation in egg extracts.  Notably, 
it may be necessary to mutate multiple lysines as there may be redundancy in this 
process.  Alternatively, mass spectrometry of epitope-tagged Axin may be used to 
identify ubiquitinated lysines on Axin.  Lysine mutants of Axin that prevent its 
LRP6ICD-mediated poly-ubiquitination should be tested for alterations in basal and 
GSK3 inhibition-mediated degradation.  Preferably, a mutant that does not degrade in 
response to LRP6ICD but has a normal basal half-life and an unperturbed LiCl-mediated 
decrease in half-life can be identified.  Replacement of wild-type Axin with such a 
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mutant of Axin in Drosophila (or Axin1 and Axin2 in mouse) by homologous 
recombination could be used to determine whether Axin degradation is required for 
canonical Wnt signaling in development of a whole organism.  Cell lines from such a 
mouse could be used to answer mechanistic and kinetic aspects of this question.  If 
canonical Wnt signaling is not inhibited or only partially inhibited by such mutations, 
LRP6’s direct inhibition of GSK3’s phosphorylation of β-catenin (or another mechanism) 
may be sufficient to promote Wnt signaling in vivo. 
The mechanism and role of Axin degradation could also be explored by 
identification of an E3 ubiquitin ligase responsible for LRP6-mediated Axin poly-
ubiquitination.  Such an E3 could be identified by a mass spectrometry approach to 
identify Axin binding partners or by a functional loss-of-function screen to identify E3 
ligases involved in Wnt signaling and Axin degradation.  Mutation in a whole organism 
of such an E3 ligase for Axin can also be used to determine the role for Axin degradation 
in development.  Of note, mutations that inhibit LRP6-mediated Axin degradation and 
mutations that inhibit LRP6-mediated inhibition of β-catenin phosphorylation can be 
combined to determine whether LRP6 may signal independently of both of these 
proposed mechanisms for LRP6-mediated Wnt signal transduction.                 
Identification of diseases with mutations of sites on Axin required for its LRP6-
mediated degradation or mutations in Axin’s E3 ligase may help uncover a molecular 
basis for certain human diseases.  And, this work could be used to initiate discovery of 
drugs that could inhibit Wnt signaling by inhibiting degradation of Axin. 
Thus, our work has suggested two mechanisms for LRP6-mediated activation of 
canonical Wnt signaling.  Elucidation of the molecular basis for these mechanisms will 
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help determine the role they play in development and disease and may lead to improved 
diagnosis and treatment of diseases involving misregulation of canonical Wnt signaling.  
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BOOK 1:  RECEPTER-MEDIATED ACTIVATION OF CANONICAL  
WNT SIGNALING 
 
CHAPTER 3:  THE ROLE OF HETEROTRIMERIC G PROTEINS IN 
CANONICAL WNT SIGNALING 
 
Introduction 
The Wnt co-receptors Frizzled (Fz) and low-density lipoprotein receptor-related 
receptor related proteins 5 or 6 (LRP5/6) bind Wnt ligands on the plasma membrane 
(reviewed in Logan and Nusse, 2004).  Formation of an oligomer containing these 
proteins activates the Wnt/β-catenin, or canonical Wnt, signaling pathway.  The 
mechanism by which Wnt- and LRP5/6-bound Fz transduces a signal is thought to occur 
through phosphorylation and activation of Dishevelled (Dsh) (Yanagawa et al., 1995; 
Zeng et al., 2008), which is required for phosphorylation and activation of the LRP5/6 
intracellular domain (Bilic et al., 2007; Zeng et al., 2005).  The phosphorylated LRP5/6 
intracellular domain then promotes β-catenin stabilization by two mechanisms:  direct 
inhibition of GSK3’s phosphorylation of β-catenin and promotion of Axin degradation 
(Cselenyi et al., 2008; Mao et al., 2001b).  In addition to this specific pathway, activation 
of Wnt co-receptors has other effects that promote Wnt/β-catenin signaling.  Activated 
Dsh may bind GSK3 binding protein (GBP), which directly inhibits GSK3 activity within 
the β-catenin destruction complex (Yost et al., 1998).  Activation of the receptor complex 
may also promote dissociation of the destruction complex (Liu et al., 2005).  Wnt-
dependent Ser9/Ser21 phosphorylation and inhibition of GSK3β/GSK3α may promote 
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Wnt/β-catenin signaling (Yokoyama et al., 2007b).  In addition, it has been shown that 
Wnt-mediated activation of Rac1 plays a role in transporting β-catenin to the nucleus 
where it regulates transcription (Wu et al., 2008).  Several other receptor-mediated 
mechanisms for Wnt/β-catenin signal transduction have been suggested.  Thus, a great 
deal remains unknown regarding the complex mechanisms by which activated Wnt co-
receptors stabilize β-catenin and lead to β-catenin-mediated transcriptional activity.  
Fz is a seven-transmembrane, heptahelical protein with a predicted topology that 
is similar to heterotrimeric G protein coupled receptors (GPCRs) (Josefsson, 1999; 
Malbon, 2004).  The human genome contains over 1,500 GPCRs that recognize a diverse 
set of ligands (Josefsson, 1999).  Ligand-mediated activation of GPCRs promotes 
dissociation of the G protein heterotrimer into effector subunits, a Gα monomer and a 
Gβγ dimer (reviewed in Milligan and Kostenis, 2006; Smrcka, 2008).  Specifically, 
ligand causes a conformational change of the GPCR which promotes dissociation of GDP 
from the Gα subunit to allow for binding of GTP and subsequent dissociation of the 
heterotrimer into a Gα monomer and a Gβγ dimer.  Specific classes of Gα and Gβγ 
effectors promote highly diverse downstream signaling events.  The Gα proteins may be 
classified into proteins of the Gαs (which stimulate cAMP production), Gαi (which 
inhibit cAMP production), Gαq/11 (which activate phospholipase C (PLC)), and 
Gα12/13 (which activate Rho family GTPases) families (Milligan and Kostenis, 2006).  
Importantly, many of these Gα proteins signal through multiple mechanisms that are 
distinct from those of their traditional family classifications.  Of note, certain molecular 
processes modulated by effectors of Gα and Gβγ proteins have also been shown to 
 74 
promote β-catenin stabilization, including cAMP production (Hino et al., 2005), PLC 
activation (Gao and Wang, 2007), and Rac1 activation (Wu et al., 2008).  
There are several important implications for a role for G-proteins in Wnt/β-
catenin signaling.  The majority of drugs prescribed for human diseases target GPCRs 
(Jacoby et al., 2006).  If Fz is a true GPCR, Fz may be an excellent target for drug 
discovery.  For example, a drug that inhibits Fz’s GPCR activity could be used to treat 
certain cancers caused by overactivation of Wnt/β-catenin signaling.  Second, many 
important downstream responses in cells responding to a Wnt ligand occur within five 
minutes after incubation with Wnts.  Dsh phosphorylation, recruitment of the destruction 
complex to LRP5/6, LRP5/6 phoshorylation, and inhibition of GSK3’s phosphorylation 
of β-catenin all occur very rapidly in response to Wnts (Bryja et al., 2007; Zeng et al., 
2008).  GPCR-mediated dissociation of Gα and Gβγ and activation of their signaling 
targets can also occur extremely rapidly (Milligan and Kostenis, 2006), and Fz-induced 
heterotrimer dissociation could explain the mechanism behind immediate events that 
occur in Wnt signaling.  Finally, elucidation of the effects of G proteins on β-catenin 
could suggest important crosstalk between events that activate GPCRs other than Fz and 
regulation of β-catenin activity in the cell.  As a result, major questions in Wnt/β-catenin 
signaling are whether Fz is a bona fide GPCR and whether G proteins are involved in 
Wnt signaling.  
Several lines of evidence support a model by which Fz affects Wnt signaling via 
GPCR activity.  In Drosophila, Gαo (from the Gαi family) null cells in wing imaginal 
discs are deficient in transduction of a canonical Wnt signal (Katanaev et al., 2005).  In 
this experimental system, overexpression of constituitively active GαoGTP, which 
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constituitively binds GTP, phenocopies Wnt signaling gain-of-function mutations 
(Katanaev et al., 2005).  While these genetic data are promising, they do not address 
whether Gαo plays a direct, Fz-coupled role in Wnt signaling or whether Gαo couples to 
Wnt signaling indirectly through another GPCR.   
Numerous experiments testing the role of G proteins in Wnt signaling have been 
performed in the murine F9 teratocarcinoma cell line.  In this cell line, F9 cells 
differentiate into primitive endoderm in response to Wnt3a treatment.  In F9 cells, 
Wnt3a-dependent differentiation is inhibited by pertussis toxin (PTX), which prevents 
heterotrimer dissociation via ADP ribosylation of Gα subunits of the Gαo and Gαi 
families (Liu et al., 1999b).  Gαq and Gαo depletion also inhibit this process, suggesting 
that Wnt3a-mediated differentiation of F9 cells occurs through Gαo and Gαq (Liu et al., 
1999b).  To further study this process, a β2 Adrenergic Receptor-rat Fz1 chimera (β2AR-
rFz1) was utilized that combined the extracellular and transmembrane regions of the 
β2AR and intracellular regions of Fz1 (Liu et al., 2001).  Thus, a β2AR agonist could be 
added to cells in which the chimera was overexpressed to activate the intracellular 
regions of Fz1.  While there are many caveats to the interpretations of experiments with 
such a chimeric protein, F9 cells overexpressing β2AR-rFz1 stabilized β-catenin and 
promoted β-catenin-dependent transcription in response to the β2AR agonist 
isoproterenol (Liu et al., 2001).  As in endoderm differentiation, these β2AR-Rfz1-
mediated events were PTX-sensitive and depended on Gαo and Gαq (Liu et al., 2001).  
Further work in F9 cells has led to a model in which Wnt-mediated activation of Fz 
activates Gαo and Gαq to promote PLC-dependent, casein kinase 2- (CK2) mediated 
Dsh phosphorylation, leading to β-catenin stabilization (Gao and Wang, 2006, 2007).  
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Nonetheless, the use of a single cell type and a chimeric β2AR-Rfz1 receptor in these 
studies significantly limits the interpretations that can be gleaned from these studies.  
Indeed, the majority of these data (except for a role for Gαo and Gαq) have not been 
replicated in other experimental systems. 
A role for G proteins in canonical Wnt signal transduction has also been 
suggested in L929 and 3T3-L1 cells (Liu et al., 2005).  In these cells, Wnt3a promotes a 
rapid dissociation of GSK3β from Axin1 and of GSK3α from Axin2 in a manner that is 
sensitive to PTX and dependent on Gαo and Gαq (Liu et al., 2005).  This work further 
supports a role for Gαo and Gαq in canonical Wnt signaling by showing that rapid 
effects of recombinant Wnt3a (and not Wnt conditioned media which contains many 
other signaling ligands) on destruction complex integrity are G protein-dependent.  
Notably, the Axin-GSK3 dissociation event is correlated with β-catenin stabilization but 
not β-catenin-mediated transcription.  Thus, an important caveat to these experiments is 
that these changes in destruction complex integrity and β-catenin stabilization may not be 
significant enough to affect Wnt-mediated transcription.  It should also be noted that 
rapid Wnt-mediated changes in the composition of the destruction complex have not been 
reproduced in similar experiments (Bilic et al., 2007; Yamamoto et al., 2006). 
In addition to the role of G proteins in canonical Wnt signaling, promising data 
supports a role for G proteins in non-canonical signaling.  In zebrafish embryos and F9 
cells, separate sets of Wnts and Fzs are involved in a pathway that proceeds through 
calcium flux and not β-catenin regulation (Ahumada et al., 2002; Liu et al., 1999c; 
Slusarski et al., 1997a).  PTX and depletion of Gαt, Gαo, or Gβ2 inhibit Ca++-mediated 
non-canonical signaling in these experimental systems (Ahumada et al., 2002; Liu et al., 
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1999c).  In Drosophila, overexpression of Gαo and GαoGTP promote planar cell polarity 
(PCP) (another non-canonical Wnt signaling pathway) phenotypes (Katanaev et al., 
2005).  Notably, Gαo activity but not GαoGTP activity requires Fz in this system, 
suggesting functional coupling between Fz and Gαo in PCP signaling.  While these data 
suggest that both canonical and noncanonical Wnt signaling may proceed through G 
proteins, studies of G proteins and Wnt signaling should be interpreted even more 
cautiously and be controlled for crosstalk-mediated effects between canonical and non-
canonical Wnt signaling pathways.  Overall, experimental evidence from Drosophila and 
cultured mammalian cells supports the possibility of a role for G proteins (especially Gαo 
and Gαq) in canonical Wnt signaling; however, the above data does not address whether 
Fz activates Wnt/β-catenin signaling via GPCR activity.   
Although Fz is a seven-transmembrane spanning receptor, significant divergence 
of Fz’s primary structure from bona fide GPCRs leads to its special classification with the 
Hedgehog pathway protein Smoothened (Smo) (Josefsson, 1999).  As it has been shown 
that many GPCRs have signaling properties that are independent of G proteins (Sun et al., 
2007), it is possible that both Fz and Smo are evolutionarily derived from ancestral 
GPCRs but have subsequently lost the ability to promote heterotrimer dissociation.  
Similar to Fz, promising though preliminary studies addressing the role of G proteins in 
Hedgehog signaling have been performed (Riobo et al., 2006; Ruiz-Gomez et al., 2007).  
While work from several groups has suggested that Fz is a GPCR, definitive experiments 
have not been performed.  Specifically, it has not been established that Fz promotes 
heterotrimer dissociation.  Dissociation could be assayed traditionally via [γ-32 P]GTP 
hydrolysis experiments in membranes from Fz-expressing or Fz null Drosophila S2 cells 
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incubated with recombinant Wg protein (Cassel and Selinger, 1976).  Alternatively, it 
could be tested whether Fz-Wnt affinity is modulated by incubation of cells with GTPγs 
(Guanosine 5'-(3-O-thio) triphosphate, a non-hydrolyzable form of GTP); such a shift in 
agonist binding in response to GTPγs is a characteristic common to all tested GPCRs 
(Maguire et al., 1976).  Fluorescence resonance energy transfer (FRET) could also be 
performed with candidate Gα and Gβγ subunits to assay for recombinant Wnt-dependent 
heterotrimer dissociation (Janetopoulos et al., 2001).  If indeed Fz promotes heterotrimer 
dissociation and the specific Gα and Gβγ proteins are identified, loss-of-function of these 
G proteins should lead to inhibition of Wnt/β-catenin signaling.  Such an experiment 
must be controlled to eliminate Fz-independent roles of these G proteins in Wnt/β-catenin 
signaling.  Specifically, it would be ideal to show that overexpression of constituitively 
active GαGTP displays a reduced reliance on Fz compared with overexpression of wild-
type Gα (Katanaev et al., 2005).  Thus, significant work remains in elucidating whether 
Fz acts as a GPCR in Wnt signaling.    
It is important to note that G proteins may affect canonical Wnt signaling in a 
biologically and therapeutically significant way even if they do not couple to Fz’s 
potential GPCR activity.  Indeed, G proteins activated by other GPCRs may modulate β-
catenin activity in important ways.  For example, it has been suggested that Prostaglandin 
E2 stablizes β-catenin through Gαs signaling (Castellone et al., 2005).  Also, 
gonadotropin-releasing hormone and parathyroid hormone are two hormones that bind 
their own GPCRs and modulate β-catenin levels (Gardner et al., 2007; Tobimatsu et al., 
2006).  It is likely that these G protein pathways impinge on Wnt signaling in ways that 
are relevant to development, physiology, and disease.  In addition to evaluating Fz as a 
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GPCR, it will be important to uncover how other G protein signaling events regulate 
Wnt/β-catenin signaling (Figure 3.1).    
To identify potential G proteins with a role in regulation of β-catenin stability, we 
added purified Gα and Gβγ subunits to Xenopus egg extract and assayed for modulation 
of β-catenin stability.  We find that Gαo, Gαi, Gαq, and Gβγ may play roles in 
regulating β-catenin levels and address their mechanisms of action.  
 
Methods 
 
Xenopus Egg Extract and β-catenin Degradation Assays 
Xenopus egg extract was prepared and degradation assays were performed as 
described (Salic et al., 2000).   Dsh immunodepletions were performed and confirmed as 
described in (Salic et al., 2000).  Xenopus egg extract was incubated with an equal 
volume of Protein A-Affiprep beads (BioRad) bound to Dsh polyclonal antibodies.  
Incubation was performed at 4°C for 2 hr with inversion every 10 min. 
 
Heterotrimer Dissociation  
Gαβγ heterotrimer was dissociated via incubation with AlF4- as previously 
described with modifications (Sternweis and Gilman, 1982).  Undissociated Gαβγ was 
incubated with 25 mM NaF, 0.1 mM AlCl3, and 10 mM MgCl2 for 45 min on ice before 
addition to egg extract. 
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Figure 3.1:  G Proteins May Directly or Indirectly Influence Wnt/β-catenin 
Signaling.  (Top Panel)  This schematic describes a mechanism whereby Fz acts as a 
Wnt-activated GPCR that promotes heterotrimer dissociation in a manner that leads to 
destruction complex inhibition.  Gα or Gβγ may activate Dsh or directly inhibit 
destruction complex activity.  (Bottom Panel)  This schematic describes an indirect 
mechanism whereby activation of a GPCR other than Fz indirectly promotes Wnt-
mediated destruction complex inhibition.  Gα or Gβγ may directly inhibit the destruction 
complex or activate the Wnt receptor complex.    
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Immunoblotting 
Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, 
and immunoblotted.  Bands were visualized using horseradish peroxidase-conjugated 
secondary antibodies and SuperSignal West Pico or Femto Chemiluminescent Substrate 
(Pierce).  For reblotting, membranes were stripped by incubation in NaOH (0.4 M) for 15 
min followed by 15 min in H2O and reblocking.  
β-catenin P33/37/41 antibody was purchased from Cell Signaling [1:1,000 kinase 
assay] [1:250 egg extract].  N-termal Xenopus-β-catenin antibody was a generous gift 
from Barry Gumbiner [1:3,000].  αTubulin was blotted with DM1α (Sigma) [1:5,000 
dilution].  Axin antibody for immunoblot was purchased from R & D (Anti-
human/mouse/rat Axin 1) [1:100].  Antibodies for Dsh and Axin immunopreipitation and 
immunoblotting were described previously (Salic et al., 2000) [1:100].  GSK3 was 
blotted with IH8 (Affinity Bioreagents) [1:500].  GSK3Ser9 was blotted anti-GSK3-Ser9 
(Cell Signaling) [1:500].  Gβ was immunoprecipitated and blotted with S-13 (Santa Cruz) 
[1:300].  
 
Immunoprecipitation 
For IP, egg extract (50 µl) was incubated with or without G protein and IVT β-
catenin (3 µl) for 45 min.  Buffer A (700 µl) was added to extract with Protein A beads 
covalently conjugated to Axin, Dsh, or Gβγ antibody followed by 2 hr shaking at 4°C.  
Beads were washed with Buffer A (4 ml), eluted with sample buffer, and analyzed by 
SDS-PAGE and immunoblot. 
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Kinase Assay 
Gαo (1 µM), Gαs (1 µM), GSK3 (0.79 µM) (NEB), and CK1 (1.37 µM) (NEB) 
were pre-incubated with 500 µM ATP and kinase buffer (20 mM HEPES (pH 7.5), 300 
mM NaCl, 2 mM DTT, 1 mM  EDTA, 10 mM MgCl2, and 0.2% Tween 20) for 10 min at 
RT.  His6-β-catenin (0.22 µM) was then added and samples were removed for 
immunoblotting after 45 min at RT. 
 
RNAi in S2R+ Cells 
Fifty thousand cells were plated in wells of a 96-well plate in 50 µl serum-free 
media and left to adhere at RT for 1 hr.  One microgram dsRNA per gene was then added 
to wells, and cells were incubated at RT for 30 min.  dsDNA was prepared by in vitro 
transcription of linear dsDNA by PCR of genes from the Drosophila Gene Collection 
(DGC) with primers containing flanking T3 and T7 promoters.  One hundred microliters 
serum-containing Schneider’s media was added, and cells were incubated for 4 days at 
27o C.  After this period, 150 µl of serum- and Wg-containing media was added to cells 
for 1 day.  After this period, media was removed and 75 µl Passive Lysis Buffer was 
added.  Following 15 min of vigorous shaking, 20 µl was removed for cell titer and 40 µl 
for luciferase (SteadyGlo, Promega).  Luciferase SuperTOPFlash signal was normalized 
to cell titer, and all experiments were performed in triplicate and averaged as displayed.   
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Results 
 
Dissociation of the G Protein Heterotrimer Stabilizes β-catenin in Xenopus Egg 
Extract.  
Previous work has shown that many molecular and kinetic aspects of cytoplasmic 
β-catenin regulation are recapitulated by radiolabeled, in vitro translated β-catenin in 
cytoplasmic Xenopus egg extract (Salic et al., 2000).  To determine whether G proteins 
affect β-catenin stability in egg extract, we purified a G protein heterotrimer from porcine 
brain using previously described purification protocols (Milligan and Klee, 1985).  The 
vast majority of Gα purified through this method has been shown to be Gαo (Gierschik 
et al., 1986), and we confirmed that the major Gα subunit in our purification was Gαo by 
immunoblot (Kristin Kalie Jernigan (KKJ), unpublished results).  In addition, the 
remaining two major proteins from our purification were confirmed to be Gβ and Gγ by 
immunoblot (KKJ, unpublished results).  Because this purified heterotrimer is present as 
an inactive, non-dissociated trimer that would not be predicted to activate Gα- and Gβγ-
mediated signaling, we performed in vitro activation of Gαo and Gβγ via incubation with 
GDP-AlF4- to recapitulate GPCR-mediated heterotimer dissociation and activation 
(Sternweis and Gilman, 1982).  Consistent with activation and trimer dissociation being 
required for G protein signaling, the inactive, non-dissociated G protein heterotrimer does 
not affect β-catenin stability in egg extract (Figure 3.2).  However, the GDP-AlF4- 
dissociated Gα and/or Gβγ subunits significantly inhibit β-catenin degradation in egg 
extract (Figure 3.2).  In this experiment, the inactive, non-dissociated trimer is an 
important control that suggests that the heterotrimer must be dissociated through an event  
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Figure 3.2:  Dissociation of Gαβγ  into Gαo and Gβγ  Stabilizes β-catenin in Egg 
Extract.  AlF4- treated Gαβγ (0.4 mg/ml), but not intact Gαβγ or AlF4- inhibits 
degradation of radiolabeled, IVT β-catenin in Xenopus egg extract. 
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such as GPCR activation to affect β-catenin.  Thus, similar to the characterized Wnt 
pathway activators LRP6ICD (a constituitively active fragment of LRP6) and LiCl (a 
GSK3 inihibitor) (Cselenyi et al., 2008; Salic et al., 2000), dissociated Gαo and/or Gβγ 
stabilize β-catenin and suggest that either or both of these G proteins may play a role in 
canonical Wnt signaling.  These data suggest two possible models:  a direct “Fz as 
GPCR” model in which Wnt-activated Fz promotes trimer dissociation leading to β-
catenin stabilization, or a “signaling crosstalk” model in which an unrelated, activated 
GPCR promotes trimer dissociation leading to β-catenin stabilization (Figure 3.1).  Thus 
consistent with a role for GPCR-mediated G protein signaling in Wnt/β-catenin signaling, 
we find that dissociated Gαo and Gβγ but not intact Gαβγ stabilizes β-catenin in egg 
extract.     
To determine whether Gαo or Gβγ purified from porcine brain affects β-catenin 
stability in egg extract, we tested whether recombinant Gαo or Gβγ stabilize β-catenin in 
Xenopus egg extract.  Interestingly, each recombinant protein independently inhibited β-
catenin degradation (Figure 3.3A and B), suggesting that Gαo and Gβγ may each play a 
role in regulating Wnt/β-catenin signaling.  While Gαo has been suggested to play a 
positive role in canonical Wnt signal transduction, to our knowledge there have been no 
reports identifying a role for Gβγ in Wnt/β-catenin signaling. 
 
Gαo, Gαi, Gαq, and Gβγ  Stabilize β-catenin by Inhibiting its Phosphorylation by 
GSK3. 
To further identify which Gα proteins may be involved in Wnt signaling, we 
tested whether other Gα subunits affect β-catenin degradation in Xenopus egg extract.   
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Figure 3.3:  Gαo and Gβγ  Each Stabilize β-catenin in Egg Extract.  (A)  Addition of 
bacterially expressed recombinant, myristoylated Gαo (5 µM) inhibits degradation of 
radiolabeled IVT β-catenin in egg extract.  Non-myristoylated Gαo also stabilizes β-
catenin and may be endogenously myristoylated in egg extract.  (B)  Porcine brain 
purified and dissociated Gβγ (7 µM) and SF9-expressed recombinant Gβγ both inhibit 
degradation of radiolabeled, IVT β-catenin in egg extract. 
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Gαo, Gαi1, Gαi2, Gαi3, Gαq, Gα11, Gα12, Gα13, and Gαt were expressed as 
recombinant proteins in bacteria or insect cells or were purified from tissue sources via 
conventional methods (KKJ, unpublished results).  Their activities were confirmed by 
previously described methods.  Addition of Gαo, Gαi1, Gαi2, and Gαq to Xenopus egg 
extract robustly stabilized β-catenin (KKJ, unpublished results), suggesting that these Gα 
proteins may play roles in Wnt/β-catenin signaling.  Interestingly, overlapping 
experimental evidence from other groups also identified roles for Gαo and Gαq in 
canonical Wnt signaling.  To our knowledge, Gαi has not been implicated in Wnt 
signaling; however, it should be noted that Gαo is in the same family (Gαi family) as 
Gαi1, 2, and 3 (Milligan and Kostenis, 2006).  Our screen for Gα proteins involved in β-
catenin regulation identified the two previously described Gα proteins suggested to be 
involved in Wnt signaling.  We believe these findings validate our screen and confirm the 
utility of Xenopus egg extract in analyzing the role of G proteins in Wnt signaling.  
Overall, our studies confirm roles for Gαo and Gαq in canonical Wnt signaling and 
suggest novel roles for Gαi and Gβγ in regulation of β-catenin stability. 
To identify how Gαo, Gαi, and Gαq stabilize β-catenin, we hypothesized that 
they could act either upstream or downstream of β-catenin’s phosphorylation by GSK3 at 
Ser33/37/41 which is required for binding to the E3 ubiquitin ligase β−TRCP and 
subsequent poly-ubiquitination and degradation (Logan and Nusse, 2004).  We find that 
Gαo activated by binding non-hydrolyzable GTPγs (GαoGTPγs) and Gβγ prevent 
GSK3’s phosphorylation of β-catenin (Figure 3.4A and B).  As has been previously 
described, LRP6ICD and the GSK3 inhibitor LiCl also inhibit β-catenin phosphorylation 
in this assay in Xenopus egg extract (Figure 3.4A) (Cselenyi et al., 2008).  We next  
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Figure 3.4:  Gαo and Gβγ  Each Inhibit GSK3’s Phosphorylation of β-catenin in 
Xenopus Egg Extract.  (A)  Incubation of Xenopus egg extract with LiCl (50 mM), 
LRP6ICD (1.6 µM), or GαoGTPγS (5 µM, but not 2.5 µM) inhibits Ser33/37/41 
phoshorylation of β-catenin.  (B)  Incubation of Xenopus egg extract with LiCl (50 mM) 
or porcine brain purified Gβγ (7 µM, but not 3.5 µM) inhibits Ser33/37/41 
phoshorylation of β-catenin. 
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tested which G proteins inhibit GSK3’s phosphorylation of β-catenin in Xenopus egg 
extract.  Intriguingly, we find that all of the G proteins that stabilize β-catenin act at or 
upstream of the level of GSK3 phosphorylation (Figure 3.5).  In addition, some of the 
proteins affect β-catenin phosphorylation within 30 minutes (Gαo and Gαi) while effects 
with others (Gαq) are not seen until after 2 hours of incubation in egg extract (data not 
shown).  In addition to their shared membership in the Gαi family, the kinetic similarity 
of results with Gαo and Gαi may suggest that they work by a common mechanism that is 
distinct from that of Gαq.  These data confirm our results from the β-catenin degradation 
assays and suggest a mechanism by which these proteins regulate β-catenin. 
  
Gαo Directly Inhibits GSK3’s Phosphorylation of β-catenin. 
Most studies implicating a role for G proteins in Wnt/β-catenin signaling have 
focused on Gαo.  Because there is most evidence in favor of a role for Gαo in Wnt 
signaling, we decided to focus on the mechanism by which Gαo inhibits β-catenin 
phosphorylation and degradation in biochemically amenable egg extract.  Because Fz is 
required for Wnt-mediated phosphorylation and activation of Dsh (Gonzalez-Sancho et 
al., 2004), we hypothesized that Fz-dependent activation of Gαo may promote Dsh-
mediated β-catenin stabilization.  To test whether Gαo acts upstream of Dsh in β-catenin 
stabilization, we examined whether immunodepletion of endogenous Dsh prevents Gαo-
mediated β-catenin stabilization (Salic et al., 2000).  Surprisingly, depletion of 
endogenous Dsh does not prevent Gαo from stabilizing β-catenin (Figure 3.6A), 
suggesting that Fz-mediated activation of Dsh and Gαo may be mechanistically 
independent events.   
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Figure 3.5:  Gαo (5 µM), Gαi2 (7 µM), Gαi3 (5 µM), Gαq (0.5 µM), and 
Gβγ  (7 µΜ)  (but Not Gαs (5 µM), Gαt (5 µM), Gα12 (5 µM) and Gα13 (5 µM)) 
Inhibit GSK3’s Phosphorylation of β-catenin in Xenopus Egg Extract.  G proteins 
were incubated in extract for 2 hr, which were blotted for endogenous β-catenin.  G 
proteins were obtained through methods described by KKJ, unpublished results.  Because 
GDP forms of these proteins also stabilize β-catenin in egg extract, we predict that these 
proteins exchange GDP for GTP in egg extract.   
 91 
 
 
 
 
 
 
 
 
 
 
Figure 3.6:  Gαo-Mediated β-catenin Stabilization Does Not Require Dsh or Involve 
Dissociation of the β-catenin Destruction Complex.  (A)  Gαo (5 µM) stabilizes β-
catenin in mock- and Dsh-depleted egg extract.  Depletion was confimed by immunoblot.   
(B)  The amounts of Axin, β-catenin, GSK3, and GSK3Ser9 immunoprecipitated with 
endogenous Axin do not change when extract are incubated with Gαo (5 µM). 
 92 
Previous work has suggested that Gαo stabilizes β-catenin by promoting 
dissociation of the destruction complex (Liu et al., 2005).  Specifically, Gαo loss-of-
function inhibits Wnt-mediated dissociation of Axin from GSK3.  To test whether Gαo 
perturbs Axin’s binding partners, we immunoprecipitated endogenous Axin from 
Xenopus egg extract in the presence or absence of a concentration of Gαo that stabilizes 
β-catenin.  Importantly, we find that Gαo does not affect the amount of endogenous β-
catenin, GSK3, or Axin that is immunoprecipitated by endogenous Axin (Figure 3.6B).  
Although we cannot rule out transient or subtle changes in destruction complex integrity, 
we are unable to detect Gαo-mediated dissociation of the β-catenin destruction complex. 
Given that Gαo inhibits GSK3’s phosphorylation of β-catenin independently of 
Dsh and destruction complex dissociation, we explored whether we could reconstitute 
Gαo’s effects on β-catenin phosphorylation in a kinase assay using purified components.  
Interestingly, we find that in a kinase assay with recombinant β-catenin, GSK3, and Gαo; 
Gαo directly inhibits GSK3’s phosphorylation of β-catenin (Figure 3.7).  While this 
surprising result requires further analysis, it suggests that Gαo may bind and affect the 
conformation and activity of β-catenin or GSK3.  As none of these functions have been 
previously attributed to Gαo, this experiment suggests a possible novel mechanism for 
Gαo signaling.  Thus, we find that Gαo does not act upstream of Dsh or promote 
dissociation of the destruction complex; instead, Gαo may directly inhibit GSK3’s 
phosphorylation of β-catenin.  
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Figure 3.7:  In a Kinase Assay with Purified, Recombinant Components, Gαo 
Directly Inhibits GSK3’s Phosphorylation of β-catenin.  Gαo, but not Gαs, inhibits 
phosphorylation of recombinant β-catenin in a kinase assay with GSK3 and CK1 or 
GSK3 alone. 
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Gβγ  Inhibits Destruction Complex Activity. 
Given the novelty and importance of a possible role for Gβγ in canonical Wnt 
signaling, we investigated our finding that Gβγ inhibits β-catenin phosphorylation and 
degradation.  To analyze Gβγ activity in Xenopus egg extract, we utilized porcine brain-
derived Gβγ that was dissociated and purified from Gαo.  We confirmed that activity 
from this purification was attributable to Gβγ by expressing and purifying recombinant 
Gβγ.  Both tissue-derived and recombinant Gβγ stabilize β-catenin in Xenopus egg 
extract (Figure 3.3B), suggesting that activity of brain-derived Gβγ truly results from Gβγ 
activity and not a contaminating protein from the purification.  In the following 
experiments, only brain-derived Gβγ is utilized because this purification protocol allowed 
us to obtain larger quantities for analysis. 
Because of the requirement of certain Fz residues for Dsh activation (Cong et al., 
2004) and previous work suggesting binding between Gβγ and Dsh (Angers et al., 2006), 
we tested whether Gβγ activity requires Dsh in egg extract.  As is the case for Gαo, Gβγ 
stabilizes β-catenin in Xenopus egg extract in which Dsh has been depleted  (Figure 
3.8A).  This suggests that Gβγ likely acts independently of Dsh in Wnt/β-catenin 
signaling.  We also tested whether Gβγ binds proteins of the destruction complex.  
Results from experiments in which endogenous or exogenous Gβ is immunoprecipitated 
from egg extract suggest that Gβγ may specifically bind Dsh as well as slowly migrating 
forms of GSK3 such as GSK3β(phospho-Ser9) (Figure 3.8B).  Significant binding with 
β-catenin or LRP6ICD was not detected (Figure 3.8B).  Although this experiment must 
be performed with antibody-free control beads to determine the extent of background 
binding between Gβγ and Dsh or GSK3, preliminary analysis suggests that endogenous  
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Figure 3.8:  Gβγ  Does Not Require Dsh to Stabilize β-catenin and May Bind Dsh 
and GSK3Ser9 in Xenopus Egg Extract.  (A)  Gβγ (7 µΜ) stabilizes β-catenin in 
mock- and Dsh-depleted egg extract.  Depletion was confimed by immunoblot.  (B)  
Endogenous or exogenous Gβγ (7µΜ) was immunoprecipitated from egg extract and 
blotted for Dsh, β-catenin, GSK3, LRP6ICD, and Gβγ.  Importantly, the amount of Gβγ 
detected is increased in extract supplemented with exogenous β-catenin.  An important 
caveat to conclusions drawn from this figure is that this experiment does not reveal the 
amount of protein immunoprecipitated by the Protein A agarose beads alone. 
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and exogenous Gβγ may bind Dsh and phosphorylated Ser9-inactivated GSK3.  It is 
interesting to note that Gβγ may bind Dsh but not require Dsh for activity in egg extract.  
This discrepancy could result from a functional interaction that is required in intact cells 
but not in extract; alternatively, this binding event may be non-functional in Wnt/β-
catenin signaling.  The binding between Gβγ and phospho-Ser9 inactivated GSK3 may 
suggest that Gβγ may play a role in inactivating GSK3 within the destruction complex, 
leading to inhibition of β-catenin phosphorylation and degradation.  Thus, further work 
should characterize potentially functional Gβγ interactions with proteins of the 
destruction complex. 
As a result of promising physical interactions between the destruction complex 
and Gβγ, we tested whether Gβγ promotes dissociation of certain destruction complex 
components.  In experiments in which endogenous Dsh or Axin is immunoprecipitated 
from egg extract, Gβγ does not appear to disrupt several known binding partners within 
the destruction complex (Figure 3.9).  Thus, we do not detect Gβγ-mediated changes in 
physical associations within the destruction complex.    
Because we have previously characterized effects of LRP6ICD in Xenopus egg 
extract, we thought it was possible that these proteins could synergize in the transduction 
of a Wnt/β-catenin signal (Cselenyi et al., 2008).  Thus, we tested whether addition of 
Gβγ affected LRP6ICD signaling in extract.  To our surprise, we found that Gβγ did not 
affect LRP6ICD’s ability to stabilize β-catenin but strongly inhibited LRP6ICD’s ability 
to promote degradation of Axin (Figure 3.10).  The most straightforward interpretation of 
these results is that Gβγ inhibits phosphorylation and degradation of β-catenin within the 
destruction complex (independently of Axin degradation) in a manner that prevents  
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Figure 3.9:  Gβγ  Does Not Appear to Promote Dissociation of the β-catenin 
Destruction Complex in Xenopus Egg Extract.  In egg extract in which endogenous 
Dsh is immunoprecipitated, addition of Gβγ (7 µΜ) does not change the amount of Dsh 
bound to GSK3.  Although decreases in the amount of Dsh bound to Dsh or Axin appears 
to decrease, this result is not repeated in the converse experiment shown below.  In egg 
extract in which endogenous Axin is immunoprecipitated, addition of Gβγ (7 µΜ) does 
not change the amount of Dsh bound to Dsh, β-catenin, or GSK3. 
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Figure 3.10:  Gβγ  Inhibits LRP6ICD-Mediated Axin Degradation in Xenopus Egg 
Extract.  (A)  In egg extract, incubation with LRP6ICD (1.6 µM), Gβγ (7 µΜ), or both 
LRP6ICD (1.6 µM) and Gβγ (7 µΜ) leads to stabilization of radiolabeled, IVT β-catenin.  
(B)  In egg extract, incubation with LRP6ICD (1.6 µM) but not Gβγ or LRP6ICD (1.6 
µM) and Gβγ (7 µΜ) leads to degradation of radiolabeled, IVT Axin.   
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LRP6ICD from binding Axin and promoting its degradation.  This interpretation would 
be consistent with Gβγ binding GSK3 or Dsh within the destruction complex in a manner 
that precludes LRP6ICD binding to the destruction complex and promoting Axin 
degradation.  Alternatively, Gβγ may activate known downstream effectors, such as PLC 
(Smrcka, 2008), in a manner that also precludes LRP6ICD’s ability to bind the 
destruction complex and promote Axin degradation. Further examination of the ability of 
Gβγ to sequester the destruction complex from LRP6ICD may provide clues to its 
mechanism of action.  Nonetheless, our results suggest Gβγ may promote Wnt signaling 
by binding and inactivating the destruction complex. 
 
Discussion  
This work establishes biochemically amenable Xenopus egg extract as a model 
system to study the effects of G protein signaling on β-catenin stability.  We tested a 
panel of G proteins for modulation of β-catenin stability and identified Gαo, Gαi, Gαq, 
and Gβγ as potential regulators of Wnt/β-catenin signaling.  While Gαo and Gαq have 
previously been implicated in Wnt/β-catenin signaling (Liu et al., 1999b), we also 
suggest possible roles for Gαi and Gβγ in this process.  Further work must be undertaken 
to determine whether these proteins are required for Wnt signaling and whether they 
couple directly to GPCR activity of Fz or to other GPCRs.  Answers to these questions 
along with mechanistic studies in egg extract and other systems will offer insight into 
regulation of β-catenin signaling.   
Our preliminary mechanistic studies show that Gαo may play a role in directly 
inhibiting GSK3’s phosphorylation of β-catenin.  Further work should determine whether 
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Gαo directly binds these proteins or whether it signals through known Gαo signaling 
targets.  Our studies with Gβγ suggest a novel role for this subunit in Wnt signaling.  As 
with Gαo, the mechanism by which Gβγ inhibits β-catenin phosphorylation may be direct 
or indirect, through known Gβγ effectors.  Surprisingly, neither Gαo nor Gβγ require Dsh 
for their effects on β-catenin stability.  Perhaps, Gαi or Gαq directly couple to Fz to 
promote Dsh phosphorylation and activation.  Alternatively, Fz-mediated activation of 
Dsh may not occur through GPCR-mediated G protein heterotrimer dissociation.   
Future studies unraveling the roles of Gαo, Gαi, Gαq and Gβγ should attempt to 
determine whether Fz or other GPCRs endogenously activate these molecules to regulate 
Wnt/β-catenin signaling.  These studies will lay the groundwork to determine whether Fz 
acts as a GPCR or whether G proteins are involved in crosstalk between other GPCR-
mediated events and Wnt signaling.  Such studies will be important in understanding the 
role of connections between Wnt signaling and G proteins in development, physiology, 
and disease.  Indeed, identification of GPCR-mediated events that impinge on Wnt/β-
catenin will provide a theoretical basis for the development of GPCR-modulating drugs 
with therapeutic potential for the treatment of cancers and other diseases caused by mis-
regulation of Wnt/β-catenin signaling (Jacoby et al., 2006). 
 
Future Directions 
 
Is Gβγ  required for Wnt Signaling? 
Characterization of the role of Gβγ in Wnt signaling requires determination of 
whether Gβγ is required for Wnt/β-catenin signaling.  Because there are 5 Gβ subunits 
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and 12 Gγ subunits in humans, we tested the requirement for Gβγ in Wnt signaling in 
Drosophila where there are only 3 Gβ subunits and 2 Gγ subunits.  Thus, we performed 
small interfering (si) RNA-mediated RNAi for 2 of 3 of the Gβ subunits and both of the 
Gγ subunits in S2R+ TOPFlash reporter cells.  These cells are stably transfected with a 
plasmid encoding a luciferase reporter driven by a promoter consisting of TCF/LEF 
binding sites, so β-catenin mediated transcription can be assayed by luciferase 
expression.  Importantly, none of the single subunits or combinations thereof inhibited 
Wg-mediated TOPFlash transcriptional activity (Figure 3.11).  However, we noted 
consistent increases in TOPFlash in cells where siRNA against Gβ76 was performed, 
suggesting a possible negative role for this endogenous protein in Wnt signaling (Figure 
3.11).  Nonetheless, experiments to determine whether this represents an off-target effect 
must be performed in order to validate that Gβ76 normally represses Wnt signaling.  
There are many important caveats to this experiment and the result that Gβγ knockdown 
does not inhibit Wnt signaling.  First, we were unable to determine how much, if at all, 
these proteins were knocked-down as there are not commercially available antibodies that 
recognize these specific subunits.  Second, knockdown of Gβγ has also been shown to 
inhibit all Gα-mediated signaling events, so even a positive result could not be attributed 
specifically to a role for Gβγ in Wnt signaling (Hwang et al., 2005).  Thus, a different 
approach must be taken to determine whether Gβγ is necessary for Wnt signaling.  The 
most common and rigorous approach to this question is to test whether overexpression of 
a Gβγ effector, the C-terminus of the β adrenergic receptor kinase (C-βARK), inhibits 
Wnt signaling by sequestering GPCR-activated, dissociated Gβγ (Koch et al., 1994).  As  
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Figure 3.11:  RNAi of Gβγ  Subunits in Drosophila S2R+ TOPFlash Reporter Cells 
Does Not Inhibit Wg-Mediated TOPFlash Activation.  1 µg of each siRNA was added 
to S2R+ cells for 72 hr, Wg media was then added for 24 hr, and cells were harvested for 
TOPFlash and cell-titer assays.  All experiments were performed in triplicate.  Note that 
Arm siRNA inhibits the Wg-mediated luciferase signal (as expected) and Gβ76 siRNA 
increases the Wg-mediated luciferase signal.  (RLU, relative light units; 0, no siRNA; 
Arm, Armadillo siRNA; Gdh, GAPDH siRNA)      
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preliminary results show promise, we will analyze the requirement of Gβγ in Wnt 
signaling using this approach. 
 
Does Gβγ  Directly Associate with Wnt Pathway Components? 
To assess whether Gβγ stabilizes β-catenin by binding a protein involved in Wnt 
signaling, we will utilize multiple approaches to test candidate binding events.  We will 
test whether Gβγ binds LRP6, Fz, Dsh, Axin, APC or β-catenin using co-
immunoprecipition in egg extract or cultured cells.  In cultured cells, we can determine 
whether Wnt3a treatment affects such binding events at specific time points (0, 5, 15, 30 
60, and 120 minutes after Wnt treatement).  When possible, we will perform these 
binding experiments using endogenous proteins to prevent overexpression-dependent 
binding artifacts.   We will also test Gβγ’s association with LRP6, Fz, Axin, and β-
catenin using a Bimolecular Fluorescence Complementation assay (BiFC) approach (Hu 
et al., 2002).  This method, also known as the split-YFP (Yellow Fluorescent Protein) 
approach, involves overexpressing two proteins with complementary halves of YFP in 
cultured cells.  If the proteins interact, they bring the two halves of YFP close enough to 
make a functional, fluorescent YFP detectable by fluorescence microscopy.  In addition 
to complementing results from co-immunoprecipitation experiments, BiFC has the added 
advantage of showing where in the cell the interaction is taking place.  In parallel to the 
BiFC experiments, we will test whether Gβγ overexpression in cultured cells affects 
localization of whole YFP-tagged proteins such as LRP6, Axin, and β-catenin in order to 
assay for other Gβγ-mediated perturbations of Wnt components.     
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Does Gβγ  Affect Wnt/β-catenin Signaling through Previously Described Gβγ  
Effectors? 
If Gβγ does not directly interact with core components of Wnt signaling, it may 
modulate β-catenin levels via previously characterized effectors of Gβγ signaling such as 
PLC, adenylyl cyclase, phosphoinositide 3 kinase, and phospholipase D (Smrcka, 2008).  
To test this, we will utilize small molecule inhibitors of known Gβγ effectors to identify 
the pathway by which Gβγ modulates Wnt signaling.  In egg extract, we tested whether 
incubation with small molecule inhibitors of Gβγ effectors inhibits the ability of purified 
Gβγ to stabilize β-catenin.  As many of these inhibitors have not been characterized in 
egg extract, we can apply this approach to cell culture where incubation of such an 
inhibitor may inhibit Gβγ overexpression-mediated effects on the pathway.  To further 
study such pathways, we can utilize molecular biological methods such as RNAi and 
overexpression of dominant negative proteins involved in the Gβγ-mediated signaling 
pathways.   
 
Future Studies with Gα Subunits Potentially Involved in Wnt/β-catenin Signaling   
The future directions mentioned above are also pertinent to Gα-mediated 
modulation of Wnt/β-catenin signaling.  We can test whether Gαi is required for Wnt3a-
mediated signaling in cell culture by applying small hairpin (sh) RNA to Gαi family 
members.  Unlike Gβγ RNAi, Gαi RNAi should only affect Gαi mediated processes 
(Hwang et al., 2005).  To determine whether Gαo, Gαi, and Gαq directly interact with 
known Wnt pathway components, co-immunoprecipitation in cell culture and egg extract 
as well as BiFC experiments may provide important mechanistic leads.  In addition, in 
 105 
cell culture and egg extract we can inhibit known Gαo-, Gαi-, and Gαq-mediated 
signaling processes with small molecules, RNAi, and dominant negative proteins.  These 
Gα-dependent signaling pathways may be required for their effects on Wnt/β-catenin 
signaling, providing clues to their mechanisms of action.  
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CHAPTER 4:  INTRODUCTION TO GLYCOSYLATION IN DEVELOPMENT 
 
Glycosylation in Metazoan Development. 
The addition of carbohydrate moieties to proteins regulates their maturation, 
activity, localization, and/or stability (reviewed in Varki and Chrispeels, 1999).  Several 
major types of glycosylation have been documented (Varki and Chrispeels, 1999).  In N-
glycosylation, a specific lipid-linked oligosaccharide, referred to as the LLO, consisting 
of 3 glucose molecules (Glc3), 9 mannose molecules (Man9), and 2 N-acetylglucosamine 
molecules (GlcNAc2) attached by a diphosphate linkage to a dolichol lipid is transferred 
onto a protein.  The LLO is transferred onto certain asparagine (Asn, N) residues within 
the consensus sequence Asn-X-Thr/Ser on proteins that are trafficked through the 
endoplasmic reticulum (ER).  The protein’s LLO is then modified as the protein matures 
through the ER and Golgi apparatus.  Because N-glycosylation occurs in the ER, N-
glycosylation targets proteins involved the cell’s secretory pathway such as secreted or 
membrane proteins.  In one class of O-glycosylation, a single N-acetylgalactosamine 
(GalNAc) is transferred onto a serine or threonine (Ser or Thr, O) residue on a protein in 
the ER or Golgi.  Complex carbohydrate oligomers are often added to the initial single 
GalNAc, affecting activity, localization, and stability of proteins of the secretory pathway 
in a manner similar to that of N-glycosylation.  Proteoglycans are heavily O-glycosylated 
proteins that are a major component of the extracellular matrix.  In the Golgi, long, 
anionic O-linked carbohydrate chains, called glycosaminoglycans (GAGs), are attached 
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to these proteins before they are secreted outside of the cell.  Their anionic character 
plays a role in regulating protein interactions, trafficking, and stability outside of the cell.  
A second major class of O-glycosylation involves addition of a single GlcNAc onto Ser 
or Thr sites and occurs on proteins in the cytoplasm and nucleus, not proteins of the 
secretory pathway.  In this class of O-glycosylation, the single GlcNAc is not modified 
into a carbohydrate oligomer.  Instead, this single carbohydrate moiety is a transient 
protein modification that plays a role similar to phosphorylation or ubiquitination.  Some 
idea of the importance of glycosylation in biology can be gleaned from the fact that at 
least 1% of proteins encoded in the human genome are involved in glycosylation or 
modification of glycosylated proteins (Ohtsubo and Marth, 2006).  
Given the importance and ubiquity of glycosylation in the maturation and activity 
of membrane-associated and secreted proteins, it is not surprising that protein 
glycosylation plays important roles in cell-cell communication during metazoan 
development.  It is reasonable to predict that complete inhibition of glycosylation would 
prevent many processes required for animal development.  However, many 
developmental programs proceed normally when animals are challenged with partial loss-
of-function defects in glycosylation, and various though specific development defects 
have been reported (Table 4.1) (Haltiwanger and Lowe, 2004).  Interestingly, the 
diversity of developmental defects caused by perturbation of proteins involved in 
glycosylation suggests that this is an intricately regulated biological process.  Multiple 
studies have analyzed developmental phenotypes resulting from loss-of-function of 
certain proteins involved in glycosylation and traced them to specific defects in proteins 
involved in cell signaling (Haltiwanger and Lowe, 2004).  For example, in mice and  
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Table 4.1:  Phenotypes Associated with Mutations in Mice that Perturb 
Glycosylation Are Shown in This Table Adapted from (Haltiwanger and Lowe, 
2004). 
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Drosophila, loss-of-function of O-fucose: β1,3-N-acetylglucosaminyl-transferase leads to 
defects in Notch signaling-dependent developmental programs by inhibiting O-
fucosylation of Notch proteins (Moloney et al., 2000).  In mice, a defect in an enzyme 
required for synthesis of all GAGs on proteoglycans, UDP-glucose dehydrogenase, leads 
to a severe loss of all extracellular matrix GAGs but specifically impinges on FGF (and 
not BMP or Wnt) signaling (Garcia-Garcia and Anderson, 2003).  Thus, global and 
ubiquitous regulators of glycosylation have been shown to disrupt specific signaling 
events in development. 
Because many specific developmental and molecular perturbations have been 
reported to occur as a result of defects in proteins involved in glycosylation, these 
proteins should not be considered “housekeeping” proteins as they may be dynamically 
and intricately regulated modulators of development.  For example, a cell could fine-tune 
its response to an extracellular signal through up- or down-regulation of a certain gene 
involved in glycosylation that specifically affects the activity of a protein or proteins 
involved in that signaling pathway.  Similarly, evolution of specific cell-biological 
processes could occur through genetic changes that affect cis-regulatory elements of a 
gene involved in glycosylation, which would affect its expression and lead to cell-
signaling changes in certain tissues of an organism.  Defects in several modulators of 
glycosylation have very specific biological effects, which suggests that regulation of 
these proteins may play important roles in physiology and evolution. 
While there have been many loss-of-function experiments supporting a role for 
dynamic regulation of enzymes involved in glycosylation, less work has focused on 
overexpression of these enzymes.  To further evaluate the candidacy of these genes as 
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important regulatory nodes in physiology and evolution, it will be important to determine 
whether increases in the expression of such genes also have specific and significant 
biological consequences.  In support of this hypothsis, a number of pathologic mutations 
in humans create ectopic glycosylation sites that may lead to disease (Vogt et al., 2005).  
Work exploring the dynamics of expression of genes involved in glycosylation may also 
provide some answers to these questions.   
 
Glycosylation Defects Cause Human Developmental Disorders. 
Consistent with animal studies demonstrating that many defects in glycosylation 
have specific phenotypes that are not embryonically lethal, mutations in an increasing 
number of genes involved in glycosylation have been reported to cause congenital 
disorders in humans (Figure 4.1) (Freeze, 2006).  Several human disorders affecting O-
glycosylation have been identified.  Defects in heparan sulfate proteoglycan biosynthesis 
have been shown to cause hereditary multiple exostoses (Simmons et al., 1999).  And, 
defects in O-glycosylation of FGF-23 have been linked with familial tumoral calcinosis 
(Kato et al., 2006).  In Ehlers-Danlos syndrome, patients present with delayed speech and 
motor development, failure to thrive, hypotonia, and distinctive connective tissue defects 
(Lawrence, 2005).  This syndrome is likely caused by defects in xylose-based GAG 
synthesis (Quentin et al., 1990).  Disorders affecting O-glycosylation are summarized in 
Table 4.2 (Freeze, 2006).  Disorders affecting N-glycosylation are classified as 
Congenital Disorders of Glycosylation (CDGs) (reviewed in Eklund and Freeze, 2006).  
Type 1 CDGs affect synthesis or transfer of the LLO onto Asn residue of N-glycosylated 
proteins, whereas Type 2 CDGs affect processing of the LLO on N-glycosylated proteins.   
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Figure 4.1:  The Number of Identified Human Disorders Affecting Glycosylation 
Has Greatly Increased During the Last 30 Years.  Figure from 
(http://www.burnham.org/default.asp?contentID=143).   
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Table 4.2:  Human Diseases Resulting from Defects in O-Glycosylation Are Shown 
in This Table from (Freeze, 2006). 
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CDG patients often present with mental and psychomotor retardation and dysmorphic 
features.  Coagulopathies and gastrointestinal problems are slightly less common features 
of CDGs.  In this group of disorders, partial loss-of-function, autosomal recessive 
mutations in global regulators of N-glycosylation lead to specific syndromes with shared 
and distinct features.  A summary of disorders in N-linked glycosylation is shown in 
Table 4.3 (Freeze, 2006), and a diagram displaying their underlying metabolic defects in 
N-glycosylation is shown in Figure 4.2 (Freeze, 2006).  The specific developmental and 
molecular processes perturbed in CDGs and other genetic disorders where glycosylation 
is disrupted remain important medical and biological questions.  Indeed, elucidation of 
the molecular mechanisms by which loss-of-function of certain regulators of 
glycosylation leads to the symptoms of these disorders may offer insight into targets for 
therapeutic intervention. 
Analyses of defects in glycosylation in model organisms suggest that many 
proteins involved in glycosylation could conceivably be evolutionarily modulated to fine-
tune specific aspects of biology.  In support of this concept, it has been suggested that 
CDGs may be the result of evolutionary pressure to globally downregulate N-
glycosylation.  For example, a heterozygous loss-of-function point mutation R141H in 
phosphomannomutase (PMM2) (the enzyme mutated in CDG Type 1a) is found in 1/70 
Northern Europeans, while the homozygous mutation is thought to be lethal (Schollen et 
al., 2000).  Given such a high prevalence for this mutation, there may be a selective 
advantage to a partial loss-of-N-glycosylation via PMM2 R141H heterozygosity 
(Schollen et al., 2000).  It has been suggested, though not tested, that this heterozygous 
mutation is protective against viral infections by limiting viral coat production, a process  
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Table 4.3:  Human Diseases Resulting from Defects in N-Glycosylation Are Shown 
in This Table from (Freeze, 2006). 
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Figure 4.2:  A Diagram Detailing the Molecular and Metabolic Defects Associated 
with CDGs is Shown from (Freeze, 2006). 
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that requires host N-glycosylation (Freeze and Westphal, 2001).  Although the possibility 
of a selective advantage for decreased N-glycosylation is attractive, there is currently no 
direct evidence that addresses this hypothesis. 
While a mechanistic molecular link has not been established between mutations 
found in CDGs and their signs and symptoms, clinical and experimental evidence provide 
some initial clues.  Parameters for CDG diagnosis include signs and symptoms, detection 
of hypoglycosylated serum Transferrin, specific enzymatic assays, and DNA sequencing 
(Eklund and Freeze, 2006).  As hypo-N-glycosylation of Transferrin can be readily 
detected in most CDG patients, it is possible that hypo-N-glycosylation of other specific 
proteins may directly cause CDG signs and symptoms.  As CDGs cause many diverse 
symptoms, the molecular etiology of these symptoms may or may not be identical.  In 
support of the former possibility, certain mutations in fibroblast growth factor (FGF) 
signaling lead to diseases with a similar array of signs and symptoms as CDGs.  For 
example, microcephaly, dysmorphic palate, 4,5 digit syndactyly, and strabismus are 
common to several CDGs as well as genetic disorders affecting FGF signaling (Chen and 
Deng, 2005; Toydemir et al., 2006).  However, it is also conceivable that the same 
glycosylation defect could affect different signaling events in different tissues.  Thus, it 
will be important to determine whether CDGs cause disease through one or multiple 
signaling pathways.   
Consistent with N-glycosylation playing important roles in protein folding in the 
ER, CDG Type 1a,b, and c patient-derived dermal fibroblasts display an activated 
Unfolded Protein Response (UPR) (Lecca et al., 2005; Shang et al., 2002).  The UPR 
promotes cellular adaptation to ER stress via expression of ER chaperones, enhanced 
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production of mature LLOs, global inhibition of translation, and/or apoptosis (reviewed 
in Schroder, 2008).  The precise UPR-induced program has been shown to depend on the 
level of ER stress:  expression of ER chaperones and enhancement of mature LLOs 
occurs at a lower level of UPR activation, while apoptosis is the most drastic response 
that occurs when there is a higher level of ER stress and UPR activation.  In CDG Type 
1a,b, and c dermal fibroblasts, enhanced production of mature LLOs is detected, but other 
aspects of UPR are not activated (Shang et al., 2002).  Thus, UPR-mediated adaptive 
responses to ER stress have been noted in CDG patient cells.  It is not known whether 
CDGs cause more drastic UPR responses in other tissues during different developmental 
periods.  This is an important question because developmental defects that result from 
CDGs could be caused by UPR activation in certain tissues (not by hypo-N-glycosylation 
of certain proteins per se).  Although several loss-of-function studies of enzymes 
involved in glycosylation in model organisms have demonstrated UPR activation, it is not 
clear whether the developmental phenotype results directly from hypoglycosylation or 
indirectly through upregulation of the UPR (Haecker et al., 2008; Yuan et al., 2007).  
Thus, it will be important to determine whether chronic UPR activation contributes to the 
developmental disorders and phenotypes resulting from perturbations in glycosylation.    
Finally, the relationship between defects in N- and O-linked glycosylation 
requires further experimental inquiry.  A number of patients have presented with defects 
in both N- and O-linked glycosylation (Jaeken and Matthijs, 2007).  In some cases, it is 
not known whether these patients have defects in an enzyme that affects both N- and O-
linked glycosylation or whether perturbation of one process affects the other via UPR-
mediated responses or other uncharacterized mechanisms.  Interestingly, certain 
 134 
symptoms of Type 1 CDGs can be alleviated by subcutaneously delivered heparin 
therapy (Liem et al., 2008).  It was unexpected that a defect in N-glycosylation could be 
treated with an O-glycosylated GAG.  Perhaps, the primary N-glycosylation defect could 
perturb O-glycosylation; alternatively, the primary N-glycosylation defect could be 
suppressed by heparin-mediated alteration of the extracellular matrix.  In support of the 
former possibility, several aspects of the UPR would be expected to affect expression and 
maturation of secreted O-glycosylated proteins.  A defect in N-glycosylation could 
activate the UPR, which could inhibit O-glycosylated proteoglycan secretion, a defect 
that could be suppressed by exogenous heparin therapy.  Alternatively, hypo-N-
glycosylation of certain proteins may be rescued in trans by alteration of the extracellular 
matrix with exogenous heparin.  Thus, the relationship between O- and N-linked 
glycosylation defects should be further studied to better understand the mechanism by 
which CDGs cause their symptoms.   
Many rudimentary questions remain in understanding the mechanism by which 
CDG mutations cause their respective diseases.  It will be important to determine whether 
CDGs impact a single or numerous of cell signaling pathways.  The extent of the 
contribution of the UPR to CDG symptoms should also be explored.  And, crosstalk 
between O- and N-linked glycosylation defects in producing CDG symptoms requires 
study.  In addition to furthering our understanding of these diseases and their effects on 
human development, answers to these questions will help determine whether drugs that 
activate or inhibit cell signaling pathways, drugs that inhibit UPR, or GAGs or small 
molecules that affect O-linked glycans will have therapeutic potential in treatment of 
CDGs.       
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Of the 18 identified CDGs, therapy has only been effective in two subtypes 
(Freeze, 2006).  Patients with CDG Type1b have mutations in phosphomannose 
isomerase (PM1), which converts fructose-6-phosphate to mannose-6-phosphate.  The 
patients’ coagulopathy, protein-losing enteropathy, and liver fibrosis can be drastically 
improved when their diets are supplemented with mannose (Niehues et al., 1998).  
Patients with CDG Type2c have mutations in the GDP-fucose transporter and exhibit 
immunological defects and neurological deficits, which can be improved when their diets 
are supplemented with fucose (Marquardt et al., 1999).  Given that these CDGs are 
metabolic enzymes, supplementing the product or substrate of the defective enzyme 
seems a reasonable and cost effective therapeutic goal.  Because these disorders are often 
quite rare, however, this therapeutic strategy has not been attempted for many CDGs.  
Moreover, there may be issues concerning effective delivery, solubility, and stability of 
these metabolic intermediates that must be overcome.  As a result, there is a need for 
patient cell lines and whole organism models to test candidate therapies for these 
diseases.   
Currently untreated CDGs may have fairly straightforward but untested therapies.  
To begin to address this medical problem, development of whole organism animal 
models of these diseases should be initiated.  Such models could then be used to test 
candidate therapies.  Certain CDG genes such as PMI have been knocked-out in mice, but 
the null mutation causes embryonic lethality and is, thus, a poor model for the human 
disease (DeRossi et al., 2006).  Instead of creating null mutations, endogenous CDG 
genes in the mouse could be replaced by genes containing mutations orthologous to those 
found in CDG patients.  Alternatively, partial loss-of-function of CDG genes could be 
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analyzed more quickly in other vertebrate organisms such as Xenopus or zebrafish by 
partial knockdown with Morpholino oligonucleotides.  In addition to utility in developing 
therapeutics, animal models for CDGs will be an invaluable resource for establishing the 
link between loss of function of CDG genes and the molecular mechanisms by which 
they promote their disease phenotypes.  In any of the above organisms, defects in tissue 
development could be identified and traced to their molecular roots.  In addition, the 
contribution of UPR and crosstalk between N- and O-linked glycosylation to disease 
phenotype could be explicitly tested.  Thus, development of model organisms to study 
CDGs will be beneficial to patients suffering from these disorders and will offer 
researchers an opportunity to directly identify the molecular mechanisms by which CDG 
mutations cause their diseases.  Overexpression studies in these organisms as well as 
study of CDG gene expression patterns will also shed light on the question of whether 
these genes are dynamically regulated in biological processes.  If so, it should be 
productive to study whether dysregulation of these genes plays a role in the pathogenesis 
of other diseases such as cancer or neurological disease.  Consistent with this hypothesis, 
inhibition of N-glycosylation with tunicamycin shows greater toxicity in certain cancer 
cells than in non-transformed cells, implying therapeutic potential for regulation of N-
glycosylation in cancer (Contessa et al., 2008).  
Basic biological studies as well as clinical studies of patients with congenital 
disorders that perturb glycosylation suggest that enzymes that regulate glycosylation 
could potentially be dynamically regulated in development, physiology, disease, and 
evolution.  Studies that directly address these hypotheses will be of general value to 
understanding biology as well as curing human disease. 
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CHAPTER 5:  NAGK AND DPAGT1 REGULATE ANTEROPOSTERIOR 
PATTERNING IN XENOPUS EMBRYOGENESIS 
  
Introduction 
More than 1% of the human genome encodes proteins that are involved in 
glycosylation (Ohtsubo and Marth, 2006).  The extent to which proteins involved in 
glycosylation are dynamically regulated in physiology, development, disease, and 
evolution is not known.  Two major types of glycosylation have been identified:  N-
(Asn)-linked and O-(Ser or Thr)-linked glycosylation (reviewed in Varki and Chrispeels, 
1999).  In N-glycosylation, a specific 14-residue, lipid-linked precursor oligosaccharide 
(LLO) is transferred to certain Asp residues on proteins trafficked through the 
endoplasmic reticulum (ER).  This LLO is then trimmed and modified in the ER and 
Golgi apparatus.  N-glycosylation occurs primarily on proteins that are secreted outside 
the cell or that span the plasma membrane.  N-glycosylation regulates the proper 
maturation and folding of these proteins as well as their localization, activity, and 
stability.   
Although complete inhibition of N-glycosylation is likely incompatable with any 
proper functioning of biological processes that occur on the plasma membrane or in the 
extracellular matrix, partial loss-of-function of proteins regulating N-glycosylation leads 
to a group of human diseases called Congenital Disorders of Glycosylation (CDGs) 
(reviewed in Freeze, 2006; Haltiwanger and Lowe, 2004).  CDGs are caused by 
autosomal, partial loss-of-function, recessive mutations in a several global regulators of 
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glycosylation.  Most CDGs are diagnosed in part via detection of hypo-N-glycosylated 
serum Transferrin (Eklund and Freeze, 2006).  While symptoms of CDGs differ 
depending on the particular mutated gene, many CDGs have similar symptoms.  Patients 
with CDGs often present with psychomotor retardation, characteristic dysmorphic 
features, coagulopathies, and gastrointestinal problems.  The biological and molecular 
defects by which mutations in CDGs cause their symptoms are not known.  To better 
understand the how global perturbation in N-glycosylation causes specific aspects of 
CDG disease, it will be important to develop a whole organism model system whereby 
effects of partial loss of N-glycosylation on vertebrate development can be studied in 
detail.   
In addition to a better understanding of CDG pathogenesis, a model organism for 
CDGs could be used to test candidate therapeutics for these rare diseases.  Therapies for 
only two types of CDG have been identified.  However, dietary mannose 
supplementation for CDG Type 1b (Niehues et al., 1998) and dietary fucose 
supplementation for CDG Type 2c (Marquardt et al., 1999) are cost-effective therapies 
that work by supplementing the product or substrate of the defective enzyme.  
Development of therapies for CDGs could be significantly accelerated given animal 
models for these diseases.   
Here, we suggest use of the Xenopus laevis embryo as a model organism to study 
pathogenesis and treatment of CDGs.  In a screen for kinases that regulate Xenopus 
embryogenesis, we identified N-acetylglucosamine kinase (NAGK) as a regulator of 
anteroposterior pattering.  The developmental defect was phenocopied by perturbation of 
expression of dolichol-phosphate N-acetylglucosamine phosphotransferase (DPAGT1), a 
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rate-limiting enzyme required specifically for N-glycosylation (Lehrman, 1991; Lehrman 
et al., 1988) and a CDG gene mutated in CDG Type 1j (Wu et al., 2003).  Analysis of 
loss-of-function phenotypes from these embryos suggests that they have defects in FGF 
signaling.  In addition, overexpression of these genes and study of their expression 
patterns through development suggest that NAGK and DPAGT1 are dynamically 
regulated modulators of vertebrate development. 
 
Methods 
 
DNA Constructs, mRNA synthesis, and MOs 
cDNAs encoding 232 human kinases from the Harvard Institute of Proteomics 
(HIP) FLEXGene human kinase cDNA collection (pDNR-dual complete set) 
(www.hip.harvard.edu/research/kinases/index.htm) were amplified by PCR with primers 
designed to facilitate in vitro transcription followed by translation in Xenopus embryos or 
egg extracts.  A PCR-amplified fragment of the pCS2 Poly(A) sequence was first 
obtained (5’ oligo sequence:   GACCATTCGTTTGGCGCGCGGGCCTGAGATCC-
AGACATGATAAGATAC; 3’ oligo sequence:  GAATTAAAAAACCTCCCACACC-
TCCCCCTGAACCTG).  A second PCR-amplified fragment of the human kinase with a 
3’ oligonucleotide designed to overlap with the 5’ oligonucleotide of the CS2 Poly(A) 
fragment primer was also obtained (5’ oligo sequence: GGCCCGCGCGCCAAACGA-
ATGGTC and 3’ oligo sequence: CCAAGCCTTCTAATACGACTCACTATAGGG-
AGACAGTGAGCGAGGAAGCGGCCGC).  Both fragments were then “sewn” together 
in a third PCR reaction to constitute a single fragment with a 5’ human kinase and a 3’ 
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poly(A) tail.    For experiments performed subsequent to the screen, kinases were cloned 
into pCS2.  Kinase-dead NAGK T128M was created by inducing a T-M mutation in 
human NAGK by a PCR-based approach.  DNA encoding full-length human DPAGT1 
was obtained from OpenBiosystems (#7207845).  Recombinant human NAGK protein 
was made by bacterial expression of pMAL-NAGK with 4 hr IPTG induction at 370C and 
purified on amylose resin.  Capped RNA was synthesized using mMessage mMachine 
(Ambion).  MOs designed against NAGK’s 5’ UTR (CTCCCCCATATACAGCA-
GCCATCGC) and DPAGT1’s 5’ UTR and start sequence 
(CCGGCATGTTTGCCAATAGTTTACG) were obtained from Gene Tools, LLC.   
 
Xenopus Egg Extract Degradation Assay 
Xenopus egg extract was prepared and degradation assays were performed as in 
(Salic et al., 2000). 
 
In Situ Analysis    
In situ analysis was performed as described (Harland, 1991).  Probes against 
Brachyury (Smith et al., 1991), Chordin (Sasai et al., 1994), Wnt8 (Christian et al., 1991), 
Twist (Hopwood et al., 1989), N-Cam (Kintner and Melton, 1987), Otx30 (Pannese et al., 
1995), and Collagen 2 (Su et al., 1991) were made and used as previously described.  
Probe against NAGK was constructed against a 1.4 kb fragment of Xenopus laevis 
NAGK (#5515556, OpenBiosystems, pCMV-SPORT6) using Sp6 for the antisense 
strand. 
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FGF Animal Cap Assay 
Embryos were soaked 0.1X MMR (Marc’s Modified Ringers) with or without 
tunicamycin (2 ug/ml or 4 ug/ml) or glucosamine (100 mM) starting at the 8-cell stage.  
At stage 8 (before the onset of gastrulation), ectodermal caps were explanted from 
tunicamycin, glucosmaine, or control treated embryos and cultured in 0.75X MMR 
supplemented with recombinant xFGF8 (100 ng/ml).  After 1 hr incubation, animal caps 
were transferred to an Eppendorf tube, media was removed, and caps were homogenized 
in SDS-PAGE sample buffer and flash frozen.   Lysates were thawed and analyzed by 
SDS-PAGE and immunoblot for phospho-ERK (Cell Signaling) and total ERK (Cell 
Signaling).    
 
Results 
 
NAGK Overexpression Posteriorizes Xenopus Embryos. 
In an overexpression screen to identify novel kinases that regulate vertebrate 
development, 29 pools each consisting of 8 mRNAs encoding different human kinases 
were injected into four-cell stage Xenopus laevis embryos.  Embryos were then analyzed 
for developmental defects.  mRNAs from pools that perturbed development were then 
injected individually to identify the overexpressed kinase mRNA affecting development.  
In Figure 5.1, we show embryological phenotypes associated with overexpression of two 
single kinases without characterized roles in early vertebrate development, B-lymphocyte 
tyrosine kinase (BLK) and dual-specificity tyrosine-phosphorylation regulated kinase 2 
(DYRK2). BLK and DYRK2, along with hematopoetic cell kinase (HCK) and cyclin  
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Figure 5.1:  Overexpression of BLK and HCK Ventralize or Posteriorize Xenopus 
Embryos.  Injection into each dorsal blastomere of 2- and 4-cell embryos of mRNA 
ecoding either human BLK (100 pg) or HCK (170 pg) inhibits development of anterior 
trunk and head tissues in Xenopus embryos.  Screen performed by E.T. and C.S.C. 
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dependent kinase 2 (CDK2) (data not shown), prevented formation of head and trunk 
tissues in Xenopus embryos.  Interestingly, both BLK and HCK belong to the c-Src 
family of kinases (Kefalas et al., 1995). 
In parallel to the developmental screen, a screen utilizing the same mRNA pools 
was performed in cytoplasmic Xenopus laevis egg extract to identify kinase regulators of 
β-catenin stability (Salic et al., 2000).  In canonical Wnt signaling, β-catenin stability is a 
major regulatory node by which the pathway is activated or inhibited (Logan and Nusse, 
2004).  Single exogenous mRNAs were translated in Xenopus egg extracts to assay for 
effects on β-catenin stability.  Overexpression of several single kinases had effects on β-
catenin levels that may relate to their perturbations of Xenopus development.  For 
example, BLK and DYRK2 overexpression both appeared to stabilize β-catenin in this 
assay (data not shown).  Further characterization must be performed to determine 
whether these candidates modulate Xenopus development through regulation of β-
catenin. 
Overexpression of NAGK did not affect β-catenin levels but had one of the 
strongest and most penetrant phenotypes identified from the developmental screen.  
Overexpression of mRNA encoding NAGK and injection of recombinant human NAGK 
protein both robustly inhibited formation of anterior trunk and head structures, a 
phenotype described as posteriorized (Figure 5.2).   
 
NAGK Loss-of-Function Anteriorizes Xenopus Embryos. 
As overexpression of NAGK inhibited formation of anterior structures, we 
hypothesized that NAGK plays an endogenous role in antagonizing or limiting  
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Figure 5.2:  Overexpression of NAGK Posteriorizes Xenopus Embryos.  Injection 
into each dorsal blastomere of 4-cell embryos of mRNA encoding human NAGK (1 ng) 
or recombinant protein encoding MBP-tagged human NAGK (20 pg) prevents formation 
of anterior structures in Xenopus embryos assayed at Stage 35. 
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specification of anterior structures.  If this were the case, inhibition of NAGK would be 
expected to promote expansion of anterior structures at the expense of truncated posterior 
structures; such a phenotype is commonly referred to as “anteriorized”.  We performed 
NAGK loss-of-function through three experimental perturbations.  First, we designed 
Morpholino oligonucleotides (MOs) to inhibit translation of endogenous NAGK.  Dorsal 
injection of NAGK MO anteriorized Xenopus embryos (Figure 5.3B).  Second, we 
hypothesized that overexpression of a kinase-dead mutant of NAGK (NAGK T128M) 
would compete with endogenous NAGK for substrate binding and prevent 
phosphorylation of the substrate.  An orthologous T228M mutation in the ATP binding 
site of the similar sugar kinase, glucokinase, has been shown to potently abolish kinase 
activity (Mahalingam et al., 1999), and this ATP binding region is highly conserved 
between glucokinase and NAGK (Berger et al., 2002).  In support of this “dominant 
negative” strategy, dorsal overexpression of NAGK T128M anteriorized embryos, 
phenocopying MO-mediated NAGK loss-of-function (Figure 5.3C).  Third, we injected a 
small molecule competitive inhibitor of NAGK that mimics its substrate (3-O-methyl N-
acetylglucosamine) (Miwa et al., 1994; Zeitler et al., 1992) into dorsal blastomeres, 
which also promotes anteriorization of embryos (Figure 5.3D).  Thus, NAGK 
overexpression posteriorizes embryos, and NAGK loss-of-function (via three distinct 
experimental perturbations) anteriorizes embryos.  These experiments demonstrate that 
endogenous NAGK is required to limit anterior structure formation in Xenopus embryos. 
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Figure 5.3:  Endogenous NAGK Is Required in Xenopus Development to Limit 
Specification of Anterior Tissues.  (A)  Uninjected control embryos for experiments 
shown in B,C, and D.  (B)  Injection into each dorsal blastomere of a 4-cell embryo of 
NAGK MO (1.3 pmol) leads to increased specification of anterior structures at the 
expense of posterior structures (anteriorization).  (C)  Injection into each dorsal 
blastomere of a 4-cell stage embryo of mRNA encoding NAGK T128M anteriorizes 
embryos.  (D)  Injection into each dorsal blastomere of a 4-cell embryo of 3-O-methyl N-
acetylglucosamine (4 uM) anteriorizes embryos though to a lesser extent than NAGK 
MO or NAGK T128M.  Note ectopic cement gland (another indicator of anteriorization) 
in upper panel.  
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Perturbations of NAGK and DPAGT1 Lead to Similar Developmental Defects. 
NAGK is the first enzyme in the salvage pathway that converts free, cytoplasmic 
N-acetylglucosamine (GlcNAc) generated from degradative cellular pathways into UDP-
GlcNAc, which is then transferred onto oligosaccharides that are incorporated into 
glycosylated proteins or glycosaminoglycans (Hinderlich et al., 2000).  Given structural 
studies performed with NAGK, the active site of the kinase is not predicted to have 
kinase activity towards protein substrates (Berger et al., 2002).  Of note, we did not 
discover any phenotypes when we overexpressed two other enzymes from this pathway 
(GlcNAc-6-P mutase and UDP-GlcNAc pyrophosphorylase) (data not shown), possibly 
suggesting that NAGK is a rate-limiting step in this process.  We were initially surprised 
that an enzyme that appeared to play a global role in promoting glycosylation has such a 
strong and specific effect on tissue specification during development.  
To test whether NAGK acts on anteroposterior patterning via alteration of 
glycosylation and to determine whether NAGK disrupts development through effects on 
N- or O-linked glycosylation, we investigated the effect of perturbation of a rate-limiting 
enzyme with a specific role in N-linked glycosylation, DPAGT1.  DPAGT1 transfers the 
first sugar (GlcNAc) onto ER lipid-linked dolichol to initiate construction of the LLO 
that is transferred onto the Asn residue of N-glycosylated proteins in the ER (Lehrman et 
al., 1988).  Embryos in which DPAGT1 was overexpressed were posteriorized to an 
extent similar to those injected with NAGK (Figure 5.4A).  Moreover, DPAGT1 MO and 
tunicamycin, a potent, well-characterized DPAGT1 inhibitor (Lehrman et al., 1988), both 
strongly anteriorized embryos (Figure 5.4B and 5.4C).  Thus, developmental phenotypes 
produced by alterations in NAGK phenocopy those caused by alterations in the rate- 
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Figure 5.4:  Gain- and Loss-of-Function of a Key Rate-Limiting Enzyme Specific to 
N-Linked Glycosylation Phenocopy NAGK Disruption in Xenopus Embryos.  (A)  
Injection into each dorsal blastomere of a 4-cell embryo of mRNA encoding DPAGT1 
(0.4 ng) posteriorizes embryos.  An uninjected embryo is shown above. (B)  Injection 
into each dorsal blastomere of a 4-cell embryo of DPAGT1 MO (1.3 pmol) anteriorizes 
embryos.  An uninjected embryo is shown above.  (C)  Soaking Xenopus embryos from 
the 8-cell stage until Stage 16 in .1X MMR with 2 ug/ml tunicamycin anteriorizes 
Xenopus embryos.  A control embryo is shown above.  (D)  Soaking Xenopus embryos 
from the 8-cell stage until Stage 16 in .1X MMR with 100 mM glucosmaine anteriorizes 
Xenopus embryos. 
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limiting step of N-glycosylation.  Previous work in cultured cells demonstrated that 
incubation with glucosamine inhibits both N- and O-linked glycosylation (Little et al., 
2008); and, soaking Xenopus embryos with glucosamine promotes anteriorization, similar 
to what is seen with NAGK and DPAGT1 loss-of-function (Figure 5.4D).  These data 
support a model in which NAGK regulates anteroposterior patterning of Xenopus 
embryos by its effects on N-glycosylation. 
In addition to its well-characterized role as a rate-limiting enzyme in N-
glycosylation, DPAGT1 is mutated in CDG Type 1j (Wu et al., 2003).  Like many 
patients who suffer from severe CDGs, the patient identified with defective DPAGT1 
presented with mental retardation, microcephaly, seizures, and muscular hypotonia 
(Eklund and Freeze, 2006).  Because the specific developmental and molecular 
perturbations that link deficits in N-glycosylation and CDG disease symptoms have not 
been identified, the DPAGT1 (and NAGK) loss-of-function phenotypes that we have 
identified in Xenopus embryos may provide a model system to study the molecular 
pathogenesis of CDGs. 
 
Specific Tissues Are Misspecified in Embryos with N-glycosylation Defects.    
To determine which tissues are improperly specified in embryos in which NAGK 
or DPAGT1 are overexpressed and inhibited, we utilized in situ analysis of well-
characterized developmental mRNA markers.  In a preliminary experiment performed 
towards this end, we analyzed markers for early mesoderm (Brachyury) (Smith et al., 
1991), Spemann’s organizer (Chordin) (Sasai et al., 1994), ventral mesoderm (Wnt8) 
(Christian et al., 1991), neural crest (Twist) (Hopwood et al., 1989), neural tissue (neural 
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cell adhesion molecule (N-Cam)) (Kintner and Melton, 1987), anterior neurectoderm 
(Xenopus orthodenticle 30 (Otx30)) (Pannese et al., 1995), and axial/somitic mesoderm 
(Collagen 2) (Su et al., 1991).  We compared wild-type albino embryos with embryos 
treated with tunicamycin.  While differences between expression of certain markers such 
as Twist, Otx30, N-Cam, and Collagen-2 were noted, expression of these mRNAs is so 
dynamic that there is significant variation even between identically treated embryos 
(Figure 5.5-5.7).  Although tunicamycin treatment is experimentally simple, tunicamycin-
treated embryos exhibit certain off-target phenotypes that differ from NAGK or DPAGT1 
loss-of-function phenotypes (Figure 5.4C).  To avoid these problems, future experiments 
will be performed in which only one side of the embryo will be injected with NAGK MO 
or GPT MO and the contralateral side will be injected with lacZ mRNA for β-
galactosidase lineage tracing to mark the contralateral side and serve as an injection 
control (Hassler et al., 2007).  As a result, wild-type and perturbed tissue can be more 
easily compared, and MO-mediated perturbation will decrease off-target effects seen in 
tunicamycin-treated embryos. 
 
FGF Signaling Is Impaired in Embryos with N-Glycosylation Defects. 
The phenotype that results from NAGK or DPAGT1 loss-of-function most 
closely resembles the phenotype of embryos in which FGF signaling has been impaired 
(Delaune et al., 2005; Park et al., 2002; Tsang et al., 2002).  In embryos in which FGF 
signaling, NAGK, or DPAGT1 have been inhibited, a characteristic expansion of anterior 
structures at the expense of trunk and tail tissue, which become ventrally curved, is noted 
(Figure 5.8).  This precise phenotype does not occur in embryos in which other signaling  
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Figure 5.5:  In Situ Analysis of Early Embryonic Markers for Mesoderm, 
Organizer, and Ventral Mesoderm Suggest These Tissues Are Not Perturbed in 
Tunicamycin-Treated Embryos.  (A)  Analysis of Brachyury RNA expression in Stage 
10.5 embryos suggests tunicamycin does not disrupt mesoderm early formation.  (B)  
Analysis of Chordin RNA expression in Stage 11 embryos suggests tunicamycin does not 
disrupt formation of Spemann’s organizer.  (C)  Analysis of Wnt8 RNA expression in 
Stage 10.5 embryos suggests tunicamycin does not disrupt ventral mesoderm formation. 
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Figure 5.6:  In Situ Analysis of Early Embryonic Markers for Neural Crest and 
Somites Suggests These Tissues May Be Misspecified in Tunicamycin-Treated 
Embryos.  (A)  Analysis of Twist RNA expression in Stage 26 embryos suggests 
tunicamycin may promote anterior displacement of branchial arch derivatives and 
decreased Twist expression around optic placodes.  Thus, development of neural crest 
development may be disrupted in these embryos.  (B)  Analysis of Collagen 2 RNA 
expression in Stage 26 embryos suggests tunicamycin promotes increased posterior 
staining of tissues expressing Collagen 2, a marker of somitic mesoderm.  This alteration 
in expression pattern suggests a convergence and extension defect (Ela Knapik, personal 
communication). 
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Figure 5.7:  In Situ Analysis of Early Embryonic Markers for Anterior 
Neurectoderm and Pan-Neural Tissue Suggests These Tissues May Be Misspecified 
in Tunicamycin-Treated Embryos.  (A)  Analysis of Otx30 RNA expression in Stage 
15 embryos suggests tunicamycin may promote expansion of anterior neurectoderm, 
consistent with the anteriorized phenotypes of these embryos.  (B)  Analysis of N-Cam 
RNA expression in Stage 15 embryos suggests tunicamycin may promote expansion of 
neural tissue in neurula stage embryos.  Note expansion of N-Cam expression in the 
neural folds.  (C)  Analysis of N-Cam mRNA expression in Stage 26 embryos suggests 
tunicamycin may also affect neural tissue later in development.  Note disparate N-Cam 
staining around optic placodes and neural tube.  The alterations in N-Cam expression 
patterns suggest convergence and extension defects (Ela Knapik, personal 
communication). 
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Figure 5.8:  NAGK and DPAGT1 Loss-of-Function Phenocopy Loss-of-Function of 
FGF Signaling in Xenopus Embryogenesis.  (A)  Panel from (Delaune et al., 2005).  
Embryos soaked in increasing concentrations of the FGF receptor inhibitor SU5402 
display increasingly shortened A-P axes, anteriorization, and dorsal curvature of the tail.  
(B)  Panel from (Tsang et al., 2002).  Dorsal mRNA injection of a negative regulator of 
FGF signaling, Sef, also promotes a shortened A-P axis anteriorization, and dorsal 
curvature of the tail.  (C) and (D)  Like embryos shown in (A) and (B) where FGF 
signaling is inhibited, loss-of-function of NAGK (1.3 pmol MO) and DPAGT1 (1.3 pmol 
MO) causes a shortened A-P axis, anteriorization, and dorsal curvature of the tail. 
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pathways such as Wnt, bone morphogenetic protein (BMP), or Hedgehog are perturbed.  
As result, we directly tested whether FGF signaling is inhibited in embryos in which N-
glycosylation has been inhibited using a previously described method (Wang et al., 
2004).  Embryos were soaked in tunicamycin-containing medium starting at the 8-cell 
stage.  At stage 8 (before the onset of gastrulation), ectodermal caps were explanted from 
tunicamycin or control embryos and cultured in media supplemented with recombinant 
xFGF8.  Importantly, FGF signaling as assayed by immunoblot for phospho-ERK was 
compromised in tunicamycin-treated embryos (Figure 5.9).  Although this experiment 
should also be carried out with NAGK MO or DPAGT1 MO (to control for off-target 
effects of tunicamycin) and with rescue by overexpression of NAGK or DPAGT1 (again 
to determine specificity), the data from this experiment suggest that loss-of-function of 
N-glycosylation directly inhibits FGF signaling in Xenopus embryos. 
 
NAGK Has a Dynamic Developmental Expression Pattern.   
Although metabolic genes such as NAGK and DPAGT1 are sometimes 
considered “housekeeping” genes that are not dynamically controlled to regulate 
important biological processes during development, our data suggests that this is not the 
case for NAGK and DPAGT1.  Of note, both genes have contrasting partial gain- and 
loss-of-function phenotypes.  This implies that levels of the activity of these proteins 
must be tightly regulated to allow for proper development.  As a result, we hypothesized 
that NAGK and DPAGT1 would display dynamic patterns of expression.  Indeed, in situ 
analysis of NAGK expression demonstrates that this gene is dynamically regulated 
(Figure 5.10).  In blastula stages, NAGK is preferentially expressed in the cells of the  
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Figure 5.9:  Tunicamycin Directly Inhibits FGF Signaling in Animal Caps.  Embryos 
were soaked .1X MMR with or without tunicamycin (2 ug/ml or 4 ug/ml) or glucosamine 
(100 mM) starting at the 8-cell stage.  At stage 8 (before the onset of gastrulation), 
ectodermal caps were explanted from tunicamycin, glucosmaine, or control treated 
embryos and cultured in .75X MMR supplemented with recombinant xFGF8 (100 
ng/ml).  After 1hr incubation, FGF signaling was as assayed by immunoblot for phospho-
ERK and total ERK. 
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Figure 5.10:  Endogenous NAGK Is Expressed in Tissues Undergoing FGF 
Signaling.  XLPTP1 is a protein involved in FGF signaling with an expression pattern 
that is similar to that of several FGF receptors.  The expression pattern of XLPTP1 shown 
here has been taken from figures from (Park et al., 2002).  (A)  Like XLPTP1 (Park et al., 
2002) (side view, animal side up), NAGK is expression is enhanced at the animal 
hemisphere of early blastula stage embryos (left and right embryos: top view of animal 
hemisphere; center embryo: bottom view of vegetal hemisphere).  (B)  Like XLPTP1 
(Park et al., 2002), NAGK expression is enhanced at the neural folds (NF) of neurula 
stage embryos.  (C)  Like XLPTP1 (Park et al., 2002), NAGK in the tailbud stages is 
enhanced at optic placodes, otic placodes, throughout head tissues, and in the somites.     
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animal pole.  In neurula stages, NAGK seems to be preferentially expressed at the neural 
folds.  And in tailbud stages, NAGK is strongly expressed in the somitic and head 
regions.  Although we have not obtained data regarding the spatiotemporal regulation of 
DPAGT1 in Xenopus embrygenesis, studies suggest DPAGT1 is dynamically expressed 
in the hamster (Mota et al., 1994). 
Given the data that suggests that inhibition of N-glycosylation directly inhibits 
FGF signaling, we considered the possibility that NAGK could be more highly expressed 
in tissues that undergo FGF signaling.  Intriguingly, the expression pattern of NAGK 
strongly resembles the expression patterns of certain FGF receptors as well as 
intracellular modulators of FGF signaling (Figure 5.10) (Golub et al., 2000; Park et al., 
2002).  These data suggest that certain global regulators of N-glycosylation may need to 
be upregulated in tissues undergoing FGF signaling.  Our finding suggests a further 
possibility:  certain global regulators of N-glycosylation may be direct transcriptional 
targets of FGF signaling.  Nonetheless, overexpression data and expression pattern 
analysis suggest that expression levels of NAGK and DPAGT1 must be dynamically 
adjusted to certain levels that allow for proper regulation of developmental events.    
 
Discussion 
 
N-glycosylation Regulates FGF Signaling in Xenopus Development. 
We have characterized the sugar kinase NAGK as a novel regulator of 
anteroposterior patterning in Xenopus embryogenesis.  Given the similarity of phenotypes 
derived from perturbation of NAGK and DPAGT1 (Figure 5.2, 5.3, and 5.4), we suggest 
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that NAGK affects development through its role in N-glycosylation.  Although we were 
surprised that perturbations of global regulators of N-glycosylation had such specific 
developmental phenotypes, defects in such proteins (e.g. DPAGT1 (Wu et al., 2003)) 
cause CDGs with very specific symptoms in humans.  Because the phenotypes of 
embryos with loss-of-function in NAGK or DPAGT1 resemble the phenotype of embryos 
in which FGF signaling is inhibited (Figure 5.5), we tested whether inhibition of 
DPAGT1 directly inhibits FGF signaling and found this to be the case (Figure 5.9).  
Moreover, examination of NAGK’s expression pattern reveals that the gene displays 
dynamic temporal-spatial regulation through development and is most highly expressed 
in tissues undergoing FGF signaling (Figure 5.10).  Thus, we suggest that NAGK is a 
dynamically regulated modulator of FGF signaling in vertebrate development. 
It is not known how global perturbation of N-glycosylation inhibits FGF 
signaling.  Partial inhibition of N-glycosylation may lead to hypoglycosylation of an FGF 
signaling component and thus reduce its proper maturation, trafficking, activity, or 
stability.  Direct analysis of FGF ligands, receptors, or other N-glycosylated components 
of FGF signaling may reveal defects in such a protein that could suggest a molecular 
basis by which perturbation of N-glycosylation inhibits FGF-directed developmental 
processes.  It will also be interesting to speculate why a certain component of FGF 
signaling is more sensitive to changes in N-glycosylation than other N-glycosylated 
proteins required for development.  Nonetheless, identification of the FGF-associated 
protein inhibited by partial loss-of-N-glycosylation will help elucidate the connection 
between defects in N-glycosylation and FGF signaling.  While we only noted defects in 
FGF signaling, it is possible that partial loss-of-N-glycosylation impacts other 
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developmental events in Xenopus.  To test this, it will be important to determine whether 
activation of FGF signaling downstream of the glycosylation-induced defect can suppress 
all or only some of the developmental defects induced by partial loss-of-N-glycosylation.     
Unexpectedly, we find that overexpression of NAGK and DPAGT1 also cause a 
defect in anteroposterior patterning (Figure 5.2 and 5.4).  While loss-of-function 
anteriorizes embryos, gain-of-function posteriorizes embryos.  These data suggest that the 
amount of N-glycosylation must be titrated within a certain range to allow for proper 
development.  This hypothesis is supported by the dynamic temporal-spatial pattern of 
NAGK’s mRNA expression pattern.  Overall, these data suggest that certain regulators of 
N-glycosylation are not merely “housekeeping” genes but are dynamically regulated 
modulators of development.  Future work testing whether overexpression of these genes 
actually promotes enhanced FGF signaling may suggest that precise NAGK and/or 
DPAGT1 levels directly determine the extent of FGF signaling in cells.   
Elucidation of NAGK and DPAGT1 as developmental regulators implies that 
these genes and possibly other global regulators of glycosylation may be modulated to 
control certain physiological, pathological, and evolutionary events.  As a result, we 
suggest that activation or inhibition of expression of these genes may have direct and 
specific effects on a variety of biology phenomena that deserve detailed experimental 
investigation.  Such studies may reveal how alterations in the level of N-glycosylation 
play important and specific roles in physiology, pathology, and evolution.  For example, 
mutations that upregulate expression of NAGK or DPAGT1 may be oncogenic by 
promoting FGF-mediated carcinogenesis.  In evolution, mutations in the cis-regulatory 
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elements of NAGK or DPAGT1 may alter the amount of FGF-mediated signal 
transduction in a certain tissue to alter its morphology and function.  
 
Xenopus May Be Used as a Model Organism to Study Pathogenesis and Treatment 
of CDGs. 
The mechanism by which loss-of-function mutations in global regulators of N-
glycosylation cause symptoms of CDGs has not been identified (Freeze, 2006).  To 
address this problem, we suggest that partial loss-of-function of DPAGT1 in Xenopus 
embryos may constitute a model system to study CDGs. Specifically, our work implies a 
hypothesis for the molecular basis of CDG pathogenesis:  mutations in CDG genes 
perturb human development by specifically impinging upon proper FGF signaling.  
Consistent with this hypothesis, certain mutations in FGF signaling in humans cause 
developmental disorders with symptoms identical to those caused by CDGs.  For 
example, microcephaly, dysmorphic palate, 4,5 digit syndactyly, and strabismus are 
common to several CDGs as well as genetic disorders affecting FGF signaling (Chen and 
Deng, 2005; Freeze, 2006; Toydemir et al., 2006).  While much work remains to test the 
link between CDGs and defective FGF signaling in humans, our use of Xenopus as a 
model system to study CDGs has generated a hypothesis regarding the molecular 
pathogenesis of this group of human disorders.      
Xenopus may also be used as a model system to understand other important 
aspects of CDGs.  It has been shown that cells derived from CDG patients display an 
activated UPR (Lecca et al., 2005; Shang et al., 2002).  Inhibition of N-glycosylation may 
cause hypo-N-glycosylated proteins to fold incorrectly.  As a result, protein trafficking 
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through the ER is defective and the UPR is activated.  It is thus possible, though untested, 
that chronic activation of UPR may indirectly promote CDG pathogenesis.  To test 
whether UPR plays a role in the developmental phenotypes seen in embryos with loss-of-
function in NAGK or DPAGT1, one can examine whether downregulation of certain 
UPR-mediated events suppresses the primary developmental defect.  Alternatively, one 
can test whether small molecule activators of the UPR that do not directly inhibit N-
glycosylation cause similar developmental defects to those seen in cells where NAGK or 
DPAGT1 are perturbed. 
In addition to serving as a model system to understand the pathogenesis of CDGs, 
Xenopus could also be used to test candidate therapeutics for specific CDGs.  As CDGs 
are caused by defects in metabolic enzymes, supplementation of the product or substrate 
of an enzyme mutated in a particular CDG has successfully alleviated disease symptoms 
of two types of CDGs (Marquardt et al., 1999; Niehues et al., 1998).  Such a therapeutic 
strategy could be tested in Xenopus for treating currently intractable CDGs.  First, 
knockdown of the Xenopus ortholog of the particular CDG gene could be used to model 
the disease.  Then, it could be tested whether supplementation with a certain carbohydrate 
metabolite via soaking or direct injection could suppress the phenotype.  A proof-of-
principle experiment could first be undertaken to validate this approach.  CDG patients 
with mutations in PMI are treated with mannose therapy (Niehues et al., 1998).  Can 
PMI-mediated developmental defects in Xenopus be similarly suppressed with mannose 
supplementation?  Other therapeutic strategies may also be tested in Xenopus, such as 
activation of FGF signaling.  Thus, we suggest the use of Xenopus to develop treatments 
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for CDGs.  As a final note, the similarity of phenotypes caused by perturbation of NAGK 
and the CDG gene DPAGT1 suggests that NAGK could itself be a candidate CDG gene. 
 
Future Directions 
The experiments described in this chapter are part of a work in progress.  Here, I 
describe further experiments that must be performed to support the stated results. 
To confirm MO-mediated knockdown of NAGK and DPAGT1 translation, it is 
necessary to immunoblot for these proteins in control embryos and MO-injected 
embryos.  As these proteins are highly conserved in human and mouse to which multiple 
antibodies have been raised, I predict that commercially available antibodies will suffice 
to confirm MO-knockdown of these genes. 
To test whether NAGK and DPAGT1 MO-dependent phenotypes specifically 
result from decreases in translation of these proteins, we must rescue MO-mediated 
knockdown of NAGK and DPAGT1 with mRNA overexpression of NAGK and 
DPAGT1, respectively.  This experiment is absolutely required to interpret the current 
MO data.  Given that our overexpression experiments employ human NAGK and 
DPAGT1, these overexpressed mRNA’s themselves will avoid MO-mediated translation 
inhibition.  However, as we note phenotypes for both gain- and loss-of-function with 
these genes, we will likely need to carefully titrate the amount of mRNA to obtain rescue.  
In addition to mRNA-mediated rescue of NAGK MO, rescue of NAGK MO with 
the NAGK’s metabolic product GlcNAc-6-P would be an even more specific rescue than 
that performed with mRNA.  This rescue would confirm that NAGK’s role in these 
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phenotypes concerns its conversion of GlcNAc to GlcNAc-6-P and not some 
uncharacterized role for NAGK outside of glycosylation and GlcNAc phosphorylation. 
I have assumed that NAGK and DPAGT1 affect the same developmental and 
molecular processes based on their similar embryonic phenotypes.  To be able to state 
this with greater confidence, we must assay for functional interaction between these 
genes.  For example, does NAGK overexpression increase the severity of DPAGT1 
mRNA-mediated developmental defects?  Does NAGK-MO increase the severity of 
DPAGT1 MO-mediated developmental defects?  In addition, can NAGK overexpression 
rescue DPAGT1 MO-mediated defects, and can DPAGT1 overexpression rescue NAGK-
MO-mediated defects?  While the former two experiments seem more likely to be 
successful as the perturbations need only converge on a single process, positive results 
with the latter two experiments would have interesting and unexpected implications for 
cross-regulation of N-glycosylation that could inform CDG therapy development. 
As stated in the text, the developmental survey for tissues perturbed in embryos 
with gain- and loss-of-function in NAGK or DPAGT1 should be performed in a different 
manner than shown in Figure 5.6, 5.7, and 5.8.  The left or right side of the embryo 
should be injected with NAGK (or DPAGT1) MO or mRNA, and the contralateral side 
should be injected with a lineage tracer to mark control injection.  It will be easier to 
interpret differences in highly dynamic and specific expression patterns if a control side 
of a single embryo can be compared with an experimentally perturbed side (Hassler et al., 
2007). 
The animal cap assay directly assaying FGF signaling should be repeated with 
NAGK MO or DPAGT1 MO instead of the less specific drug tunicamycin.  In addition, 
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mRNA rescue of these MO effects in this assay would better support the conclusion that 
knockdown of these genes inhibits FGF signaling.  To increase the sensitivity of the 
assay, animal caps could be incubated with FGF ligand for periods significantly shorter 
than 1 hr (e.g. 5 or 10 minutes) (Wang et al., 2004). 
Lastly, in situ analysis of temporal-spatial mRNA expression of NAGK and GPT1 
in the embryo must be repeated to obtain embryos with less background staining.  The 
use of albino embryos or bleached pigmented embryos may aid this endeavor because 
many of the stained tissues are located in highly pigmented areas of the embryo.  
While the previous suggested experiments are required for reasonable 
interpretation of the current data, the following future directions are aimed to further 
probe interesting aspects of this project. 
If loss-of-function of NAGK and DPAGT1 perturb development through FGF 
signaling, experimental activation of FGF signaling via injection of mRNA encoding 
FGF ligand or receptor may suppress these defects in N-glycosylation.  If complete 
rescue of the phenotype is achieved, it is likely that NAGK and DPAGT1 completely act 
through FGF signaling.  If only certain aspects of the developmental phenotypes are 
rescued, it is possible that NAGK and DPAGT1 also affect other biological processes that 
could be further explored. 
Although the phenotypes of embryos in which NAGK or DPAGT1 are perturbed 
most closely resemble defects in FGF signaling, certain aspects of the phenotypes could 
also be explained by alterations in Wnt or BMP signaling.  The extensive survey of tissue 
specification via in situ hybridization for developmental markers may shed light on 
whether disruptions of tissue resembles perturbations of pathways other than FGF 
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signaling.  In addition, the animal cap assay where FGF signaling was directly assayed 
could also be performed for Wnt and BMP signaling.  To directly assay for disruption of 
Wnt signaling in embryos with perturbed N-glycosylation, embryos could be injected 
with mRNA encoding Wnt8, and after 1 hr whole blastulas could be assayed for 
decreases in phosphorylated β-catenin.  To directly assay for disruption of BMP 
signaling, embryos could be injected with BMP ligand and after 1 h whole embryos could 
be assayed for phospho-Smad. 
Immunoblotting for endogenous or exogenous, tagged N-glycosylated proteins 
involved in FGF signaling could reveal mobility shifts induced by mRNA or MO-
mediated perturbation of NAGK or DPAGT1.  Such shifts may result from hypo- or 
hyper-glycosylation of these proteins, which could be further tested by treatment of 
lysates with N-glycosidases to remove N-glycans from these proteins.  These experiments 
could identify improperly glycosylated proteins involved in FGF signaling.  In addition, 
mutation of existing N-glycosylation sites (or creation of new ones) on these proteins 
could directly test whether improper glycosylation of these proteins causes the 
developmental phenotypes observed in embryos in which NAGK or DPAGT1 are altered.  
In this manner, the molecular target by which perturbation of NAGK or DPAGT1 disrupt 
FGF signaling can be elucidated. 
As expression of NAGK appears to be highest in tissues where FGF signaling 
occurs, it is possible that NAGK could be a transcriptional target of FGF signaling in the 
embryo.  This could comprise a positive feedback loop to regulate FGF signaling.  
Determination of such a mechanism would support the role for NAGK as an important, 
dynamic regulator of FGF signaling in development.  One could easily test whether gain- 
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or loss-of-function of FGF signaling (by conventional mRNA or MO injection) enhances 
or decreases expression of NAGK (as assayed by RT-PCR or in situ hybridization for 
NAGK). 
Because I have suggested the use of Xenopus as a model organism to study CDGs 
and their therapies, it would be fairly straightforward to test this hypothesis with a proof-
of-principle experiment.  I propose that CDG Type 1b or CDG Type 2c and their 
successful treatments could be recapitulated in Xenopus embryos.  CDG Type 1b is 
caused by a mutation in PMI and treated with mannose supplementation (Niehues et al., 
1998).  CDG Type 2c is caused by a mutation in FUCT1 and treated with fucose 
supplementation (Marquardt et al., 1999).  I predict that MOs directed against PMI and 
FUCT1 would cause developmental defects in Xenopus similar to those seen with NAGK 
or DPAGT1 MO and that the defects could be suppressed by injection or soaking with 
mannose or fucose, respectively.  Such experiments would greatly strengthen the case for 
using Xenopus as a model for CDGs. 
It is predicted that CDGs are vastly undiagnosed, and mutations in genes causing 
CDGs continue to be identified.  Thus, it is possible that mutations in NAGK, like 
mutations in DPAGT1, may cause CDGs in humans.  Databases with partially mapped 
congenital disorders may be used to explore such a possibility (Taniguchi et al., 2006).   
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